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Abstract 
Hepatitis C Virus (HCV) exists as a population of sequence variants that evolves during 
infection adapting to host pressures. The main targets for the immune response are the 
envelope glycoproteins E1 and E2, which also mediate viral cell entry. The first 
hypervariable region (HVR1) of E2, previously implicated in the outcome of acute 
infection, has been a focus of many studies. However more broadly neutralising 
antibodies tend to target epitopes outside this region, yet evolution of full length E1E2 
heterodimer is poorly understood. The HCV transmission and window period as well as 
seroconversion are the evolutionary events shaping primary infection hence 
influencing outcome of acute infection. However, due to the asymptomatic character of 
the early phases of HCV infection, evolutionary data describing this interval is still 
lacking depth. Defining the genetic and phenotypic characteristics of HCV population of 
sequence variants that establish infection in a new host would aid vaccine and new 
therapy design. 
This study aimed to identify patterns of HCV envelope glycoprotein evolution upon 
transmission and during early phases of disease. We studied this in three settings: 
experimental transmission of immunocompromised mice by known inoculum; 
occurrence of horizontal transmission in a haemodialysis unit between hypothesised 
source and index case individuals; and unrelated cases of acutely infected HCV patients. 
The single genome amplification (SGA) approach was utilised, which allowed us to 
accurately assign linkage between substitutions and determine the frequency 
distribution of E1E2 variants in analysed viral populations. 
Data from the first experimental setting indicates that a selective sweep occurs upon 
HCV transmission, with selective amplification of envelope sequence variants that 
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possess fitness advantage at entry level. Molecular determinants associated with this 
enhanced infectivity have also been identified. In further part of the project we 
confirmed a horizontal infection in haemodialysis unit with use of phylogenetic 
methods and suggested revision of current safety guidelines. Analysis of sequences 
from the last setting showed that indeed HVR1 might not be a good enough indicator of 
evolutionary events in the acute phase, as linked substitutions occur also outside this 
region. Seroconversion is associated with increasing population diversity indicating 
role of antibodies in driving HCV evolution, which is host specific. 
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1 Introduction 
1. Introduction 
1.1. Hepatitis C Virus as a pathogen 
1.1.1. Discovery and classification 
For many years viral hepatitis was believed to be caused by only two viruses: Hepatitis 
A Virus (HAV) and Hepatitis B Virus (HBV). Despite establishing robust screening for 
these agents, post-transfusion hepatitis continued to occur. Such cases were described 
as Non-A-Non-B (NANB) hepatitis and the unknown agent proved difficult to identify 
[1, 2]. In 1989, a group of scientists from the Chiron Corporation succeeded in isolating 
cDNA from the sera of a chimp infected with NANB,  and identified this as a unique 
infectious agent which they called Hepatitis C Virus [3]. This virus was confirmed as the 
causative agent of NANB hepatitis. Sequence analysis showed that the genome 
structure was similar to members of the Flaviviridae family, but was distinct enough to 
place HCV into a new genus called Hepacivirus [4, 5]. 
1.1.2. Epidemiology and worldwide distribution 
The HCV genome exhibits extensive genetic variation, with at least 6 genotypes and 
over 70 subtypes having been described [6, 7]. Each genotype differs from other 
genotypes in 31 to 33% at nucleotide level [8, 9]. HCV genotypes exhibit regional 
differences in distribution [7]. The high levels of genetic variability apparent within 
genotypes in sub-Saharan Africa and South-East Asia indicate that HCV is endemic to 
these regions. Introduction of HCV to non-tropical countries occurred with recent 
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development of new risk groups, such as blood recipients, vaccinees and drug abusers 
[10, 11]. HCV is mainly transmitted via contaminated blood and/or blood products. 
HCV infection occurs following large or repeated percutaneous blood contact (i.e. drug 
injections, transfusion or transplantation). Viral transmission is less efficient when 
single exposures to small amounts of blood are concerned [10-15].  
The HCV has been divided into 6 genotypes and further subtypes [7] which show 
specific geographical distribution shown in Figure 1.1. Transmission of specific 
subtypes, namely 1a, 1b and 3a, by blood transfusion and needle sharing between 
intravenous drug users (IVDUs) has resulted in the exponential spread of these 
subtypes [16]. Indeed, these three HCV subtypes represent majority of HCV infections 
in Europe and the United States. Despite increasing knowledge about HCV molecular 
evolution and epidemiology, the origins of infection in humans remain unclear. 
However recently a canine homolog of HCV has been characterised opening new 
possibilities for understanding worldwide HCV outbreak [17]. More than one million 
new cases of HCV are reported annually, and reports estimating the number of people 
infected with HCV varies between 130 to 170 million [9]. These numbers correspond to 
a 2.2% prevalence of HCV positive persons worldwide. Figure 1.2 presents 
geographical differences in HCV prevalence. The United Kingdom is amongst countries 
with the lowest HCV prevalence.[18]. An estimated 250,000 - 600,000 (about 0.5%) 
individuals in UK carry HCV [19]. The HCV prevalence in Europe varies from 0.4% in 
Germany, Netherlands and Sweden to 2Ȃ3% in some Mediterranean countries [20]. To 
control a parasitic disease common in Egypt, schistosomiasis, a mass eradication 
programme was conducted from the 1960s until the 1980s. Unfortunately, non-sterile 
needles were used throughout the campaign resulting in Egypt having the highest 
global HCV prevalence of around 20% [21]. Many developing countries still lack any 
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HCV prevalence data. On average, a quarter of cirrhosis and hepatocellular carcinoma 
cases worldwide result from HCV infection [9].  
 
Figure 1.1. Worldwide distribution of HCV genotypes [22]. 
 
 
Figure 1.2. Worldwide prevalence of Hepatitis C Virus [23]. 
1.1.3. Diagnosis 
HCV infection is determined by assaying for the presence of anti-HCV antibodies and 
viral RNA. These detection methods are based on recombinant HCV peptides in the 
context of enzyme immunoassays (EIA). Third generation assays are now available and 
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in routine use [24]. . These assays contain a mixture of HCV epitopes from Core, NS3, 
NS4 and NS5 regions, which detect a broader spectrum of anti-HCV antibodies as 
compared to previous generation methods and allows estimated specificity up to 99% 
[24]. 
Specific anti- HCV antibodies occur upon seroconversion that follows a window period 
of infection that can last up to six months post infection. The HCV diagnosis by means of 
antibody testing is thus unreliable for recognition of early phase of infection [25], hence 
HCV-RNA diagnostics are essential in identifying individuals during the pre-
seroconversion window period [4, 5, 26, 27]. The presence of viral RNA and thus 
diagnosis of HCV replication can be detected and quantified with use of PCR techniques. 
All commercially available tests implement IU/ml of HCV RNA as a quantitative unit 
[24, 28]. Automated platforms, which are currently used for HCV RNA detection, are 
based on real-time PCR technique. Real-time PCR as compared to standard PCR 
technique is more sensitive and has a broader dynamic range of detection and 
quantification of viral nucleic acids. As low as 10-15 IU/ml can be detected and 
quantification can be carried out up to a range of 7-8 log10 IU/ml [28]. Detection and 
quantification of viral RNA is not only crucial as a diagnostic method but serves as 
means to monitor the virological response to therapy. 
1.1.4. Clinical manifestations 
Acute HCV infection is difficult to recognize as symptoms like hyperbilirubinemia are 
apparent in less than 20% cases [29]. The acute phase of infection is characterized by 
elevated levels of liver enzymes- alanine aminotransferase (ALT) and asparagine 
aminotransferase (AspAT) [25]. Raised liver enzymes in sera are due to developing 
necrosis of hepatocytes and rising cell membrane permeability in the target organ. The 
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phase of raised AAT can be very short and unnoticed. It is preceded by a point when 
virus reaches the highest titre. Levels of viremia do not usually correlate with severity 
of disease or prognosis [30]. 
The acute phase in 75- 85% of cases develops into chronic hepatitis which is marked by 
persistence of HCV RNA despite arising of anti- HCV antibodies [25]. The most common 
histopathologic symptom of HCV is liver fibrosis. Fibrotic changes seem to develop 
during chronic hepatitis, when continuous destruction of infected cells and mass 
production of cytokines and growth factors occurs. A prolonged state of developing 
fibrosis leads to bile duct damage which results in cirrhosis. The final complication in 
HCV infection is cirrhosis, which most often leads to liver decompensation and the need 
for liver transplantation [31, 32]. Natural history of HCV infection is summarised in 
Figure 1.3. 
 
Figure 1.3. Natural history of HCV [32]. 
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1.2. Molecular Insight 
1.2.1. Genome and encoded proteins 
The HCV genome consists of a single open reading frame (ORF) of around 9000 ǡ    ?ǯ   ?ǯ - Ǥ   ?ǯ (Un-Translated 
Region), is 341 nt long and possesses an internal ribosome entry site (IRES), which has 
the ability to start cap-independent translation [33]Ǥ   ?ǯ     
poorly conserved stretch of nucleotides followed by polypyrimidine tract and a unique  ? ?  Ǥ 	ǡ     ?ǯ ǡ      
structure and is important for the initiation of replication [4, 34]. Model of the HCV RNA 
structure is presented in Figure 1.4. 
The ORF of HCV encodes a single 3000 amino acid polyprotein precursor that is cleaved 
into at least 10 mature proteins [34, 35].  ?ǯ	
proteins followed by non- ?ǯǤThe core protein is located at 
the N-terminus of the precursor protein and is released by host signal peptidase [5]. 
This protein is highly basic and is able to form multimeric complexes which eventually Ǥ ?ǯ
genome, both of which may be essential for virus morphogenesis [36]. It has been 
shown that due to ribosome frame shifting in the core region, an additional gene 
product, called the F protein, might be produced, although its function is yet unknown 
[37].  
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Figure 1.4. HCV genome and polyprotein structure.  
Points of protease cleavage are indicated by asterisks. SPP- signal peptide peptidase, SP- 
signal peptidase [38]. 
The envelope glycoproteins, E1 and E2, are located downstream of the core protein and 
are also released via signal peptidase action. These are heavily glycosylated proteins of 
about 35 and 70 kDa respectively [39], and their functions, including their role in 
cellular entry and immune escape will be described in detail further.  
Encoded next, in the HCV genome, is p7- a small hydrophobic polypeptide that was 
shown to be essential for the production of infectious virions in vivo [40]. It forms an 
ion channel in lipid bilayers consistent with its classification into viroporins [41]. 
Downstream of the structural protein region are the genes encoding non-structural 
proteins, which are responsible for viral replication and protein release. Two 
proteinases are coded in the non-structural region: NS2/3 metalloproteinase and NS3 
serine proteinase [34]. NS2 is a protein rich in hydrophobic residues and undergoes 
autocatalytic cis cleavage from its precursor protein [42]. NS3 is a protein that contains 
characteristic motifs for serine proteases (in N-terminal part) and for RNA helicases 
and nucleoside phosphatases (in C-terminal part) [42, 43]. The protease consists of a 
catalytic subunit of NS3 activated by NS4A cofactor. The proteolytic activity of this 
heterodimeric protease is targeted to releasing non-structural proteins from the 
  
8 Introduction 
polyprotein precursor [42]. The section of NS3 not engaged in polyprotein cleavage 
forms a helicase domain [43] which is essential in HCV replication. 
Located downstream is a hydrophobic NS4B protein for which function was not 
immediately ascribed. It has been localised on ER membranes and lipid rafts, and 
further indicated in formation of membranous web, interactions with cellular  factors 
and scaffolding RNA replication [44]. 
The next protein coded within the ORF, NS5A, is present as two differently 
phosphorylated proteins: 56kDa and 58kDa [45]. The latter is hyper phosphorylated 
form of p56. NS5A has been shown to interact with IFN- induced protein kinase (PKR) 
[46]. The IFN sensitivity-determining region (ISDR) has been mapped in C-terminal 
part of NS5A which is also responsible for the interaction with protein kinase PKR [47]. 
The NS5A has been indicated in virus assembly and RNA replication [45]. 
The sequence of the last protein released from the polyprotein precursor is highly 
conserved between HCV strains. NS5B is an RNA-dependent RNA polymerase (RdRp), 
which synthesizes RNA using an RNA template [48]Ǥ    Ǯǯǡ [49]. The active site of this 
enzyme is located within the palm, which is fully encircled due to thumb and fingers 
subdomains creating a tunnel. The latter domains are thought to possess allosteric sites 
modulating the enzyme interaction with RNA [49, 50].  
All HCV proteins have amino acid sequences that localise them to ER membrane, 
providing evidence that the ER is the site of virus replication and assembly (shown in 
Figure 1.5).  
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Figure 1.5. ER retention of HCV proteins and their indicated functions [51]. 
1.2.2. Envelope glycoproteins 
HCV viral particle contains E1 and E2 glycoproteins in its bilayer envelope. These 
surface proteins are essential for virus life cycle as they mediate entry into the host cell 
and have also been shown to possess epitopes targeted by host immune system. 
1.2.2.1. Biogenesis and glycosylation 
HCV glycoproteins E1 and E2 are type I transmembrane proteins with N-terminal 
ectodomains and C-terminal membrane anchors [52]. E1 and E2 are cleaved from the 
HCV polyprotein as soon as translation of their coding region occurs. Cleavage site 
between E2 and p7 seems to be recognised less efficiently by signal peptidase giving 
rise to different pools of E2: fully cleaved E2 and E2p7 [53, 54]. Folding of E1 is a 
relatively slow process which is dependent on E2 [55, 56]. Cysteine cross-linking that 
supports the conformation in E2 occurs in a time sufficient for its cleavage from the 
rest of the precursor protein [57]. Both E1 and E2 possess ER retention signals and 
undergo maturation in this cellular organelle. The C-termini of E1 and E2 are 
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responsible for translocation of glycoprotein ectodomains into the ER lumen [55]. HCV 
glycoproteins associate in ER with chaperones like calreticulin, Binding 
Immunoglobulin Protein (BiP) and calnexin [58, 59]. Trafficking of E1 and E2 between 
these chaperone proteins depends on proper processing of N-linked glycans that, 
among other roles, has an impact on folding of these proteins. Calreticulin and BiP 
interact preferentially with misfolded aggregates, whereas calnexin associates with 
properly folded heterodimers [58, 59]. 
Domains responsible for heterodimerisation of HCV glycoproteins have not been 
characterized accurately. Initially, that process seemed to depend only on ectodomains 
[60, 61]. However, experiments on HCV glycoproteins with TM domains deleted 
showed a tendency for aggregation. Changing of TM domains of E1E2 for TM domains 
of other proteins disturbed folding of functional heterodimers. Moreover, the N-
terminal part of transmembrane E1 domain possesses highly conserved motif GXXXG 
that enhances interaction of hydrophobic parts of TM proteins [60, 61]. Together these 
data suggest that important determinants of heterodimerisation reside in the TM 
domains. 
Inconsistent with most Flaviviruses, HCV envelope proteins undergo extensive 
glycosylation as part of the maturation processes [62]. Mapping of glycosylation sites 
showed that E1 has up to 6 and E2 - 11 potential N-linked glycosylation sites [63-65] 
(see Figure 1.6). Glycans present on HCV envelope proteins nearly double their mass. 
Digested by Peptide-N-Glycosylase F (PNGase F) E1 and E2 are about 37 and 17 kDa, 
whereas glycosylated proteins migrate at about 65 and 30 kDa, respectively [66]. The 
characterisation of HCV glycoproteins has shown that glycosylation patterns differ 
between various truncated and full length proteins indicating their different properties. 
Absence of E2 or E1, during expression of the other glycoprotein, leads to production of 
different glycoforms [62-64, 67, 68]. Analyses with conformation- dependent 
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antibodies show that folding of HCV glycoproteins is a slow process. In addition it has 
also been shown that although some degree of folding can be observed in E2 expressed 
alone, both glycoproteins need to be co-expressed to acquire functional properties [57, 
59, 69]. 
E1 
 
E2 
 
Figure 1.6. Schematic presentation of glycosylation sites on linear E1 and E2 [70].  
N indicates N-linked glycan positions numbered according to H strain. Black- trans 
membrane domains, grey- ectodomains. 
Functions of the E1E2 glycans in the HCV life cycle have been studied [65, 71]. Site 
directed mutagenesis revealed that glycans E1N1, E2N8, E2N10, and E2N11 are 
essential for correct particle assembly [65]. Glycans E2N1, E2N2, E2N4, E2N6, and 
E2N11 shield neutralisation sensitive epitopes from immunological targeting [65]. 
Finally glycans E2N1, E2N2, E2N4, and E2N6 were shown to have a role in E2 
interaction with CD81 [65]. 
A previously mentioned study [66] describes detailed characterization of glycosylation 
patterns of intracellular, HCVpp- and virion-associated E1 and E2. Intracellular E1 and 
the majority of E2 glycosylation sites harbour high- mannose- type glycans in both- 
HCVpp and HCVcc expression systems [66]. Whereas glycans on E1 remain unmodified 
upon secretion, E2 secreted in the context of HCVcc authentic virions harbour a mixture 
of high- mannose and complex- type glycans [66]. This observation is not consistent 
with HCV pseudotypes containing E2 with majority complex- type glycans [66].  
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All described studies highlight that the HCV glycoproteins maturation depends on a 
complex and dynamic relationship between cleavage by signal peptidases, close 
proximity of both E1 and E2, their translocation, folding and glycosylation. 
 
Figure 1.7. Schematic representation of high-mannose and complex N-linked glycan. 
1.2.2.2. Structure and function 
The current hypothesis assumes that virions acquire lipid envelope from host cell 
membranes- either external cell membranes or internal membranes of ER and Golgi 
structures. Immunolocalisation and analysis of E1E2 glycan structure suggests that 
they are connected to the ER membrane and most probably undergo glycosylation 
while virus budding [54, 72]. Functional E1E2 heterodimers, present on HCV 
envelopes, are responsible for virus-cell contact and further membrane fusion [73]. E1, 
which spans residues 171-383 of the HCV polyprotein, has been suggested as a fusion 
protein but its exact role in virus entry is not precisely described. E2 glycoprotein, 
encoded within residues 384- 746 of the HCV polyprotein is much better characterised 
and is now known to have receptor binding and fusogenic properties as described 
below. The entry process and its cellular cofactors are further described in paragraph 
1.3.1. 
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Fusion proteins in Flaviviridae family have been characterised as class II fusion 
proteins (reviewed in [74]) and noted to be co-expressed with a second membrane 
protein. E1 is thought to exist in a noncovalent complex with E2 in a similar manner to 
flavivirus precursor M protein (prM) and alphavirus precurson E2 protein (pE2) [74]. 
The usual three domain structure of class II fusion proteins has notable amouȾ-
sheet form. Domain II of the protein contains the fusion loop, flanked by domain I at 
carboxy, and domain III at amino terminus. Such architecture was thought to be true 
for E2 ectodomain as well [74]. The model of flavivirus fusion protein and its mode of 
action are presented in Figure 1.8 and described in the figure legend. 
 
Figure 1.8. Model of flavivirus class II fusion protein triggering membrane fusion [74].  
This model has been proposed to be true for HCV E2 as well. Domains are as in figure 
above: Domain I- red, Domain II- yellow, Domain III- blue. Upper membrane- cell surface, 
lower membrane- viral envelope. Ectodomain of viral fusion protein binds to cellular 
receptor and virus is internalised (A). A pH change in the endosomal compartment triggers 
conformational change, attachment of domain II to host membrane, and trimerisation of 
ectodomains (B). Further rotation of domain II places the transmembrane domain in close 
proximity to fusion loop (C), which in effect should lead to membrane fusion (D) [74]. 
High glycosylation and ER retention of HCV glycoproteins contradict their classification 
as class II fusion proteins. Due to high level of glycosylation, presence of trasmembrane 
domains and tendency to misfolding E1 and E2 have been difficult to express at high 
enough levels to allow crystalisation [57] and deciphering their structure. Krey et al. 
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[75] designed an effective production system to obtain large amounts of high purity E2 
ectodomain that retains functionality and is thought to present a native conformation. 
In spite of unsuccessful crystallisation efforts, basing on a conserved manner of 
disulphide bonds across E2 and other structural data the group revealed the tertiary 
structure presented in Figure 1.9. This model confirms the hypothesised three domain 
structure in agreement with class II fusion protein model. Domain I consists of eight  Ⱦ-sheets (B0-I0) and was mapped to possess most of the CD81 binding 
epitopes. Strands D0 and E0 are separated by a long amino acid sequence which in 
tertiary structure takes form of Domain II. Domain III is at C terminus of the E2 
receptor binding domain and is followed by a stem region. 
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Figure 1.9. Tertiary structure of E2 ectodomain [75]. 
A- Beads represent sequential amino acids, B- simplistic representation of E2 domains 
parallel to the structure in panel A. Black bars represent cysteine bridges. Green beads 
represent glycosylation sites. Beads contoured in blue- amino acids of CD81 binding 
epitopes, contoured in red- putative fusion loop. Unstructured regions- brown beads. 
HCV glycoproteins show high extent of variability with several hot spots termed hyper 
variable regions (HVR). Hypervariable Region 1 consists of 27 amino acids at N 
terminus of Domain I. HVR2 was mapped to 15 amino acids of Domain II and 
intergenotypic variable region (IgVR)- 10 amino acids in a region between domains I 
and III [76]. Functions of hypervariable regions have not yet been fully ascertained, 
although HVR1 has been proposed as an immunological decoy [77] and these regions 
have been shown to have a role in glycoprotein formation and viral infectivity [78]. 
HVR1 is known to engage in SR-BI receptor [79] and antibody binding. The variability 
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of HVR1 sequences in acute infection have been shown to be predictive of disease 
outcome[80]. Other regions across the E2 ectodomain have been indicated in antibody 
binding and T cell recognition (described later). 
1.2.3. Virus life cycle 
The HCV entry into host cells (fully described in section 1.3.1) occurs via attachment to 
set of co-receptors, endocytosis and pH dependent membrane fusion. Capsid released 
from endosomal body is unpacked and genome RNA is released into the cytosol [5, 81]. 
The HCV RNA of positive polarity serves as mRNA and its translation is dependent on 
Internal Ribosome Entry Site (IRES) which directly interacts with 40S ribosomal 
subunit [33]. Translation occurs on cytoplasmic side of rough Endoplasmic Reticulum 
(rER). HCV proteins, released from the polyprotein by host and viral proteases, form a 
membranous web anchored in ER (see Figure 1.5) where HCV genomes are amplified 
and further encapsidated into new viral particles [81]. The HCV capsids of about 50nm 
consist of multimeric form of Core protein and viral RNA. They are enveloped in lipid 
bilayer harbouring glycoproteins E1 and E2 [5, 38]. The mature virus particle has been 
described to be between 50 and 80 nm in size.  Other proteins: p7, NS2 and NS4A have 
been reported to take part in the assembly process (reviewed in [38]). Viral assembly 
and release are thought to occur in tight association with lipids. Several host factors 
related to VLDL metabolism have been indicated in the process which supports the 
hypothesis of HCV existing as a Lipo-Viral Particle [38, 82]. Schematic of HCV life cycle 
is presented in Figure 1.10. 
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Figure 1.10. Hypothetical Hepatitis C Virus lifecycle [83].  
HCV virions bind to the host cell and are internalised via interaction with a set of 
coreceptors (described further in text). After uncoating of the genome translation occurs on 
membranes of rough ER and HCV proteins induce formation of membranous web (bottom 
inset) which is thought to be a scaffold for replication machinery. The middle inset depicts 
model of HCV genome replication with double stranded replicative form (RF) and 
replicative intermediate (RI). Progeny virions are assembled on ER membranes in 
connection with lipid droplets (not shown here and described in further chapters). Model of 
HCV virion is presented in top right inset. 
  
18 Introduction 
1.3. Host factors and their interplay with HCV 
1.3.1. Cellular receptors and HCV entry 
Since the discovery of HCV, several cell surface molecules have been proposed as 
receptor candidates. The first step in viral entry is attachment to host cell membrane 
followed by endocytosis and then pH- dependent fusion of membranes. It has been 
proposed that entry events occur in detailed sequence and that cell surface molecules 
interact with HCV glycoproteins at different stages of the entry process (presented 
inFigure 1.11).  
1.3.1.1. Molecules involved in attachment 
Initial attachment of HCV Viro-Lipo particles, viral particles made of core protein and 
envelope glycoproteins E1 and E2 in association with lipoproteins, has been reported 
to engage factors like lectins [52, 84, 85], lipoprotein receptor [86, 87] and 
glycosaminoglycans [88]. 
Classical C-type lectins act as adhesion molecules and pathogen recognition receptors 
that uptake, internalise and lead to elimination of pathogens. Some viruses have been 
shown to evade degradation and use C-type lectins as entry receptors. Both L-SIGN and 
DC-SIGN have been shown to capture different forms of HCV glycoproteins and 
transport them to neighbouring permissive cells [52, 84, 85]. Their ectopic expression 
does not sustain permissiveness so it has been proposed that they contribute in virus 
capture and delivery to hepatocytes [52, 84, 85].  
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The low-density lipoprotein receptor plays a role in lipid uptake and metabolism, and 
has been indicated in cell attachment for a number of viruses [86]. It preferentially 
binds to low density lipoproteins (LDL) and very low density lipoproteins (VLDL) 
which were shown in complex with HCV [38]. Indeed data suggests that attachment of 
HCV to host cell involves low- density lipoprotein receptor as one of the factors [86, 87, 
89]. 
Glycosaminoglycan [90] chains, although present on surface of many cells, differ in 
their composition between various cell types [91]. Heparan sulphate has been indicated 
as primary docking structure for attachment of viruses including a member of the 
Flaviviridae - Dengue virus [92]. Structural analyses of the glycoprotein E2 derived 
from various HCV strains reported conservatism of positively charged amino acids in 
HVR1 necessary for interaction with GAGs, and were followed by demonstration of the 
E2 interaction with heparan sulphate [88, 93]. 
1.3.1.2. CD81 
CD81 was identified as a first putative HCV receptor by using soluble E2  (sE2) as a bait 
for possible interaction with surface molecules [94]. CD81 belongs to the tetraspanin 
family. It contains four transmembrane domains spaced with short intracellular loops 
and two extracellular loops- small and large (SEL and LEL). The latter one contains 
specific binding regions for E2 [95] 
Initial data on the CD81- HCV interaction had to be treated cautiously as it was mostly 
obtained in studies with soluble E2. This truncated form of E2 has structural 
differences in comparison to the full-length E1E2 heterodimer [96]. It was proposed 
that E1 affects structure and properties of E2 which suggest that results obtained in 
studies with sE2 might not truly reflect the HCV-CD81 interaction [96]. Studies 
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performed with HCVpp (HCV pseudo particles) and HCVcc (cell culture HCV) showed 
that anti-CD81 antibodies and recombinant soluble CD81-LEL inhibit infection of 
hepatoma cell lines [97, 98]. HepG2 cells, which do not express CD81, are not 
permissive for HCVpp and HCVcc. Ectopic expression of CD81 in the HepG2 line makes 
it susceptible to HCV infection providing additional proof of CD81 engagement in virus 
entry to cells [97, 99]. Two out of four disulfides in CD81-LEL are required for 
interaction with E2 [100]. The predominant site of replication and infection by HCV is 
liver and indeed HCVpp show tropism limited to liver cells expressing human CD81 
[101]. A tetraspanin web- in which members of tetraspanin family interact with non 
tetraspanin molecules, is cell-type specific regarding its composition [102]. Moreover 
Bitzegeio et al. determined species specific determinants residing in CD81 and using 
these adapted mouse CD81 for HCV entry [103] 
Receptor competition studies suggest that CD81 plays a role after viral attachment [84, 
104]. Although tetraspanin members are known to play part in membrane fusion, CD81 
does not seem to mediate endocytosis as it undergoes poor trafficking from cell surface 
to vacuolar web [100].   
1.3.1.3. SR-BI 
SR-BI is a membrane protein with a large extracellular domain separating two 
membrane-spanning domains and short terminal internal domains. It is involved in 
metabolism of lipids acting as a lipoprotein receptor and has been found to interact 
with HCV [79]. As in the case of CD81, SR-BI was initially characterised by binding with 
sE2. That interaction has been shown to be selective, as neither closely related human 
scavenger receptor CD36, nor mouse one was able to bind sE2 [79]. SR-BI binding is 
dependent on presence of hypervariable region 1 (HVR1) at the N-terminus of sE2 and 
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can be blocked by anti-HVR1 antibodies [79, 97]. However, interaction of this molecule 
with the E1E2 heterodimer has not yet been demonstrated, studies with HCVpp are in 
agreement with SR-BI engagement in HCV entry [97, 105, 106]. Lipoproteins were 
indicated to mediate HCVpp entry via SR-BI [106], however different regions of SR-B1 
are responsible for HCV and HDL recognision [105] indicating that initial lipid 
mediated binding could be followed by E2-SR-BI interaction. Experiments performed 
with use of HCVcc showed that SR-BI is engaged in a post attachment step closely 
linked with CD81 [107]. 
1.3.1.4. Tight junction proteins 
Claudin-1 (CLDN-1) is a tight junction protein that spans plasma membrane four times. 
It has been recently described as HCV entry coreceptor [108]. Evans et al. showed that 
this receptor is crucial for HCV infection of hepatoma cell lines and confers 
susceptibility when ectopically expressed on cell lines non-permissive to HCV [108]. 
Recent study shows that cell type specific claudin localisation might influence cellular 
tropism of HCV [109]. Residues within the first extracellular loop of claudin-1 were 
mapped as critical for HCV entry [110]. Alanine substitutions in these highly conserved 
motifs impaired claudin-1 cell-to-cell contact, which further supports importance of 
claudin localisation and/or function in tight junctions for HCV entry process [110]. 
Additional members of the family: claudin-6 and claudin-9 have been identified as HCV 
entry coreceptors [111]. Further study localised claudin-1, in association with CD81, at 
the basolateral surface of hepatoma cells [112] and demonstrated role of these 
complexes in HCV infection that would be consistent with sinusoidal vessels as route of 
infection.  
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SR-BI and CLDN-1 were attributed to have influence on species specificity of HCV. 
However, until another tight junction protein, occludin (OCLN), has been demonstrated 
in context of HCV entry process [113], only CD-81 was proved to be responsible for 
restricting the infection to human and chimpanzee cells [103]. OCLN expression on 
human cells was demonstrated as a requirement for human cells susceptibility to HCV 
[114]. Overexpression of OCLN on non-permissive cells renders them susceptible to 
HCVpp infection and silencing of the receptor in permissive cells hampers HCVpp and 
HCVcc entry [114]. Similarly to CD81, OCLN has to be of human origin to support 
efficient entry, and determinants of species specificity are located in its second 
extracellular loop [115].  
1.3.1.5. pH mediated endocytosis 
In summary the HCV entry is postulated to be primed by attachment of viral particles in 
complex with lipoproteins to GAG and/or LDLr. This step is thought to be followed by 
interaction with CD81 and SR-BI. Late entry steps include binding to tight junction 
proteins. Then receptor- virus complexes undergo internalisation via clathrin mediated 
endocytosis [73, 116]. Upon delivery of clathrin-coated vesicles to endosomes, pH 
change triggers membrane fusion and lipoproteins and particles bound to them are 
released [117].  Fusion domains have not yet been exactly mapped, however envelope 
glycoprotein heterodimers are thought to mediate the membrane fusion (described in 
1.2.2.2) in a fashion shared by Flaviviridae members [74]. 
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Figure 1.11. Schematic representation of current hypothesis on HCV entry and 
endocytosis via interplay of envelope glycoproteins and lipoproteins with a set of cellular 
receptors [118].  
Individual steps marked in this figure are described in text (1-attachment, 2- binding to 
CD81 and SR-B1, 3- interaction with CLDN and OCLN, 4- endocytosis and membrane fusion). 
1.3.2. Host factors and immune response 
HCV infection triggers complex antiviral responses and the interplay of viral and host 
factors results in either virus eradication or persistence. In recent years more light has 
been shed on particular steps of this interplay; however there is much to be discovered 
before we understand the mutlifactorial host and viral determinants that underlie HCV 
infection. 
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1.3.2.1. Innate immune response 
The HCV firstly affects signalling pathways leading to production of type I interferon 
and interferon stimulated genes (ISGs). HCV appears to be able to down regulate these 
signalling pathways and block their interfering activity [9]. Although much has been 
learned, the full mechanism by which HCV establishes persistence is not yet known 
(further described in section 1.5.4). 
Innate immune responses are transiently activated by high level of HCV RNA [119]. 
Initiation occurs through pathogen- associated molecular patterns (PAMP) that are 
recognised by 3 major classes of pattern recognition receptors (PPRs) [120]. These are: 
toll like receptors (TLRs), nucleotide oligomerisation domain-like receptors (NLRs) and 
retinoic acid-inducible gene-I (RIG-I) like receptors (RLRs). Their function is partially 
regulated by their cellular localisation. RLRs and NLRs are present in cytoplasm of most 
cells whereas TLRs are located on endosomes and cell surface. 
NRLs are thought to be majorly involved in recognition of bacterial PAMPS and their 
role in antiviral response is not well described [121]. TLRs identified to take part in 
antiviral detection include TLR 2, 3, 4, 7/8 and 9. Their activation effects in production 
of proinflammatory cytokines and IFN-Ƚȋ[122]). Main target cells for the 
HCV- hepatocytes are deficient in TLR signalling [123]. RLRs are expressed in vast 
majority of cells (including hepatocytes) which strongly suggests their role as primary 
cytoplasmic detectors of the HCV infection [124]. RLR family consists of RIG-I (retinoic 
acid- inducible gene- I), MDA5 (melanoma differentiation- associated gene 5) and LPG2 
(laboratory of genetics and physiology 2) [124]. These receptors have a RNA helicase 
domain binding RNA ligands and 2 N-terminal caspase activation and recruitment 
domains [125]. RIG- I has been shown to detect specific set of ssRNA viruses including 
flaviviruses [124, 126]. 
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Interferon regulatory factor 3 (IRF3) is a transcription factor expressed in cytoplasm in 
an inactive form. Transfection of HCV RNA into human hepatoma cell lines triggers 
activation of IRF3 by C-terminal phosphorylation, followed by its dimerization and 
transport to nucleus. There transcriptional activation of several ISGs occurs [127]. RIG- 
I deficient cells do not show such effect upon transfection, but it can be restored with 
functional RIG- I [128]. This suggests that RIG- I is necessary part of pathway leading to 
IRF3 activation by HCV and might be the primary intracellular sensor of the virus. 
Another factor activated by HCV transfection is IFN- Ⱦ[127]. IFN-Ⱦ
neighbouring cells to induce ISGs as well. These ISGs include some of anti-HCV nature- 
like protein kinase R (PKR) and ISG56 that prevent translation of viral proteins [129]. 
RIG-    ǡ  ?ǯ ȋȌ  ǡ   
motifs that are rich in uridine or adenosine [130]. As HCV RNA is not capped it   ?ǯ Ǥ         ?ǯ
containing poly U region has been recognised as the primary HCV PAMP detected by 
RIG- I [127, 128]. Different HCV strains have been tested and unsurprisingly genotype 
2a strain JFH1 proved to be a weak RIG- I activator, which could in part explain this ǯ  [130]. It is not yet clear at which point of HCV replication, and in 
which exact cellular location, the activation of RIG-I happens but it proves to be the key 
element in innate intracellular anti-HCV response. HCV has been shown to evade 
interferon response by subverting RIG-I pathway by NS3/4A protease cleavage of 
specific adaptor proteins [131-133]. In the early hours post HCV infection liver cells 
relocalise IFN-3 to nucleus. NS3/4A cleaves interferone promoter stimulator-1 (IPS-1) 
and prevents downstream signal pathway of IFN-3 and NF-ߢB which abrogates 
production of IFN- and ISGs [133].  
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1.3.2.2. Adaptive immune response 
HCV reaches high titres in serum of infected patients in period as short as 1 week post 
infection [9]. Compared to the speed of HCV propagation, adaptive immune responses 
are relatively delayed. Adaptive cell responses are activated relatively late [9, 25, 134]. 
Lack of clinical symptoms like jaundice (caused by T-cell mediated liver injury) might 
be related to the delay in immune activation by HCV.  Interestingly symptomatic 
infection correlates with the virus clearance. About 8-14 weeks into acute infection, 
alanine aminotransferase (ALT) level peaks. High levels of ALT are associated with liver 
damage. At the same time production of adaptive immune components is unregulated 
and HCV RNA titres fall [9, 25, 134]. This is followed by seroconversion and detection 
(in some cases) of anti-HCV antibodies. This event does not always correlate with 
outcome of infection. Around 20% of patients spontaneously clear the virus[135]. 
Clearance has been positively correlated with both- strong cell and humoral response, 
but exact determinants of clearance are not well defined.  
It has been reported that spontaneous eradication of HCV is correlated with a strong 
cellular immune response [136-138]. HCV specific T cells can be detected in blood 
around 5-9 weeks and in liver 6-12 weeks post infection. As compared to anti HBV cell 
response, anti HCV is not only delayed but also impaired on the level of proliferation, 
cytotoxic activity and IFN- ɀ production [9, 138]. All this might contribute to low rate of 
viral clearance.  
As already mentioned, anti-HCV antibodies arise relatively late in the infection or in 
radical cases not at all. Moreover they show restricted isotype profile and can 
disappear after recovery [139]. Antibodies specific to envelope glycoproteins E1 and E2 
have been a major focus point [118, 140, 141]. It was shown that these antibodies can 
neutralise HCV pseudoparticles [101], and also protect chimpanzees from homologous 
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infection [142]. Unfortunately most of the neutralising antibodies tested so far seem to 
be strain specific and it can take as long as a year post infection for cross-reactive Abs 
to arise [143]. However our group and others described widely cross- reactive 
antibodies [141, 144, 145], which sustains their importance in HCV eradication 
strategies. The highest levels of neutralising antibodies are present in chronically 
infected patients, whereas resolved individuals do not maintain anti- HCV antibodies 
permanently [101]. 
1.4. Treatment 
1.4.1. Current therapy 
Current anti-HCV standard of care (SOC) is based on combination of PEG-IFN and 
ribavirin for a period of between 12 and 48 weeks. Interferons (IFN) were identified in 
1957 after it was shown that cells infected by viruses secrete a factor protecting 
neighbouring cells against infection. Humans produce three types of IFNs: IFN-ȽǡȾ and ɘare classified in type I, IFN-ɀ is type II, and IFN-ɉ. Binding of IFN to cellular 
receptor triggers rapid expression of interferon-stimulated genes (ISGs), such as genes 
coding for MHC particles of class I and II, receptor for Fc of IgG, chemokines, protein 
kinase R [146, 147].  
HCV seems to be easier to eradicate by treatment on early stages of disease. However, 
infections tend to be detected in chronic phase, usually years after HCV exposure when 
liver damage cannot be reversed. According to recent estimations, the current therapy 
is successful in more than 50% cases [147]. 
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Currently, pharmaceutically produced IFNs are recombinant proteins obtained from 
cell culture systems. IFN with polyethylene glycol (PEG-IFN) shows longer lasting 
action and better absorption by cells. An additional compound that is used in anti-HCV 
therapy is the nucleoside analogue ribavirin. Ribavirin triphosphate is used by 
polymerase as GTP or ATP analogue during transcription. In HCV treatment ribavirin as 
mono-therapy failed to eradicate virus, however showed to enhance therapeutic effect 
when combined with IFN.  However, many associated side effects and not satisfactory 
rate of success leaves room for improvement to this therapy regimen [147]. 
1.4.2. Differential responses to combination therapy 
Combination therapy has a significant clinical toxicity, which in many cases prevent 
completion of the regime. Differences in virological responses have been reported to 
correlate both with viral and patient related factors. Individuals harbouring genotype 2 
or 3 HCV are more likely to clear the virus as compared with genotype 1 infected ones 
[148, 149]Ǥ     ǯ    ated with 
treatment outcome. Prognosis seems to be worse for males than women and 
individuals of African origin as compared with Caucasians. Other negative prognostic 
factors include high levels of liver fibrosis, age over 50 years, BMI (Body Mass Index) 
over 25 [150, 151]. 
Recently published independent genome-wide association studies revealed a genetic 
polymorphism suggested to be linked with treatment response [152-154]. These 
studies have been carried out in populations of Japanese [154], Australian [152], and 
American patients [153]. In the latter individuals of European and African ancestry 
were included. Several Short Nucleotide Polymorphisms (SNPs) located near the IL28B 
gene, which encodes interferon-ɉ-3, strongly associate with differential response to 
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anti HCV treatment. Suppiah et al. [153] note, that genotype observed to lead to a better 
response to treatment is more prevalent in European populations, which might explain 
previous findings of better sustained virological response (SVR) for patients of 
Caucasian origin. Together these data imply that host genetic make-up has implications 
for prognosis of anti-HCV treatment response. 
1.4.3. Direct acting antivirals and potential vaccine design 
The limited success rate and severe side effects of PEG-IFN and ribavirin therapy 
generated rising interest in direct acting inhibitors of HCV life cycle. In recent years, 
following development of HCV cell culture system and resolution of tertiary structure 
of some of HCV proteins, putative targets for direct-acting antiviral agents have been 
identified. Figure 1.12 depicts HCV life cycle as a chain of sequential steps of which 
everyone offers a target for direct-acting drugs [155]. Many promising families of drugs 
have been identified in in vitro tests, some reaching clinical phase trials. Two families of 
molecules have been the biggest focus of antiviral strategies: inhibitors of NS5B RNA 
dependent RNA polymerase and inhibitors of the NS3/4A protease [155-157]. 
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Figure 1.12. HCV life cycle- each steps representing potential target for antiviral therapies 
[155]. 
1.4.3.1. Protease inhibitors 
Posttranslational processing of the HCV polyprotein engages a number of host 
peptidases and two viral proteases. The NS3/4A protease is responsible for cleavage at 
the NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B sites [42]. Research in 
developing NS3/4A protease inhibitors has seen the biggest success so far with two 
drugs: Telaprevir and Boceprevir being approved in Europe and United States in 2011 
[157]. Monotherapy, despite showing high antiviral potential, is linked with 
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development of resistant HCV variants, often ending in viral relapse. However- 
protease inhibitors administered in combination with PEG-	Ƚ
sustained virological response in both: treatment naïve patients and individuals who 
have previously undergone unsuccessful therapy [157].  
Telaprevir is an orally administered linear, ketoamide protease inhibitor. This DAA was 
initially assessed in monotherapy with patients harbouring genotype 1 HCV. Median 
viral load decline of 4.4 log10 IU/ml HCV RNA was achieved with a dose of 750 mg 
every eight hours [158]. Unfortunately viral breakthrough with arising resistant 
variants was observed in majority of treated individuals [159]. Many subsequent short 
and long term trials of Telaprevir in combination with PEG-	 Ƚ  
achieved more pronounced viral decline with reduced resistance profile (reviewed in 
[157]). Trials with ribavirin removed from treatment were not as successful, 
highlighting the importance of ribavirin in the drug combination. 
Trials with Boceprevir, another ketoamide NS3/4A protease inhibitor, in genotype 1 
infected patients that underwent earlier treatment showed HCV RNA reduction up to 
2.88 log10 IU/ml [160]. Similarly as for Telaprevir resistance profiles were discovered 
as well as reduced potency against HCV genotype 2/3 [157].  
Newly developed HCV protease inhibitors are currently being tested, with some in 
phase 1 and 2 clinical trials, all seem to exhibit similar SVR rates as described here 
Telaprevir and Boceprovir. Newly developed protease inhibition strategies could 
potentially overcome some of the side effects and, when used with SOC, reduce 
premature termination of treatment. Ritonavir, a compound enhancing a number of 
protease inhibitǯ         
pharmacokinetics [157]. 
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1.4.3.2. Polymerase inhibitors 
Replication being a complex multifactorial process offers many possible targets for 
antiviral interference. Most common approaches include nucleoside and non-
nucleoside inhibitors of HCV polymerase and cyclophilin B inhibitors. Nucleoside 
polymerase inhibitors target the enzyme active site. Non-nucleoside molecules 
interfere with allosteric sites within RdRP. Drugs inhibiting cyclophilin B alter its 
ability to modulate RNA binding capacity of the viral polymerase [155]. 
Conservatism within NS5B active site is an obvious advantage in development of 
nucleoside inhibitors which so far are the only DAA in clinical trials conferring broad 
cross-genotype activity. Up to date several compounds targeting NS5B have been 
reported to induce a promising early virological response. Although they do not induce 
a mutational breakthrough, unfortunately most have severe adverse effects and their 
development has been put on hold [157]. 
Among the nucleoside polymerase inhibitors under trial a cytidine analogue- 
Mericitabine (RG-7128) is most developed and promising. In monotherapy the 
compound decreased HCV RNA levels by 2.7 log10 and when used in addition to SOC by 
5 log10 IU/ml [161]. Observed viral resistance to Mericitabine is marginal. The 
compound is processed in kidneys without liver metabolism being involved and severe 
side effects have not been recorded [156]. 
The structure of HCV polymerase,    ǯ ǡ  
compromised by non-nucleoside inhibitors. Four allosteric sites have been mapped as 
potential targets- two sites in thumb like domain and two in palm like domain [155, 
157]. Benzimidazoles target thumb-1 domain, thumb-2 domain interacts with 
thiophenes. Palm-1 domain binds benzothiadiazines, palm-2 is targeted by 
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benzofurans. Drugs representing all above classes have entered clinical trials stage, 
however, resistant mutations are selected more frequently than for the nucleoside 
NS5B inhibitors. This is thought to be due to the non-nucleoside inhibitors binding sites 
being located away from the active site [157]. 
1.4.3.3. NS5A inhibitors 
Recently much focus has been directed to NS5A inhibitors. NS5A having no known 
enzymatic activity for many years was considered less often for a target of direct acting 
antivirals. However in 2010 Gao et al. [162] reported development of BMS-790052, a 
small molecule inhibitor of NS5A. In vitro this molecule showed picomolar potency 
against a wide range of genotypes [162]. This molecule, also known as Daclatasvir, 
inhibits HCV RNA replication via interaction with NS5A, a crucial component of HCV 
replication complex [163]. Further studies showed that small molecules targeting NS5A 
influence subcellular localisation of this protein relocalising it from ER to lipid droplets 
[164]. Combination therapies of daclatasvir with NS3 inhibitors [165], or with IFN-Ƚ
and RBV [166] have shown promising results in early clinical phases. 
1.1.3.1. HCV cell entry as a possible antiviral target 
Currently developed DAAs focus on non-structural protein targets and intracellular 
steps of HCV life cycle. From a mechanistic point of view HCV entry offers another 
attractive target for inhibition, encompassing multiple steps of virus-host interactions.  
To date several receptors have been defined as factors interacting with HCV envelope 
glycoproteins in a proposed concerted process of attachment, endocytosis and 
membrane fusion (described in 1.3.1). In vivo, inhibition of HCV entry process has been 
demonstrated for neutralising anti-E2 antibodies [141, 144], antibodies targeting 
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receptors: CD81 and SR-BI [97, 107, 167], cyanovirin-N [168], compound affecting E2 
glycosylation and molecules preventing pH dependent endocytosis [73]. Studies 
performed in chimeric Alb-uPA SCID mice have proved that neutralising antibodies can 
protect against HCV infection [169], similar results were reported for chimpanzees 
[170]. Small synthetic molecules targeting the entry process were also found and are at 
various pre-clinical stages of development [171]. So far only anti-envelope antibodies 
have reached the clinical trials phase [155].   
Entry being the first and crucial step in viral life cycle offers a chance for a prophylactic 
compound design. However, high variability of E1E2 glycoproteins coupled with 
asymptomatic progress of acute HCV infection might hamper the design of successful 
entry inhibitors. This highlights the importance of studies focusing on early stages of 
infection and HCV glycoprotein evolution under differing selective pressures present in 
infected host. 
1.4.3.4. Vaccines 
Viral evasion is a complex process engaging both host and viral factors; hence 
identification of protective immunity has been elusive. Although HCV in majority causes 
a chronic infection, neutralising antibodies and robust T cell immune responses have 
been correlated with viral clearance and thus point out a possibility of designing both 
preventive and therapeutic vaccines. Major concern in vaccine development is selection 
for escape mutants. A key issue in designing a HCV vaccine is the choice of target 
antigens. It is thought that an effective vaccine design will have to elicit both strong and 
broad cross reactive T cell, as well as neutralising antibody response to clear or prevent 
HCV infection.  
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Currently several classes of vaccines are being tested in clinical trials. Recombinant 
proteins are generated by isolation of the sequence coding for viral antigen and cloning 
into a heterologous expression system.  Proof of concept behind prophylactic value of 
recombinant proteins was gained with the successful Hepatitis B vaccine [172]. This 
vaccine consists of HBV surface antigen produced in yeast cells and elicits protective 
antibody response. Contrary to HBV, HCV envelope glycoproteins are highly variable, 
especially in antibody binding regions. However, vaccines targeting envelope were 
designed and Phase I study of a recombinant E1/E2 vaccine with adjuvant MF59 
reported [173].  In this study subjects tolerated the vaccine well and showed both 
neutralising antibody and T-cell proliferation in response to antigen [173]. A core 
derived vaccine ISCOMATRIX® [174] was reported to elicit specific humoral response 
in subjects receiving the highest dose. Due to very low level of HCV-specific T cells 
being detected this vaccine was proposed to be evaluated in a therapeutic approach. 
Synthetic peptide vaccines are designed to induce HCV specific immune response by 
directly presenting vaccine epitopes to the T-cell receptor via HLA molecules. Amongst 
synthetic peptide vaccines IC41 (Intercell AG, Vienna, Austria) has progressed furthest. 
This vaccine is composed of five synthetic peptides containing four, highly conserved 
HCV epitopes that are prevalent in genotypes 1 and 2. When administered in healthy 
volunteers, IC41 adjuvanted with poly-L-arginine was well tolerated [175]. When given 
to HCV infected individuals, this vaccine has effectively elicited HCV-specific Th1/Tc1 
responses. However this response did not have a significant effect on HCV viral load 
[176] suggesting that further optimisation is necessary.   
An interesting approach to peptide based vaccine was presented by a Japanese group 
[177]. HCV infected patients were administered a peptide vaccine in stages, with 
personalised vaccination at the follow up stage, consisting only of these peptides that 
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were successful in eliciting immune response after first immunisation. Significant 
decrease of serum HCV RNA level was reported for 8 out of 12 study subjects [177]. 
Vector based vaccines have been an appealing concept as contained immunogens are 
not HLA restricted and can be of a broader spectrum than those within peptide 
vaccines. A highly attenuated poxvirus strain: Modified Virus of Ankara (MVA) lacking 
several immunomodulatory genes has previously been used as a vaccine platform for 
HIV [178]. Phase I trial of a MVA vector vaccine TG4040, containing NS3, NS4 and NS5B 
antigens, showed it was well tolerated [179]. In five out of 15 patients viral load 
reduction was observed (0.5-1.4 log) and associated with increase in T-cell response 
[178]. A trial of TG4040 in combination with SOC has been proposed. Recombinant 
adenoviral strategies delivering HCV NS3 to NS5B proteins are also tested in Phase I 
trials [180]. Two vectors Ad6 and AdCh3, to which humans are rarely exposed hence 
would not possess adenoviral specific antibodies, are used.  
Another strategy in developing a T cell based vaccine is DNA vaccination. A Swedish 
company Tripep AB has recently produced a codon optimised, CMV promoter 
controlled, NS3/4A DNA gene vaccine [181]. This well tolerated vaccine has reduced 
HCV RNA load in four patients out of 12, which coincided with production of HCV 
specific T cell responses in three of them. These trials proved that electroporated in 
vivo DNA-therapeutic vaccination against HCV was a viable concept and further trials 
should be undertaken. 
Although HCV has remarkable ability to persist and lead to chronic infection, a robust 
cellular and humoral response leading to virus eradication can be produced. A vaccine, 
to be effective, will have to elicit such broad and cross-reactive immune response. To 
date only few emerging vaccine constructs have entered clinical trials and their 
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reported success rate is limited. However, various approaches can be pursued, one 
being use of the therapeutic vaccines as additives supporting SOC. 
1.5. Evolution of HCV 
HCV has been classified into 6 genotypes consisting of many subtypes and further 
characterised by remarkable strain variability [7]. Recent years had shed some light on ǯ   ǡ
intrahost level. However further studies are required to uncover reasons for HCV 
success in establishing chronic infection and possible ways of clearing the virus. 
1.5.1. Origin of HCV genotypes 
In the absence of historical data regarding time of Hepatitis C Virus occurrence its 
evolutionary origin can only be estimated by means of phylogenetic data analysis of 
sequences collected over last 20 years. Whilst some regions of the HCV genome can be 
easily used for such analyses, there are parts of genome that show greater and more 
rapid variability. These are mainly E1 and E2, with typical difference between 
genotypes of about 50% [11]. Some of the variability observed can be explained by 
Darwinian selective pressure. Envelope glycoproteins, especially hypervariable regions 
may be a target for neutralizing antibodies and virus sequence change effects in 
immune evasion and persistence of infection [182, 183].  
Phenotypic differences between genotypes have been described for HCV. The most 
striking is the differing response to interferon treatment. On average, only 40-50% of 
chronically infected patients harboring genotype 1 HCV show long term response to 
combination treatment, as compared to 70-80% in those infected with genotype 2 or 3 
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[148, 149]. So far the exact mechanism underlying this difference has not been 
established. Less clear-cut are differences in HCV pathogenicity. There is some evidence 
to suggest that patients infected with a heterogeneous genotype 1 population are more 
likely to establish a persistent infection that goes on to develop severe liver disease 
[184, 185]. However, these issues need clarification via more in-depth longitudinal 
evolutionary studies coupled with phenotypic characterization. 
Divergence of HCV genotypes has proved difficult to establish. Previously reported 
short times of origin contradict the high prevalence and diversity of HCV across the 
globe. Simmonds [186] has reviewed some of the divergence times that seem to 
correlate with historical evidence. Diversity amongst 1b unrelated sequence indicates a 
divergence time of about 60-70 years [11] which is supported by lack of geographical 
groupings of subtypes. Time of origin of genotype 2 has been predicted to be 90-150 
years [11].  Relatively recent divergence of genotypes like 3a which is common for IDUs 
is consistent with their rapid spread via shared needles in 1960s [11]. Current 
phylogenetic analysis of genotype 4a in Egypt is compatible with its mass spread 
through treatment of schistosomiasis with non- disposable needles in 1950s. [187]. 
Smith et al. [188] estimate the time of HCV genotypes origin greater than 500 years ago. 
However recent studies appear to correctly describe the spread of HCV it is worth 
noting that sequences collected over last two decades might not be sufficient. 
1.5.2. HCV intrahost population diversity and quasispecies 
dispute 
HCV exists as a viral intrahost population and evolution of the variants results in virus 
immune escape and establishment of a persistent viral infection. The high rate of 
mutation is a direct effect of the low fidelity of the RNA dependent RNA polymerase 
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[189, 190]. It is known that random nucleotide substitutions occur at a very high rate. 
In chronic infection the mutation rate is 1.5-4.0x10-3 per site per genome per year [188, 
191, 192]. Variability is not distributed evenly through the genome, instead it is 
concentrated in regions like the E1E2 glycoproteins [182]. Although positive selection 
has been described, much of the observed HCV genetic diversity can be attributed to 
neutral sequence drift [189, 190, 193]. 
Sequence drift underlying diversification has been of major interest. The neutral theory 
of evolution suggests that changes should occur at a constant rate and represent 
accumulation of neutral changes [194]. Studies revealed that in coding regions of the 
HCV genome changes occur predominantly at synonymous sites [16, 189]. Some of the 
variability observed can be explained by Darwinian selective pressure. The relative 
pressure at a locus can be represented by the ratio of nonsynonymous to synonymous 
mutations [16]. Envelope glycoproteins, especially hypervariable regions may be a 
target for neutralizing antibodies and virus sequence change effects in immune evasion 
and persistence of infection [182, 183]. The nature and rate of substitutions in E1E2, 
especially in HVR1 during acute infection, has been demonstrated to correlate with 
disease outcome [80, 195]. Eradication of the virus in acute infection correlates with a 
stable HVR1 sequence population whilst chronic infection is associated with rapid 
evolution of the intrahost variants [193]. Although HVR1 is highly variable some sites 
exhibit extreme negative (conservatory) pressure, suggesting a key biological role for 
these region. [196]. 
Previously mentioned Farci et al. reported that diversity of HVR1 sequences was 
predictive of HCV infection outcome [80]. More diverse HVR1 seqences in acute 
infection correlated with progression to chronicity and less diverse HVR1 with resolved 
infection. This was described as evidence of HCV acting as a quasispecies [80]. 
However, term quasispecies is not a surrogate for genetic diversity; quasispecies 
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theory predicts that the population as a whole is a target for selection rather than 
individual variants from within the population [197-199]. To date there has been no 
experimental data which confirms that HCV behaves as a classical quasispecies. So far 
the only experimental data supportisng quasispecies theory in viruses was delived by 
Vignuzzi et al. [200]. Using artificially expanded Polio virus populations a link between 
viral population complexity with disease pathogenesis in experimentally infected mice 
was demonstrated. However quasispecies behaviour has yet to be definitively 
demonstrated in naturally occurring viral populations.  
1.5.3. Transmission as an evolutionary event 
The transmission of HCV can occur by different routes. Prior to discovery of non-A-non-
B hepatitis and establishment of robust blood screening techniques major source of 
new infections was via transfusion of contaminated blood or blood products [13, 201, 
202]. Transmission between sexual partners has been reported  [203, 204] but risk of 
infection was correlated stronger with injecting drug usage than sexual behaviours 
[204]. Both horizontal and vertical intrafamilial cases of HCV seem to be mostly 
associated with parenteral route of infection [205]. However transmission has also 
been reported to occur before birth [206]. Although nosocomial and iatrogenic risks of 
HCV infection have been reduced in industrialised countries they are still prevalent in 
countries like Egypt where estimated 500 000 new infections occur yearly [207]. Major 
risks of HCV infections in countries with well-developed screening procedures are 
associated with injection drug usage [208, 209] but occupational risk of infections like 
through needle-stick are still present [210, 211].  
Modelling events of transmission and acute HCV infection is challenging due to 
difficulty of virus detection at the earliest stages (patients are usually asymptomatic). 
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Most studies of acute HCV infection were lacking samples from donor populations to 
assess the dynamics of viral transmission. Studies in experimentally infected 
chimpanzees present many drawbacks and limitations. Research utilising 
immunocompromised mice with human liver grafts may provide a more robust model 
to enable study of HCV envelope glycoprotein evolution at transmission.  
The majority of previous reports of HCV sequence evolution upon transmission have 
focused on the hyper variable region 1 (HVR1) at the N-terminus of E2 [90, 193, 212]. A 
number of groups have reported that identical HVR1 variants occur in donor/recipient 
pairs during viral transmission events tracked in both humans and chimpanzees [213-
217]. Moreover, HVR1 variants can remain stable for several years after transmission 
in humans [13, 213], during transmission from human to chimpanzee [215, 217] and 
after further passaging of the virus in chimpanzees [217]. However differences were 
observed in dynamics of HVR1 evolution between different individual recipients of HCV 
transmission events [13, 212, 213], reflecting variable fitness requirements provided 
by different selective environments. The low intrapopulation genetic divergence of 
viral sequences observed in window phase of HCV infection [218] suggests that 
selective amplification or selective transmission occurs. HIV-1 transmission studies 
demonstrated that productive infection can be achieved by a single virus after 
heterosexual transmission [219, 220]. In contrary, in men who have sex with men 
multivariant transmission was observed to initiate HIV-1 infection [221]. Up to 16 
variants were reported to establish infection in intravenous drug users, amongst which 
60% of infections are attributed to multivariant transmission [222]. Transmission data 
regarding establishment of HCV infection is limited. However, deep sequencing 
technologies have been used to analyse viral genetic complexity in serial samples from 
patients undergoing acute HCV infection [223]. Contrastingly, these analyses report 
that HVR1 is highly variable at the intra-host level in acute infection. They also 
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demonstrate productive infection is achieved by a single or just a few viral particles, 
indicating a bottleneck at transmission [224].  
The exact mechanism of HCV persistence is not known but the evolutionary adaptation 
of the virus to host selective pressure seems to play the crucial role. Adaptations in the 
founder virus population are shaped by equilibrium of beneficial factors and possible 
fitness costs of substitutions. The envelope glycoproteins have been of major interest as 
the viral proteins most readily in contact with host cells and the immune system. Their 
adaptation was suggested to be driven two ways. Substitutions allowing immune 
escape may be beneficial only if the adapted glycoproteins retain phenotype necessary 
for receptor binding and cell entry (see schematic model in Figure 1.13). Elucidating 
the evolutionary mechanisms underlying HCV transmission events and persistence of 
the infection will have implications for designing antiviral strategies targeting the HCV 
entry process. 
 
Figure 1.13. Representation of hypothesis of E1E2 glycoproteins evolution being driven 
by immune pressure and limited by conformational restraints of interactions with entry 
receptors. 
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1.5.4. Establishment of chronic HCV infection 
The turning point between acute and chronic phase of HCV infection and factors 
involved are poorly understood. Anti HCV immune response develops with a delay 
whereas HCV propagates at an estimated rate of 1012 virions per day [119]. It is 
understandable that at this rate, and without proof reading capability, the RdRP will 
introduce changes which will be deleterious, selectively neutral or advantageous. 
Evolution of HCV within an individual is driven by a combination of drift and immune 
escape [189, 217]. Variants most fit to enter into host cells, replicate efficiently and 
evade eradication, will be selected for and predominate in a population, although 
selection pressures will change transiently. Outpacing of immune recognition by 
extreme sequence variability is one of the suspected mechanisms of HCV persistence.  
Several studies reported mutations enabling HCV escape from CTL response in 
chimpanzees and humans (reviewed in [225]), the outcome of infection is also 
correlated with antibody driven escape substitutions within E2 during seroconversion 
[80]. 
Selection pressures exerted by CD4 T cells are thought to be limited as substitutions in 
epitopes of the major histocompatibility complex (MHC) II are rare [226]. However, 
selection of escape HCV variants by CD8 T cells is broadly reported [226-228]. 
Mutational escape in the context of MHC-I epitopes was first proved for RNA viruses in 
mice infected with murine lymphocytic choriomeningitis [229]. This mechanism was 
confirmed by observations made in natural HIV-1 infection [230]. Escape mutations 
were shown to be exerted by CD8 T cell pressure, especially in acute phase of infection 
[231], and to correlate with development of AIDS [232]. Statistically sufficient proof of 
similar selection in HCV infection was established first in chimpanzee model [233], 
where escape mutations were observed in multiple regions and were due to selective 
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pressure, indicated by relatively high ratio of non-synonymous to synonymous 
substitutions  in these epitopes. Mutational escape from cellular immune responses 
was preliminary indicated in natural HCV infection by comparison of HCV sequences 
circulating in host to available prototypical sequences [234]. Further studies with 
identified donor inoculum constituted a critical mass of evidence of T cell mediated 
development of HCV escape [226-228] and indicated numerous T cell targets.  
 
Figure 1.14. Schematic of the course of acute HCV infection followed by recovery (A) or 
chronic infection (B) [134]. 
HCV RNA level rises rapidly during incubation phase (first 2-3 months post infection). T cell 
responses and anti-HCV antibodies become detectable at the same time ALT levels elevate 
as an effect of liver damage. In a resolving infection (A) clearance of the virus is followed by 
decrease of anti-HCV antibodies levels that may eventually become undetectable. T cell 
responses remain detectable and antigenic recall is strong. Chronic infection (B) is 
characterised by persistent HCV RNA at level lower than during acute phase. Levels of HCV 
specific antibodies rise and T cell responses wane, with in vitro recall becoming weak or 
undetectable. 
Role of humoral immune response in the outcome of acute HCV infection is 
controversial. However, HCV specific antibodies have been indicated to drive viral 
envelope evolution throughout acute and chronic phase [80, 235, 236]. Chronic 
infection is associated with detectable HCV-RNA levels beyond 6 months [25] despite 
presence of anti- HCV neutralising antibodies [237, 238], which often are high in titre 
B A 
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and broadly cross reactive [134]. A number of amino acid sites within and around 
known receptor and antibody binding regions are positively selected [192, 239]. Proof 
of mutational escape driven by humoral response has been provided in studies with 
sera sampled sequentially during HCV infection. Given serum sample was not able to 
neutralise envelopes of viral strains derived from the same sampling point, but had 
strong neutralising activity towards variants from earlier time points [235, 240, 241]. 
Neutralising antibodies accelerate HCV glycoprotein evolution during transition from 
acute to chronic phase [240] and maintain further selection of escape variants 
throughout the course of infection [241]. 
Together this data highlights that the knowledge of the sequence of incoming viral 
variants, or if lacking- sequential samples, might lead to determination of the capacity 
for, and extent of HCV evolution under immune pressure. This in turn would aid 
vaccine and DAA development. 
A second hypothesis regarding viral persistence is that anti-HCV immune response is 
too weak to clear total virus from all hepatocytes and prevent persistent infection. HCV 
antigens being displayed at relatively low level might not stimulate initial response 
efficiently [136]. T cell responses have been demonstrated to correlate with the 
outcome of HCV infection [242-244], however production of both HCV specific T cells 
and antibodies is relatively late [134]. Patients followed into recovery from HCV 
infection showed readily detectable levels of specific CD4 T cells. Lack or weakening of 
initially strong response are associated with development of chronic infection or 
relapse of vireamia despite initial control respectively. Progression of HCV infection to 
chronic phase associated with continuous antigenic stimulation is thought to lead to 
exhaustion of HCV- specific T cells. Arising responses are of reduced breadth and 
impaired function [245]. 
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Some of the HCV proteins have been identified to directly interfere with host immune 
response. The HCV Core protein has been shown to bind the receptor for the 
complement component C1q in vitro [246].  In in vivo mice study Core has been shown 
to downregulate T cell responses [247]. Additionally HCV proteins interfere with IFN 
activated pathways, which may further explain prevalence of chronic HCV infection. 
Strains poorly responding to IFN therapy- 1a, 1b as opposed to 2a, 2b and 3a possess 
within their E2 sequence domain homologous with phosphorylation site of the PKR and 
eIF2a. They compete for binding thus are able to inhibit kinase activity of PKR [248]. 
Furthermore PKR is also inhibited by NS5A [47] which has a broader anti-ISG activity. 
NS5A amino acids 2209 and 2248 have been termed interferon sensitivity- determining 
region (ISDR) which has been shown to be the PKR-binding domain with its affinity 
modulated by mutations [46]. NS3/4A serine protease has been indicated to disrupt 
IFN signaling by degrading RIG-I immune adaptor proteins [249]. 
Despite the fact that type I IFN can successfully block HCV replication in cell culture 
[148, 149] the anti- HCV therapy of pegIFN-Ƚ
40- 80% of cases with response differing depending on genotype of the HCV infecting 
patient. So far the exact mechanism underlying this difference has not been established.  
HCV seems to be able to down regulate IFN signalling pathway probably by preventing 
activation of a specific anti- HCV ISGs. In a study of biopsies taken from HCV infected 
patients, non- responders had highly activated ISGs both prior and post IFN treatment, 
hence it was suggested that HCV interplays with a tight subset of anti-HCV ISGs [250]. 
Moreover pre-existing high activation of many ISGs might itself have a negative effect 
on treatment efficacy, which preferably should aim to boost only specific anti-HCV 
responses. Ericson et al [251] found that consensus IFN, showing increased anti-HCV 
efficacy as compared to IFN-Ƚǡ     
Ǥ   specific 
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and anti-HCV potent ISG and learning how they are controlled could possibly lead to 
enhancing the therapy success rate. 
1.6. Laboratory models in HCV study 
1.6.1. Animal models 
As mentioned above HCV afflicts significant part of worldwide population and is a 
leading cause of liver transplantation [14], a vaccine being unavailable and current 
treatment in many cases ineffective and poorly tolerated [151]. The development of 
vaccine or alternative therapies has been hampered by the lack of suitable animal 
models of infection; however recent years have seen substantial breakthroughs in 
several new study models. 
1.6.1.1. Chimpanzee, tamarin and tupaia 
Resulting from HCV narrow species tropism for many years the common chimpanzee 
(Pan troglodytes) was the only animal available as experimental system. Experiments 
conducted on these animals enabled identification of basic facts related to the virus. 
Transmission of established non-A, non-B hepatitis from human to chimpanzee proved 
that causative agent was enveloped RNA virus, and that measurable RNA levels 
persisted within this host [252]. This further provided source of infectious serum for 
the initial molecular cloning of the HCV genome [3, 4]. A close genetic relationship 
between chimpanzees and humans offered possibility to study viral evolution [253] as 
well as host responses [254]. Unfortunately HCV infection progression and persistence 
in chimpanzees differs in some respects to humans. Antibody immunity is either weak 
or absent in this animal model. Multiple infections of chimpanzees did not result in 
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their immunity to both homo- and heterologic strains of HCV [139]. Direct 
immunisation of chimpanzees with recombined HCV antigens triggers production of 
anti- HCV antibodies which protective effects were disputable [139, 255]. Nowadays 
they continue to play a role in infectivity study and screening of antiviral molecules and 
vaccine candidates [256-258].  
Unfortunately chimpanzee model has serious drawbacks and limitations. Retrospective 
analyses showed that hepatitis in chimpanzees does not reflect exact routes of 
pathogenicity of HCV in humans. While vast majority of infections in people lead to 
chronicity only 30-50% of chimpanzees develop chronic disease. The liver cirrhosis 
and fibrosis that are observed in humans does not occur in the chimpanzee liver [256, 
259-261]. Such dissimilarities in HCV pathogenesis between humans and chimpanzees, 
in addition to both moral and financial considerations, have been integral in the 
development of additional animal models. 
1.6.1.2. Surrogate virus model: GBV-B  
Possible alternatives to chimpanzee model were identified. The GB virus B (GBV-B) is a 
flavivirus closely related to HCV [262]. Although persistent infections were reported 
after intrahepatic inoculation with synthetic GBV-B RNA, in most cases the virus causes 
acute, resolving disease in tree shrew (Tupaia belangeri chinensis) [263], tamarin 
(Saguinas Ursula) [264], marmoset (Callithrix jacchus) [265] and owl monkey (Aotus 
trivigatus) [266]. The possibility of using GBV-B as a platform for HCV chimeras might 
prove its potential for indirect testing of therapeutics [267]. 
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1.6.1.3. Transgenic mouse model 
Limitations of chimpanzee model in studies of liver pathology highlighted the need of 
obtaining small animal models for HCV infection. So far three types of murine models 
were designed: transgenic mice that express HCV proteins from tissue specific 
promoters in liver, immuno-compromised mice with human liver grafts and humanised 
rodents expressing human receptors. Use of the first model has been limited to studies 
of liver pathology under expression of HCV proteins like induction of hepatocellular 
carcinoma [268]. The second model seems to be more robust as it enables study of HCV 
propagation directly in a human tissue. The third model has been introduced recently 
[269]. These newly established animal models are still not widespread. Generating 
transgenic animals is technically difficult and very expensive; hence they have not yet 
been introduced into routine studies. 
Additional model- Trimera mice have proved efficient in production of monoclonal 
antibodies against several pathogens including HCV [270, 271]. This human/mouse 
radiation chimera is achieved by total body irradiation and further rescue by SCID 
mouse bone marrow, and engrafted with human lymphocytes. It may serve as a model 
of infection if transplanted with infected human tissue [271]. 
Rodent species, even when highly immune deficient are not susceptible to HCV. The 
lack of permissiveness is most likely multifactorial including block in HCV entry [114]. 
Transgenic mice expressing human CD81 were not permissive to HCV suggesting that 
another host receptor is crucial [272]. Mouse cells expressing human CD81 and 
additionally OCLN were rendered permissive [114].  Although mouse CD81 is more 
than 90% identical to its human homolog, the 4 amino acid positions identified as 
crucial for the interaction with HCV envelope are variable in mouse derivative [273]. 
Nevertheless mCD81 can support HCV entry but at much lower levels than human 
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CD81 which enabled in vitro selection of E1E2 adaptations. Murine- tropic HCV could in 
principle efficiently enter mouse cells but there seems to be poor proof of successful 
assembly and release of infectious progeny (reviewed in [114]). Recently, drawing on 
the knowledge of CD81 and OCLN bearing species specific determinants for HCV entry, 
Dorner et al. [269] developed a genetically humanised mouse model for HCV infection. 
This system is the first one to allow HCV entry in immunocompetent rodent opening 
opportunities for HCV pathogenesis, entry and entry inhibitors in vivo [269]. 
Another approach in obtaining rodent HCV infection models is host adaptation by 
engrafting them with human primary or transformed cells [274]. This was achieved by 
transplanting human hepatocytes into murine host with severe immunodeficiency and 
liver injury. In most often used model transgenic mice overexpress urokinase-type 
plasminogen activator (uPA) driven by an Albumin promoter [275]. Hepatotoxic effect 
in homozygous mice leads to severe loss of hepatocytes which can be rescued by 
xenotransplantation of human hepatocytes. These chimeric mice are susceptible to HCV 
infection which is characterized by rapid increase of viral loads that are sustained for 
several weeks [276, 277]. 
Xenomice model holds the potential to facilitate assessment of antiviral agents [277]. It 
was previously used to show that HCV infection can be modulated with antibodies 
[169]. We retrospectively assessed evolution of E1E2 sequence pre and post 
inoculation of mice. 
Although transgenic mice proved most advantageous of small animal models obtaining 
xenomice chimeras is still very cost and time consuming, limiting their use. The new 
humanised rodents might bring solution to these problems 
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Figure 1.15. Chimeric Alb/uPA SCID mice production scheme [275]. 
1.6.2. Tissue culture models 
For a considerable time the only measures available to study HCV life cycle were based 
on observation of infected patients' viral populations, experimental infections of 
chimpanzees and comparison with other Flaviviridae members. However, additional 
data on viral enzymes and structural proteins came from heterologous expression 
systems in different kinds of cells. Attempts to introduce different approaches in HCV 
study have succeeded in establishing widely used tissue culture experimental systems 
[278]. Most of these models allow only limited look on isolated aspects of viral life 
cycle, replication and pathogenicity. 
Transient and stable expression of HCV proteins in different cells created a root for our 
current knowledge. Various expression systems were applied to identify cellular 
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localization, folding and structure as well as interactions between viral proteins and 
their influence on cellular proteins. As mentioned before most cellular receptors for 
HCV were identified in studies based on recombinant envelope glycoproteins. This 
approach however, has many limitations as expression environment is far from a 
natural one, which occurs during liver infection. 
1.6.2.1. Subgenomic and genome length replicons  
For many years studies of HCV replication were hampered by lack of permissive cell 
culture systems, hence subgenomic replicon systems were developed [279]. 
Subgenomic replicons contain sequence encoding antibiotic marker fused in frame in 
the core sequence which is followed by heterologous IRES to drive translation of 
described ORF containing non-structural HCV region. Dicistronic RNAs containing and 
expressing full length ORF have also been developed [280]. 
Introduction of a replicon system was a big step forward in studies on HCV replication 
and translation. In 1999, long before establishment of chimeric transgenic mice as 
rob   ǡ ǯ     
system[279]. HCV replicons either contain genetically engineered whole genomes or 
shorter sub-genomic fragments. The latter ones comprise minimal non-structural 
region of HCV genome [281]. The first subgenomic replicon was based on genotype 1b 
non- structural region with two heterologous elements- neomycin phosphotransferase 
gene (introducing G418 resistance) and encephalomyocarditis virus IRES. In this 
system subgenomic RNA consisted of non-structural proteins coding regions as the 
NS2/3 protease, NS3/4A serine protease, NS3 NTPase- helicase, and NS5B[279]. In 
vitro transcription of cDNA resulted in RNA that could be used to transfect Huh-7 cells. 
Upon selection with G418 survivor cell clones were bearing up to 5000 replicons per 
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cell [281]. Interestingly, efficient replication of these HCV replicons correlates with 
acquiring so called cell-culture adaptive mutations [280, 282]. It is not clear how 
exactly these mutations influence viral replication especially that their introduction has 
not been observed in vivo. These mutations are thought to be responsible for the 
inability to raise infectious viral particles from full genome replicons [280, 282]. 
Replicon models played a crucial role in deciphering replication steps of HCV life cycle. 
However, to study viral entry or assembly and release of the progeny virus, a 
productive and robust system of viral infection in cell culture must have been 
established. 
1.6.2.2. Viral pseudoparticles 
As much as replicon systems shed a light on genuine HCV RNA replication and 
translation of polyprotein, retrovirus based HCV pseudoparticles (HCVpp) were 
important in study of virus entry into host cells. 
Several surrogate models of HCV entry have been developed. Initially the problem was 
approached by use of insect cell lines infected with recombinant baculovirus containing 
the cDNA of HCV structural proteins [283]. Virus- like particles produced in this 
manner were not infectious and retained in an intracellular compartment. Therefore, it 
was difficult to evaluate how closely these particles resembled native HCV virions. 
Another approach was to produce virosomes by incorporating E1E2 glycoproteins into 
liposomes. Although these virosomes interact with cell surface receptors it has not 
been shown whether they can induce fusion [284]. 
The notion that HCV glycoproteins, when over expressed in heterologous systems were 
retained  on the cell surface as well as in original site of replication on the ER, led 
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scientists to develop the retroviral pseudotype system. Retroviruses are well known to 
be able to incorporate into their envelope a variety of engineered viral glycoproteins. 
Moreover, the fact they can easily integrate long heterologous DNA sequences, allows 
the introduction of genetic markers. Murine leukaemia virus (MLV) or human 
immunodeficiency virus  vectors were used to create particles pseudotyped with HCV 
E1E2 and containing reporter genes, that allow monitoring of infection [101, 285].  
Pseudoparticle production relies on co-transfection of producer cell line with 
plasmid(s) containing coding sequences of retroviral core, packaging signals, reporter 
(like GFP or luciferase) and HCV glycoproteins (see Figure 1.16Figure 1.16). Viral 
capsids assemble in transfected cells and are subsequently transported to cell surface, 
where they acquire envelope from host cell membrane that contains E1E2 
glycoproteins present as an effect of overexpression. HCVpp released into media of 
producer lines carry reporter gene that is released upon infection of naïve cells. 
Resulting expression of reporter transcript can be detected and measured, which 
reflects infection efficacy [101, 286]. Data collected with use of HCV pseudoparticles 
(HCVpp) proves their potential to mimic first steps of HCV infection. They exhibit 
preferential tropism to hepatocytes and are neutralised by monoclonal anti-E2 
antibodies and sera from HCV-infected patients. Characterisation of E1E2 incorporated 
on HCVpp with conformation-sensitive antibodies confirms that functional unit in this 
system is a noncovalent heterodimer [66]. In addition coexpression of both 
glycoproteins has been shown to be crucial for production of infectious 
pseudoparticles. So far HCVpp are the only tool to study functional characteristics of 
HCV envelope glycoproteins derived from various genotypes and strains [97]. 
HCVpp can be produced in large quantities at a convenient safety level. Furthermore 
they offer great flexibility in terms of incorporation of marker genes and allow 
investigation of viral entry independently of replication [287]. The introduction of 
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pseudoparticle assay proved to be a great advance in HCV entry studies. Previously 
known putative receptors were confirmed in this assay, candidate receptors were 
characterized [288]. It has been revealed that none of the putative receptors alone is 
sufficient to mediate HCVpp infection in non-permissive cells and that set of 
coreceptors requires both CD81 and SR-BI [97]. 
 
Figure 1.16. HCVpp production process (adapted after [289]). 
Although HCVpp are similar to HCV virions they do not mimic the natural infection 
pathway. Pseudotypes do not interact with lipoproteins in the same way natural HCV 
virions do, hence lipoprotein mediated entry and role of LDL receptor cannot be 
dissected in this system. 
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1.1.3.1. Cell cultured HCV 
A breakthrough in HCV research was discovery of a HCV strain that was able to 
replicate and produce infective particles in cell culture. Many groups tried to establish a 
system that would sustain HCV replication, most attempts were based on primary 
human or chimpanzee hepatocytes exposed to HCV contaminated patient sera, or on 
cultivation of cells from chronically infected patients [290-293]. HCV has been 
described to infect several types of cells- both primary and transformed, but replication 
detected is at a limited level [48]. Despite reported infectivity of HCV particles in some 
of those studies reproducibility of results was poor and none of the systems sustained 
efficient and long term replication. 
Full replication cycle in tissue culture was obtained by electroporation of infectious 
RNA into a hepatoma cell line [294]. This most recent significant advance in HCV 
research started with isolation of a genotype 2a HCV strain, termed JFH-1, from a 
patient with fulminant hepatitis [295]. Initially JFH-1 was introduced as a new 
subgenomic replicon that possessed efficient replication despite lack of adaptive 
mutations. It was subsequently found that upon replication, viral particles assemble 
and are secreted outside the cell and are infectious for Huh-7 cells.  It provided 
opportunity to study many aspects of the host-virus interaction and the whole life cycle 
including viral entry, assembly and release. Particles generated in this system not only 
resemble virions present in patient sera in their morphology but also interact with 
lipoproteins. Thus, lipoprotein-mediated entry pathway and virion release could now 
be studied [276, 296]. HCVcc infectivity was neutralized by CD81 specific antibodies 
and immunoglobulins derived from patient sera. Like for HCVpp, HCVcc infection 
showed specificity to hepatoma cell lines. Chimpanzees experimentally infected with 
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HCVcc developed disease symptoms identical to those generated upon infection with 
human derived virus [294, 297, 298].  
Original strain JFH-1 remains unique in its ability to infect, replicate and successfully 
produce viral particles, with underlying reasons still unknown. JFH1 has been 
recombined to create various chimeras of which only wholly genotype 2a chimeras 
replicate efficiently in Huh-7 cells (reviewed in [282]). This model possesses a major 
drawback- only genotype 2a, which is not representative of the genotype 1 associated 
with highest risk of liver disease and least SOC responsive, can be propagated in such 
manner [299]. 
Currently many chimeras of different genotypes with parts of JFH-1 genome are being 
generated and introduced into the system. However it is still not known which region 
of JFH-1 genome is responsible for effective replication and infectivity of HCVcc. 
1.7. Summary 
Hepatitis C Virus is a positive sense enveloped RNA virus and the sole member of 
Hepacivirus genus within Flaviviridae family [4, 5]. Globally HCV infects an estimated 
170 million people with a high rate of persistence. Only about 15-20% of the 
population resolve acute HCV infection; the vast majority goes on to develop a chronic 
infection, which is implicated in liver cirrhosis and hepatocellular carcinoma [4, 12, 
300]. Current anti-HCV therapy is based on combination of pegylated Interferon alpha 
(pegIFN-ȽȌ   ? ?  ? ?
weeks. Combination therapy is successful in around 40%-80% cases with a resistance 
profile correlated to genotype of the infecting virus [146, 147, 301], coupled with host 
SNPs close to the IL28B locus which are associated with successful treatment outcomes 
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[152, 154]. However, combination therapy is not specifically targeted, with the 
mechanisms of action poorly understood. Although development of small molecule 
inhibitors specifically targeting HCV proteins has been extensively reported [302-306], 
none target the entry step of the viral life cycle. Moreover the significant genetic 
heterogeneity of the virus can result in selection of drug resistant strains, viral 
breakthrough and treatment failure [307-309]. 
HCV circulates within an infected host as a swarm of genetically distinct but closely 
related variants [310]. The diverse nature of HCV infection is a direct effect of the low 
fidelity of the RNA dependent RNA polymerase (RdRp) coupled with a high replicative 
rate in vivo. Estimates indicate the viral RdRp makes 1 error per 10-100 kbp copied 
[311] and that more than 1012 virions are produced each day in an infected host [119]. 
However, genetic variability is not distributed evenly through the viral genome. Instead 
it is concentrated in specific regions, the most variable of which are the E1E2 genes 
encoding the envelope glycoproteins [182]. Although positive selection has been 
demonstrated to contribute to the evolution of E1E2 [183, 192, 195, 239], much of the 
observed HCV genetic diversity can be also attributed to neutral sequence drift [189, 
190]. The E1 and E2 glycoproteins mediate cell entry and membrane fusion [312] as 
well as possess major determinants for neutralising antibody responses [313]. Some 
neutralising antibody epitopes overlap or are positioned closely to receptor binding 
sites [79, 313, 314]. HCV envelope glycoproteins are heavily glycosylated [56]. These 
potential N-linked glycosylation sites (PNGS) have been shown to possess various 
functions including masking of antibody epitopes, controlling correct folding and 
facilitation of entry into permissive cells [71, 140]. Non-synonymous substitutions at N-
linked motifs may result in glycan knockouts, resulting in phenotypic changes affecting 
both receptor- ligand and antibody- epitope affinities. Interactions between the host 
organism and virus selects for sequence variants which are fittest to facilitate entry and 
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replication, as well as evading host immune responses [315]. The entry step of the viral 
lifecycle, facilitated by the envelope glycoproteins, presents a potential target for 
specific anti-viral drugs and/or monoclonal antibody therapies.  
HCV is a blood-borne viral infection. Presently the main risk of infection in well 
developed countries is associated with IVDU, however nosocomial transmissions still 
happen [208, 209, 316]. Due to asymptomatic course of acute phase of hepatitis C 
infection, studying early evolutionary events of transmission and establishment of 
infection in natural setting have been challenging.  
The majority of previous studies of HCV intrahost evolution have suffered from 
exclusion of important regions outside HVR1. HVR1 variants have been shown to 
remain stable upon transmission and even up to several years later [213-217]. 
Differences in HVR1 sequence evolution are patient dependent [13, 212, 213]. Some 
research indicates that like HIV-1, HCV can establish productive infection with a single 
or just a few viral particles. 
Almost 20 years after discovery of Hepatitis C Virus it still remains one of major 
worldwide problems. Much knowledge has been gained about different aspects of life 
cycle, morphology of the virus or its pathogenicity. In face of highly dynamic evolution 
and the low success rate of current therapies, there is much still to be learned before 
satisfactory practices for managing HCV infection are developed. The study of viral 
evolution within patients at distinct disease stages, coupled with phenotypic studies of 
viral isolates to assess receptor binding and neutralization sensitivity over the course 
of infection using up-to-date methods, should shed light on HCV response to host-
immune pressure over the course of natural infection. 
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1.8. Aims of the project 
In the light of the described knowledge, we aimed to broaden understanding of 
diversity in HCV glycoproteins E1 and E2 sequences at different stages of infection. We 
were able to study samples derived from a xenomouse model of transmission and 
several samples from naturally occurring transmission as well as sequences from acute 
stage of infection.  
In this study we utilised single genome amplification (SGA) technique to recover full-
length E1E2 sequences. SGA of full-length E1E2 glycoprotein sequences, followed by 
direct sequencing minimises in vitro generated artefacts and experimental biases 
associated with the standard bulk amplification and cloning approach, giving an 
accurate representation of investigated intrahost population. Our prominent aim was 
to advocate this method, widely used in evolutionary studies of HIV, as a new gold 
standard in HCV research.  
Comparative analyses of sequences derived from three different settings were 
performed, in conjunction with a range of phylogenetic tests. As full-length E1E2 
sequences were utilised in this study, we also aimed to investigate the phenotypic 
consequences of E1E2 evolution.  
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2. Materials and methods 
2.1. Source of samples 
To investigate genetic and phenotypic variability of HCV envelope glycoproteins, 
sequences derived from three novel clinical or experimental settings were utilised.  
For the first sequence dataset, HCV RNA samples were obtained as described in a 
previously published study [169]. Eleven human liver-chimeric Alb-uPA/SCID mice   ? ? ?Ɋ ?ȋ ?Ǥ ?  ?
106 IU/ml) to simulate a natural exposure to virus. Patient KP acquired HCV via an 
unknown route and at the time of sampling was in the chronic phase of infection. 
Experimental infections were monitored over time by tail bleed sampling. HCV RNA in 
mouse serum was quantified by a real-time 24 TaqMan PCR assay [169]. RNA was 
recovered from serum aliquots with use of commercially available RNA extraction kit ȋȌ     ? ? Ɋ  2O. The sequences obtained from these RNA ǲǳȋTable 2.1 for sample details) 
The second sequence dataset was generated from a proposed hospital acquired 
transmission event where the donor and recipient were suspected [317]. The index 
case patient had been receiving haemodialysis three times a week at the same unit for 7 
years. Blood samples were screened every three months and were HCV negative until 
September 2009 when routine (unknown) HCV antibody test reached equivocal 
concentration. Retrospective analysis of stored samples revealed HCV PCR +/antibody - 
results for a sample taken 3 months earlier, suggesting acute HCV infection. 
Investigation of possible risk factors leading to index case infection pinpointed 
treatment received in March/April time for diabetic ulcer at the renal inpatient clinic. 
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Four haemodialyses were performed of which one was directly after a HCV positive 
patient.  A transmission event between these two haemodialysis patients was 
suspected and subsequent genotyping identified the infecting HCV genotype as 3a in 
both cases. The putative date of the transmission event was established to be 
26.03.2009. Sequence data was generated from serum samples obtained from these 
two patients, along with epidemiologically unrelated genotype 3a sequences from 
various sources including nine Nottingham and eight Glasgow cases. The sequences           ǲǳ  ȋsee 
Table 2.2). RNA was extracted from this set of samples utilising two different methods 
described in 2.2. 
The third set of sequences was derived directly from patient samples previously 
enrolled in the Trent Study cohort [318]. Serum samples utilised were collected 
exclusively from patients in the acute phase of infection of unknown source. Patients 
were infected with genotype 1a HCV. Window pre-seroconversion period of disease 
was determined by HCV RNA presence in serum and lack of detectable anti-HCV 
antibodies in second and third generation enzyme linked immunosorbent assays 
(unknown manufacturer). The presence of HCV RNA in samples was determined 
initially by an inhouse RT- PCR assay and, post 1995, by a commercially available 
reaction (Amplicor; Roche Diagnostics, East Sussex, UK)[318].  HCV glycoprotein 
sequences generated in this part of project were desigǲǳȋ 
Table 2.3). 
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Table 2.1. Transmission in mouse model samples details. 
Patient/ 
Mouse ID 
Population 
sampling 
Serum 
HCV (IU/ml) 
Hepatocyte 
donor 
Time post- 
inoculation 
(days) 
Donor:     
KP KP 1 ×10
6
 - - 
Recipients:     
A594 594_1 8.09 ×10
5
 II 32
 
 594_2 1.01 ×10
6
 II 59 
N666 666_1 2.69 ×10
6
 I 14 
 666_2 2.49 ×10
6
 I 28 
N714 714_1 1.16 ×10
6
 I 14 
 714_2 1.54 ×10
6
 I 28 
A931 931_1 8.61 ×10
7
 III 21 
 931_2 2.94 ×10
7
 III 42 
 A931 8.04 ×10
7
 III 28 
A594 A594 8.09 ×10
5
 II 32 
A583 A583 8.40 ×10
5
 II 32 
A596 A596 1.73 ×10
5
 II 32 
A585 A585 2.99 ×10
5
 II 32 
A587 A587 9.79 ×10
6
 II 32 
A902 A902 4.46 ×10
7
 III 28 
A909 A909 1.96 ×10
7
 III 28 
A965 A965 7.73 ×10
6
 III 28 
I = 36 year old female, II = 45 year old female 92% viability polycystic tissue, III = 4 year old male 92% 
viability normal tissue 
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Table 2.2. Transmission samples details. 
 
Sample 
Label 
Patient 
initials 
Sample 
number 
Collection 
time 
Extract or 
serum sent 
Index case 
samples 
IC1 JL 09.626410 04.06.09 serum 
IC2 JL 09.641669 03.09.09 nucleic acid 
IC3 JL 09.643461 12.09.09 nucleic acid 
IC4 JL 09.644581 19.09.09 serum 
IC4* JL 09.644581* 19.09.09 nucleic acid 
Hypothetical 
source samples 
HS1 JM 09.605096 05.02.09 serum 
HS2 JM 09.621248 07.05.09 serum 
HS3 JM 09.628582 17.06.09 serum 
Unrelated 
control patient 
samples 
PG JMK 09.636795 05.08.09 serum 
PF Bi 09.625613 03.06.09 serum 
PC O 09.618182 21.04.09 serum 
PD B 09.618221 21.04.09 serum 
PA Q 09.617409 15.04.09 serum 
PE H 09.623014 15.05.09 serum 
PB G 09.618166 21.04.09 serum 
PH M 09.639212 20.08.09 serum 
PI Be 09.638115 13.08.09 serum 
 PT N/A N/A N/A serum 
 PS N/A N/A N/A serum 
 PR N/A N/A N/A serum 
 PP N/A N/A N/A serum 
 PO N/A N/A N/A serum 
 PN N/A N/A N/A serum 
 PM N/A N/A N/A serum 
 PL N/A N/A N/A serum 
 PK N/A N/A N/A serum 
 PJ N/A N/A N/A serum 
IC- index case, HS- ŚǇƉŽƚŚĞƚŝĐĂů ƐŽƵƌĐĞ ? W ?- patient- control samples from the unit, N/A- not 
available 
* IC4- 09.644581- both serum and extract sent, only a small volume of serum left 
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Table 2.3. Acute samples details. 
 Patient 
initials 
Sample 
name 
Date of 
collection 
Special notes 
Acute 1 N/A 1A20 unknown N/A 
Acute 2 MA 1A30.3 07/10/2003 2 months after first sample 
collected, month after HCV RNA 
detected, Anti-HCV negative 
  1A30.12 04/02/2005 16 months post infection, RNA+, 
Anti-HCV+, patient deceased 
Acute 3 KB 1A57.2 02/09/2004 5 months after first sample 
collected, first time HCV RNA 
detected, no information about 
Anti-HCV, later sample still Anti-
HCV negative 
  1A57.14 01/02/2008 42 months post infection, RNA+, 
Anti-HCV+ 
Acute 4 RW 1A65.1 05/04/2005 first sample taken, positive RNA, 
negative Anti-HCV, first Ab+ 
sample collected 5 months post 
PCR+ 
  1A65.10 05/06/2006 14 months post infection 
Acute 5  1A83.1 14/12/1996 N/A 
N/A- not available 
 
  
66 Materials and methods 
2.2. HCV RNA extraction 
Two separate RNA extraction methods were employed dependent on samples.  Both    ǯ  [319]. From the acute dataset samples, RNA was 
recovered from 140-  ? ? ? Ɋ        ?
MinElute® Virus Spin RNA extraction kit (Qiagen). Serum and buffers were       Ǥ      ? ? Ɋ
    ? ? ? Ɋ     ? ? ɊȀ    
guanidine hydrochloride. Lysis was performed at 56qC for 15 minutes. Lysate was then  ? ? ?Ɋ
QIAamp MinElute column. RNA was bound to the column upon centrifugation at 6000 × 
g for 1 minute. Three steps of washing were then performed-  ? ? ?Ɋ ?ȋȌǡ ? ? ?Ɋ ? ? ? ?ɊǤǡ
removed by additional centrifugation step. RNA was then eluted with 20-  ? ? ? Ɋ 
buffer AVE.  
   ǲǳ  ȋ    Ȍ      ǯ - the NucliSens® easyMAG® platform. This system for automated 
isolation of nucleic acids from clinical samples is based on silica extraction technology 
as manual method but introduces use of magnetic particles to isolate viral RNA. Serum       ? ? ? Ɋ     ? ? ɊǤ  ?    
added to sample according to manufacǯ- ? ? ?Ɋ
silica (prepared in a 1:1 ratio with molecular grade water) introduced. RNA bound to 
silica was then washed 5 times, further by addition of final buffer and heating eluted 
from silica beads. Magnetic arrays removed silica beads from the sample and pure RNA 
eluate was retrieved. 
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2.3. cDNA synthesis 
Viral cDNA was synthesised using commercially available ThermoscriptTM RT-PCR 
System for first strand cDNA synthesis (Invitrogen). 
Ɋ ? ?ɊǤ	ǡ
was mixed with 10pmol primer OAS 1a (see Table 2.4) and 20pmol dNTPs and 
incubated at 65ºC for 5 minutes in order to denature template and primer. This step 
also removes RNA secondary structures that could impede full-length cDNA synthesis. 
 ?Ɋ
15 U ThermoScript TM RT, 40 U RNaseOUTTM and 0.1µM DTT in 1× cDNA synthesis 
buffer. Elongation was performed at 50 ºC for 1 hour or longer. Reaction was 
terminated at 85 ºC for 5 minutes and DNA:RNA hybrids were digested via incubation 
with 2 U of RNase H at 37ºC for 20 minutes. 
2.4. Amplification of E1E2 
Two PCR based methods were used in sampling viral quasispecies. The first method 
involved generating full length E1E2 glycoprotein sequences using unknown amount of 
cDNA molecules as a template, followed by direct sequencing of PCR products. This is    ǲ ǳ     -diluted cDNA samples 
were used in PCR amplification. It was mainly used to amplify E1E2 fragments from 
low titre samples or to serve as a comparison to single genome amplification method 
described below. 
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In order to avoid in vitro generated recombinants, cloning induced errors and also to 
ensure accurate and representative sampling of quasispecies populations, a single 
genome amplification (SGA) approach was utilised. The SGA method, followed by direct 
sequencing, has been previously applied to characterise viral quasispecies populations 
in HIV-1 [220, 320-322] and HCV infection [323]. In this approach viral cDNAs were 
serially diluted and aliquots of 2-fold dilutiȋ ?ɊȌ
round of a nested full-  ? ? Ǥ  Ɋ  -round product were 
subsequently used as template in second-round reactions. For each sample, end-point 
titration PCRs revealed the dilution at which the concentration of viral cDNA was <1 ɊǤ ? ?
at the end-point dilution (d3/10 PCR positives). According to Poisson distribution, 
when no more than 30% of PCR reactions are positive, more than 80% of amplicons 
will be derived from single molecule templates [321].  
These amplicons were sequenced direǲǳ
derived quasispecies sequences. Chromatograms were checked by eye for presence of 
double peaks (see Figure 2.1) that would disqualify an amplicon from further analysis 
due to being derived from multiple templates. 
Both bulk and single-molecule methods utilised a nested PCR comprised of two rounds 
of amplification primed by two sets of primers. A second pair of primers was designed 
to attach to sequences positioned internally on the template in relation to the first pair 
of primers. For every PCR carried out negative controls were used to ensure lack of 
carryover contamination. 
   ? ?Ɋ  ?
anti-sense outer primers (see Table 2.4), 0.25 mM dNTPs, 0.5 U of Platinum® Taq High 
Fidelity polymerase (Invitrogen), 1× High Fidelity polymerase buffer and 2 mM MgSO4.  
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O Ɋ          Ǥ  -cycling 
parameters were 35 cycles of 94qC for15 seconds, 50qC for 30 seconds and 68qC for 3 
minutes. Two micro litres of the first-round product was subsequently used in second-
round reactions with inner primers using identical amplification and cycling conditions 
to the first round but increasing the cycle number to 45. 
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Figure 2.1. Sequence chromatogram representing fragment of a mixed sample compared to sample derived from single molecule.  
Highlighted are double peaks in top panel- representing sequence derived from mixed sample. Bottom panel- single molecule amplified sequence, where 
clean peaks are highlighted. 
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Table 2.4. List of primers for nested PCR 
Primer PCR round Direction 
Genotype 
specificity 
Sequence Nucleotide position
1 
OAS 1a cDNA synthesis, 1
st
  Antisense 1  ? ?'''d'd'dd''d ? ? 2599 m 2616 
EOS 1st Sense Universal  ? ?''''''ddd''' ? ? 818 o 841 
1ASGT1a 2nd Antisense 1  ? ?dd'd'dd'''dd''ddd ? ? 2550 m 2582 
170gt1 2nd Sense 1,3,5  ? ?d'''dd'ddddddd ? ? 843 o 868 
OAS3 cDNA synthesis, 1
st
  Antisense 3  ? ?d''d'''''dd' ? ? 2620 m 2601 
IASGT3A 2
nd
  Antisense 3  ? ?ddd'ddd'd'd'ddd' ? ? 2555 m 2586 
142-KpnI Pre-cloning Antisense 1  ? ?dd''ddd'd'dd'''dd''ddd ? ?  ? ? ?A?<ƉŶ/ 
179-HindIII Pre-cloning Sense 1  ? ?d'ddd'''dd'ddddddd ? ?  ? ?ŽƌĞ+ HindIII 
1
 primer position numbered according to H77 genome coordinates; all primers were previously designed by other members of our group 
 
Figure 2.2. Schematic representation of primer locations (according to H77 coordinates) for primers presented in Table 2.4. 
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2.5. Agarose gel electrophoresis 
Analysis of PCR products by eletrophoresis was carried out alongside Gene Ruler DNA 
ladder mix (MBI Fermentas). Gel was obtained by boiling agarose in 1× tris-acetate 
ethylene diamine tetra acetic acid (TAE) buffer (Sigma) at 2% weight to volume Ǥ          ȋ ? Ɋ Ȁ  ? ? ? ȌǤ	Ɋ ?Ɋ ? ?ȋ ? ? ?ǡ
0.002% bromophenol blue). Samples were resolved at 6 V/cm for 40-50 minutes. 
Subsequently DNA was visualized using UV trans-illuminator (UVP). The result of each 
amplification was then recorded photographically. 
2.6. Purification of PCR products 
Before subsequent sequencing or cloning PCR products of verified size were purified  ?ȋȌǯǤ 
One volume of PCR product was mixed with five volumes of Buffer PB, which contains 
guanidine hydrochloride and isopropanol. The mixture was bound to silica-gel based 
column by applying a vacuum. To remove unincorporated nucleotides, primers, enzyme 
and salts, 750 µl ethanol based buffer PE was drawn through the column, again by 
applying a vacuum. To remove all traces of wash buffer, the column was further spun 
for one minute at 15800×g. DNA was then eluted with 30-50 µl elution buffer, 
quantified by spectrophotometry and stored at -20ºC. Measurements were performed 
with a NanoDrop spectrophotometer (Thermo Scientific) which allows accurate 
quantification of DNA concentration in 0.5-2µl sample. The peak of light absorption is 
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at 260 nm for DNA and at 280 nm for protein [324]. NanoDrop software calculates DNA 
concentration and informs about its purity. 
2.7. Sequencing reactions 
Amplification products were  ?
(Perkin Elmer).  This method is based on the dideoxy sidechain termination method 
developed by Sanger [325] combined with energy transfer dye [326]. 
       ? ? Ɋ    ?Ǥ ? Ɋ   
(Applied biosystems),  ?Ǥ ?Ɋ ?ȋApplied biosystems), 3.2 pmol primer (see Table 
2.5) and 20-40 ng of PCR product (1.7 kb). The PCR-cycling parameters were 30 cycles 
of 96qC for 30 seconds, 50qC for 10 seconds and 60qC for 4 minutes. All steps were 
ramped at 1qC per second. 
      ? ? Ɋ    Ǥ  
then performed by addition of 50Pl 100% ethanol, 2Pl 3M sodium acetate and 2Pl 
125mM EDTA. Incubation at room temperature was performed for between 1-24 hours 
in darkness. 
Depending on the reaction vessel in which sequencing was performed, centrifugation 
steps differed. Individual tubes were centrifuged at 18000 × g for 30 minutes at room 
temperature. Supernatant was then removed by careful pipetting and the pellet was 
washed twice with 70% ethanol. 96-well plates were centrifuged at 2000 × g for 45 
minutes at 4qC and supernatant discarded by centrifuging the plate upside down at 185 
× g for 30 seconds. Pellets were washed once with 70% ethanol. Residual alcohol in 
both cases was removed by evaporation on a thermoblock at 50qC 
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Sequencing reactions were read on an ABI 3130 analyser. Chromatograms were 
checked and manually adjusted in FinchTV (Geospiza) and contigs of overlapping 
sequences were assembled with use of SeqMan® (DNAStar Inc.). 
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Table 2.5. List of sequencing primers. 
Primer Template Direction Sequence Nucleotide position
1 
Origin 
T7 pcDNA3.1 Sense   ? ?dd'ddd''' ? ? 863 o 882 (upstream of insert) Invitrogen 
BGH pcDNA3.1 Antisense  ? ?d''''d''' ? ? 1111 m 1128 (downstream of insert) Invitrogen 
E1IS E1E2 Sense  ? ?d'''dd'd'd'd'' ? ? 1299 o 1319 Previously created in our group 
1A-FOR-seq E1E2, gt 1A Sense  ? ?d''''''d''' ? ? 2053 o 2071 Specifically designed for the project 
1A-REV-seq E1E2, gt 1A Antisense  ? ?''z''d ? ? 1398 m 1415 Specifically designed for the project 
3A-FOR-seq E1E2, gt 3A Sense  ? ?ddd''d'' ? ? 1866 o 1884 Specifically designed for the project 
3A-FOR2-seq E1E2, gt 3A Sense  ? ?''d'd'd ? ? 1236 o 1256 Specifically designed for the project 
3A-REV-seq E1E2, gt 3A Antisense  ? ?d'''dd''d'' ? ? 1414 m 1433 Specifically designed for the project 
1
 primer position numbered according to H77 genome coordinates apart from primers T7 and BGH- position numbered according to pcDNA3.1 V5/His© TOPO® sequence 
(Invitrogen) 
 
Figure 2.3. Schematic representation of primer locations (according to H77 coordinates) for primers presented in Table 2.5. and approximate 
overlap of sequencing products further aligned into full length E1E2 contigs. 
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2.8. Sequence Alignment 
Sequence fragments were assembled into an individual E1E2 consensus sequence for 
each amplicon using SeqMan® (DNAStar Inc.) Nucleotide sequences of full-length E1E2 
were then aligned according to their overlying amino acid translation using MEGA4 
[327] which implements CLUSTAL W [328] source code, and then manually refined to 
ensure maintenance of the open reading frame. CLUSTAL W is a progressive multiple 
alignment method [328] which allows gap penalties to vary in a position- and residue- 
specific manner.  
2.9. Phylogenetic reconstruction 
Phylogenetic trees were generated by two separate methods: neighbour-joining (NJ) 
and maximum likelihood [329]. The NJ method for tree-building from nucleotide 
sequence data requires a pre-defined distance matrix. A pair of neighbours is defined as 
a pair of operational taxonomic units (OTUs) connected through an interior node in an 
unrooted, bifurcating tree. Among the possible pairs of OTUs, the pair that gives the 
smallest sum of branch lengths is combined, and subsequently regarded as a single 
OTU.  The principle of NJ tree construction is to find operational taxonomic units 
(OTUs), or terminal nodes, that minimise the total branch length at each stage of 
successive clustering of OTUs, originating from a star-like tree. [330]. NJ trees  were 
constructed using MEGA4 under a Kimura-2 parameter model [331] of sequence 
evolution whereby differential weightings are assigned to transitions and transversions 
[332].  The NJ method combines computational speed with uniqueness of result  
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Statistical robustness of phylogenetic groupings were estimated using the bootstrap 
approach via 1000 replications (reviewed in [333]). Bootstrapping is a reliability test 
which involves generation of pseudoreplicate nucleotide alignments by randomly 
sampling (with replacement) from the sites in the original alignment. The procedure is 
repeated 1000 times and a tree is generated for each replicate dataset with scores for 
identical grouping of sequences given as percentages. Significant bootstrap values at 
internal tree node (>70%) indicates the monophyly of a group of sequences. 
The NJ method is a distance method and derives subsequent trees from pairwise 
distance matrices.  This method is therefore not appropriate to infer ancestral 
sequences from contemporaneous sequence data. To further investigate sequence 
evolution within the the generated datasets, a discrete characters method - maximum 
likelihood _- was applied to enable estimation of ancestral sequences, as implemented 
in PAUP version 4.0b10 [334] using the best-fit substitution model for the data 
calculated in Modeltest version 3.7 [335]. ML methods choose amongst competing 
hypotheses by choosing the one which maximises the likelihood: the hypothesis which 
is most likely to have generated the observed data, given the chosen model of sequence 
evolution. ML requires an explicit model of evolution to compute a tree which is 
estimated directly from the sequence data.  Modeltest is a programme that chooses the 
best fit of 56 models, applying different selection frameworks: Akaike information 
criterion (AIC), hierarchical likelihood ratio tests (hLRTs), and Bayesian information 
criterion [336, 335]. Given a model of substitution PAUP computes likelihood of 
observed nucleotides in each site given all possible combinations of ancestral states.  
This method allows the construction of high-resolution phylogenies and estimation of 
ancestral nucleotide state at internal nodes but is computationally demanding. 
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Substitutions occurring across viral populations were visualised using the 
HighlighterTool: http://hcv.lanl.gov/content/sequence/HIGHLIGHT/highlighter.html. 
Consensus sequences were generated using the Consensus Maker tool: 
http://hcv.lanl.gov/content/sequence/CONSENSUS/consensus.html. 
2.10. Cloning of PCR products into pcDNA3.1 
2.10.1. Directional TOPO cloning 
To perform protein expression HCV E1E2 amplification products, as well as 
recombinant PCR products, were ligated into a pcDNA3.1 V5/His© TOPO® expression 
vector (Invitrogen).   ?ǯ
overhang and is covalently bound topoisomerase I of Vaccinia virus. Forward primers 
for both sets of reactions were designed to contain directional cloning signal- CACC at   ?ǯ           
ends (Phusion HF polymerase, Finnzymes). The TOPO cloning technique eliminates the 
need for post PCR procedures. Directional TOPO cloning occurs at highest rate when 
molecular ratio of insert: vector is between 0.5:1 Ȃ 2:1. To perform cloning with high 
efficiency amounts of insert were calculated to closely match a vector/insert ratio of 
1:1. Cloning was performed according to manufaǯ
reaction volumes. After 30 minutes of incubation at 22qC, 3-6µl of ligation mix were 
added to 50 µl of competent TOP10 E.coli cells on ice. Transformation and screening 
steps are described in sections 2.12 and 2.13. 
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2.10.2. Restriction enzyme cloning 
Vector pcDNA3.1 V5/His D-TOPO has been modified in our group by TOPO cloning to 
obtain circularised version without insert.  
For cloning of E1E2 sequences KpnI and HindIII recognition sites were chosen. Primers 
containing restriction sites were designed (142-KpnI and 179-HindIII see Table 2.4). 
PCR products of E1E2 amplification from cDNA were used as templates in additional 
round of amplification (as described before 2nd round nested PCR in 2.4) using primers 
containing restriction sequences. Products were analysed by gel electrophoresis 
afterwards column purified and quantitated as previously described.  
Vector in total amounts of 1-3 ng was digested in buffer E (Promega). 20 units of 
HindIII, 40 units of Acc65I and 1 unit of BSA were used in the reaction in a total volume 
of 50- ? ? ?ɊǤ ?Ɋ ? ? ? ? ?ɊǤter overnight 
incubation at 37°C the reaction was heat inactivated at 80°C for 20 minutes. Digested 
products were purified and quantitated as previously described. 
Cloning reactions were assembled at a vector: insert molar ratio of between 1:3-1:4, 
with a total DNA concentration 50- ? ? ?        ? ? ɊǤ  
performed using 20 units of T4 ligase [21] in a buffer provided (50mM Tris-HCL, 10mM 
MgCl2, 10mM DTT, 1mM ATP, pH 7.5) with additional 1mM ATP. Overnight incubation 
at 18°C was followed by heat inactivation at 65°C for 15 minutes. 
Cloned plasmids were transformed into E.coli cells as described in section 2.12. 
Transformed cells were seeded on agar plates with ampicillin and after overnight 
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incubation colonies were screened for presence of the right size insert (described in 
2.13).  
Screening products were analysed via gel electophoresis and colonies containing the 
right size insert were grown overnight in Luria Broth to amplify desired plasmid. 
Column purified plasmids were sequenced (as mentioned further in section 2.15). 
2.11. Preparation of TOP10 competent cells 
Overnight culture of TOP10 E.coli cells were refreshed by 1:100 in fresh Luria Broth 
dilution and incubated in shaker at 37°C until OD600= 0.3- 0.4. Cultures were then 
centrifuged for 10 min at 4000 g at 4°C. Bacterial pellets were resuspended (gently, 
keeping cells on ice) in cold 0.1 M CaCl2 (10ml for every 100ml of LB of fresh culture). 
After 1 hour incubation on ice, cells were spun as previously. The pellet resuspended in 
cold 0.1 M CaCl2 + 5% glycerol (2ml/ 100LB) and  ? ? ?Ɋ
and stored at -80°C. 
2.12. Transformation of TOP10 competent cells 
 ? ?Ɋ ? ?
1- ?ɊǤice for 30 
minutes. Afterwards heat shock was performed at 42qC for 30-45 seconds followed by Ǥ ? ? ?Ɋ ? ?qC with 
shaking at 225rpm for one hour without antibiotics. To select bacteria that accepted ǡ          ȋ ? ? ? ɊȀ ȌǤ 
overnight incubation at 37qC colonies from the plate were picked for screening.  
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2.13. Screening of bacterial colonies 
To verify that correct insert was cloned into the vector. Single colonies were picked 
with sterile pipette tip and dipped into PCR master mix. The PCR reactions were set up  ? ?Ǥ ?Ɋ ? ?
 (Table 2.5.), 0.2 mM dNTPs, 
0.3 U of Hot Start Taq polymerase (Quiagen) and 1× polymerase buffer. Thermoblock 
cycling parameters were: initial denaturation at 95°C for 15 minutes followed by 30 
cycles of 94°C for 45 seconds, 50°C for 45 seconds and 72°C for 4 minutes.  A final 
extension at 72°C for 10 minutes was then performed. 
Products of screening were analysed on 2% agarose gel. Colonies containing clones 
with correct size insert were further picked for overnight culture in 5ml of LB with 
ampicillin to obtain 30- ? ?Ɋ ? ? ? ? ? ? ?Ɋ
preparations. 
2.14. Plasmid purification from 1-5 ml overnight culture- 
Minipreps 
Plasmids were purified on a silica membrane based method using QIAprep® Miniprep 
kit (QIAGEN). Overnight cultures of target bacteria were centrifuged at 6000 × g for 5 Ǥ ? ? ?Ɋ ?ȋning RNase    ?Ǥ ? ȀȌǤ    ? ? ? Ɋ    ?     Ǥ     ? ? ? Ɋ    ?     
hydrochloride. Samples were then centrifuged at 17900 × g for 10 minutes and clarified 
supernatants were applied onto QIAprep columns. Solutions were drawn through 
columns under vacuum pressure. Columns were then washed with 0.5 ml of buffer PB 
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which removes endonucleases. Further washes with 0.75 ml of buffer PE containing 
ethanol removes salts. Additional centrifugation ensured removal of ethanol carryover. 
Plasmid DNA was eluted in 30- ? ?Ɋ- ? ?ǏǤ 
2.15. Sequencing of clones 
To confirm that cloning was successful sequence analysis of the inserted fragment was 
performed. For full length E1E2 sequencing three primers were used. Sequencing with 
primer T7 (see Table 2.5Ȍ ?ǯ
sequence flanking this end. Similarly sequences derived from the primer BGH (see 
Table 2.5.)  ?ǯǤ
length contig third primer was applied- E1IS (see Table 2.5). 
Sequencing conditions were as described above (chapter 2.7). Amount of plasmid 
template used was 100-200ng. 
2.16. Plasmid purification from 50-150 ml overnight culture 
Midipreps 
In order to obtain sufficient volumes of HCV E1E2 containing plasmids for mammalian 
cell transfections, larger volumes of bacterial culture were used. Bacteria were 
harvested from overnight culture by centrifugation at 5000 × g for 10 minutes.     
 ?      
which features a filter syringe for clearing of bacterial lysate and a silica column which 
binds nucleic acid. Pellet was resuspended in 4 ml of Resuspension RNase solution. 
Lysis was performed by combining the sample with 4 ml of lysis buffer for 3-5 minutes 
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and then neutralised with 4 ml of neutralisation solution. A further 3 ml of binding 
solution was added and the mix was immediately applied to the barrel of filter syringe. 
Leaving the sample in an upright syringe barrel for 5 minutes allowed separation of cell 
debris from lysates. After 4 ml Column preparation solution was drawn through 
columns under vacuum pressure. Samples were filtered through syringes onto 
columns. A vacuum was applied until lysates passed through columns. Two washes 
were then performed- first with 4 ml of wash solution one and second with wash 
solution 2 which contained ethanol. Columns were dried by centrifugation at 6000 × g 
for 5 minutes to allow removal of ethanol. Plasmid DNA was eluted in 1 ml of elution 
solution and stored at - ? ?ǏǤ 
2.17. Site directed mutagenesis 
Cloned sequences were checked and aligned with original end-point sequence to locate 
polymerase or cloning induced mutations. Any differences from endpoint amplicon 
sequences were back mutated via site-directed mutagenesis. Primers for mutagenesis 
(see Table 2.6) were designed online: http://bioinformatics.org/primerx/cgi-
bin/DNA_1.cgi. 
      ? ? Ɋ   ? ? 	  ȋ	Ȍ   ? ? ǡ
0.2mM of dNTPs, 0.5 U of Phusion HF polymerase and 125 ng of each mutagenesis 
primer. Fifty ng of plasmid that required back mutation was used as a template. Cycling 
contitions were: 98ºC for 2 minutes, then 30 cycles of 98ºC for 10 seconds, 55ºC for 15 
seconds and 72ºC for 8 minutes.  
Digestion of original template was carried out with 20U of DpnI [21] in 1× concentrated 
buffer. DpnI is a restriction enzyme that cleaves methylated DNA; hence whilst original 
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template plasmid undergoes digestion, newly synthesised mutated product remains. 
After overnight incubation at 37ºC samples were resolved on an agarose gel to confirm 
presence of the plasmid DNA. Bacteria were transformed and plasmids sequenced as 
previously described. 
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Table 2.6. List of mutagenesis primers. 
Primer name/  
mutated position 
Template Direction Sequence 
Nucleotide 
position
1
 
C1358T_For lig1A20.1_1_c2 Sense 5' CATTATCCTTGTACTGTCAACTACACCATAT 3' 2190 o 2220 
C1358T_Rev  Antisense 5' ATATGGTGTAGTTGACAGTACAAGGATAATG 3' 2190 m 2220 
T943C_For lig1A30.3_26_c15 Sense 5' CCGACCAACGCCCCTACTGCTGGCACTA 3' 1780 o 1807 
T943C_Rev  Antisense 5' TAGTGCCAGCAGTAGGGGCGTTGGTCGG 3' 1780 m 1807 
G1210A_For lig1A30.3_38_c23 Sense 5' CCCTTGTGCCATCGGAAGGGTGGGCAACAAAAC 3' 2042 o 2074 
G1210A_Rev  Antisense 5' GTTTTGTTGCCCACCCTTCCGATGGCACAAGGG 3' 2042 m 2074 
C1183T_For lig1A57.2_6_c28 Sense 5' GGATTCACCAAGGTGTGCGGAGCGCCTCCTTG 3' 2016 o 2047 
C1183T_Rev  Antisense 5' CAAGGAGGCGCTCCGCACACCTTGGTGAATCC 3' 2016 m 2047 
1
 primer position numbered according to H77 genome coordinates; all primers designed by the author 
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2.18. Mammalian cell cultures 
Three different strains of mammalian cells were used for phenotypic analysis of 
proteins of interest: HEK 293 T, HEK 293 FT [337], Huh7 [338]. 
HEK 293T cells (Human Embryo Kidney cells) and Huh7 cells (Human Hepatocellular 
carcinoma cells) were cultured in DMEM (Gibco) with 10% FBS (bioSera), 5 ml of 
antibiotic/antimycotic solution (Hyclone) and 5 ml of non-essential amino acids 
(Gibco).  
HEK 293FT cells were cultured in DMEM media with additives as above and additional 
5ml of geneticin G418 (100mg/ml, Autogen Bioclear) for selection of plasmid bearing 
SV40 T antigen.  
All cells were grown in T-flasks at 37ºC and 0.5% CO2.  Passages were performed after 
cells reached monolayer confluency of 80-90%.  After washing with PBS, cells were 
trypsinised for 2-5 minutes. Trypsin was neutralised by addition of DMEM with FBS 
and cells were seeded in fresh media at a dilution 1:12 for HEK cells and 1:6 for Huh7 
cells. 
Cell stocks were stored in liquid nitrogen in growth medium with 10%FBS and 10% 
DMSO at around 1 × 107 cells per 1 ml. 
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Table 2.7. Components of mammalian cell culture media additives. 
Components of media additives Concentration  
Antibiotic/antimycotic solution 
Penicillin G 10,000U/mL 
Streptomycin 10,000µg/mL 
Amphotericin B (Fungizone) 25µg/mL 
Non-essential amino acids solution 
Glycine 750 mg/L 
L-Alanine 890 mg/L 
L-Asparagine 1320 mg/L 
L-Aspartic acid 1330 mg/L 
L-Glutamic Acid 1470 mg/L 
L-Proline 1150 mg/L 
L-Serine 1050 mg/L 
2.19. Expression of proteins in mammalian cells 
For efficient production of HCV E1E2 glycoproteins, 293FT cells were transfected with 
plasmids bearing target insert sequences. Cells were seeded in 10 cm dishes 24 hours 
before transfection in amounts allowing 40-60% confluency on the following day. 
Transfections were performed with PEI transfection reagent (Exgen 500- Fermentas). 
Twenty- Ɋ       ȋ
Ȍ       ? ? ? ɊǤ ?Ɋ  ? ? ?Ɋ
incubated at room temperature for 45 minutes. For the transfection event, cell media 
was changed from DMEM to Opti-MEM and subsequently DNA-PEI mix was added. 
After overnight incubation media was changed back to DMEM. 72h post-transfection, 
cells were harvested in 1 ml cell lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris pH 
7.4, 1 mM EDTA).  
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2.20. Polyacrylamide gel electrophoresis of proteins  
Quality of expressed proteins was analysed using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) [329, 339], followed by visualisation 
using Western Blotting [340]. 
Ten % polyacrylamide gels were cast in a slab kit [341]. The resolving gel consisted of 6 
ml of deionised water, 5ml of 30% acrylamide: bisacrylamide solution, 3.8 ml of 1.5 M    ?Ǥ ?ǡ  ? ? Ɋ   ? ? ?   ȋȌǡ  ? ? ? Ɋ   ? ? ? ȋȌ ? ?Ǥ ?ɊǤ 
Once polymerised, the resolving gel was overlayed with 5% stacking gel made with 3.4 
ml of deionised water, 0.83 ml of 30% acrylamide: bisacrylamide solution, 0.63 ml of 1   ?Ǥ ?ǡ  ? ?Ɋ  ? ? ?ǡ  ? ?Ɋ  ? ? ?  ? ?ɊǤ
inserted between slabs to form sample wells. 
The samples for analysis were prepared by mixing equal volumes of protein solution 
and gel loading buffer (125 mM Tris-HCl pH 6.8, 20% glycerol, 4% SDS, 0.002% 
bromophenol blue in water). Samples were then heated at 95ºC for 5-10 minutes to 
allow denaturation and coating with SDS, and briefly centrifuged before adding 20-30 Ɋ   Ǥ       s (Spectra 
Bright full range, Fermentas) in tris-glycine buffer (25mM Tris, 250 mM glycine, 0.1% 
SDS, pH 8.5) at 150V for around 90 minutes. 
Resolved proteins were either visualised by direct Coomassie staining or transferred 
onto a nitrocellulose membrane for further Western Blotting analysis. 
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For staining, gel was transferred into a Coomassie dye (2.5g Brilliant Blue R250, 450 ml 
water, 450 ml methanol, 100 ml glacial acetic acid) for 1 hour. Destaining was 
performed by boiling the gel in clean deionised water until protein bands were clearly 
visible. 
2.21. Western Blotting analysis of proteins 
After electophoresis, proteins were transferred from the gel onto a sensitive ECL 
membrane (GE Healthcare) in a semidry blotter (BioRad). Whatman paper and 
nitrocellulose membrane were soaked in transfer buffer (48 mM Tris, 39 mM glycine, 
20% methanol, 1.3 mM SDS) and the transfer apparatus was assembled. The gel was 
facing the negatively charged plate and the membrane facing the positively charged 
plate in order to allow protein migration. Transfer was carried out at 1 mA/cm2 for 
around 90 minutes. Efficiency of the process was assessed by eye examination of the 
amount of prestained weight marker that migrated to the membrane. 
Following electrotransfer, to prevent interactions between the membrane and the 
antibody used for detection of the target protein, ECL membrane was soaked in 
blocking solution (5% milk powder in 0.05% PBS-Tween) for one hour at room 
temperature or overnight at 4 ºC. Membrane was washed between each stage 3 times 
for 5 minutes in PBST. For detection of proteins different primary antibodies were used 
(see Table 2.8). Incubation was carried out for 1 hour at room temperature or 
overnight at 4ºC. After washing membrane was probed with secondary anti-mouse 
IgG1 HRP conjugate (DAKO) at 1:1000 dilution in 10 ml of PBST for 1 hour.  Following 
final washing membrane was immersed in ECL detecting reagent (2.5 ml solution 1+ 
2.5 ml solution 2, in house method), placed between acetate sheets and exposed onto 
Kodak BioMax Light film. Solution 1 was made up in deionised water to a total volume 
  
90 Materials and methods 
of 100 ml containing 1 ml of 250 mM Luminol in DMSO, 0.44 ml of 90mM Coumaric acid  ? ? ? ?Ǥ ?Ǥ ? ? ?Ɋ
of 30% H2O2 and 10 ml of 1M Tris pH 8.5 in deionised water. 
Table 2.8. List of primary antibodies used in Western Blotting analysis. 
Antibody Protein detected Concentration Reference 
AP33 HCV E2: soluble, bound in 
heterodimers, 
incorporated on 
pseudoparticles 
hybridoma supernatant 
diluted 1:400 in 10 ml of 
PBST 
[342], kindly provided by 
Arvind Patel 
R187 MLV core 
hybridoma supernatant 
diluted 1:200 in 10 ml of 
PBST 
ATCC CRL1912, kindly 
provided by Jean 
Dubuisson 
2.22. Generation of HCV pseudotyped particles 
Murine leukaemia virus (MLV) - HCV pseudotypes were generated by co-transfection of 
HEK 293T cells with 3 plasmids: phCMV-5349 containing the MLV polyprotein Gag-Pol, 
pTG-Luc126 encoding the reporter gene of firefly luciferase and pcDNA3.1 E1E2, a 
commercially avaiable expression vector with inserts derived from target HCV E1E2 
sequences (system first described in (Bartosch, 2003 #14)). Co-transfections were 
performed in 10 cm dishes with 40-60% confluent 293T cells using PEI transfection 
reagent (Exgen 500- 	ȌǤ   Ɋ     2O to a total 
volum ? ? ?Ɋ ? ? ?Ɋȋ ?ɊȌ
room temperature for 45 minutes. For the transfection event, cell media was changed 
from DMEM to Opti-MEM and subsequently DNA-PEI mix was added. After overnight 
incubation media was changed back to DMEM. 72h post-transfection media containing  ?Ǥ ? ?ɊǤ 
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2.23. Infectivity assay 
Huh 7 cells were seeded in 48 cell clusters, in a concentration 40 000 cells per well in 
0.5ml. Growth   ? ? ?Ɋ ? ? ?ɊǤ ? ?Ǥ       ? ? Ɋ   ȋȌ   
performed according ǯ ? ?Ɋ
(Promega). Relative light units emission (560nm) was read using a luminometer 
(Fluorostar Optima, BMG Labtech). 
2.24. Production and purification of CD81-LEL 
In order to perform receptor binding assays of target glycoproteins, large extracellular 
loop [6] of CD81 in fusion with GST was produced in bacteria. Overnight culture of E. 
coli strain BL21 bearing plasmid with GST-CD81-LEL sequence in LB with ampicillin 
was refreshed 1:100 and cultured until OD600=0.8. Expression of the protein was then 
induced by adding IPTG (0.5mM). After further 4 h of incubation cells were centrifuged 
at 4000 × g for 10 minutes at 4ºC. Pellets from 1000 ml of culture were resuspended in 
30 ml of lysis buffer (0.1% Triton, 0.5mM DTT with protease inhibitor cocktail (Roche) 
in PBS) by vortexing and frozen at -20ºC. Lysates were placed in a water bath set at 
25ºC and, after complete thawing, were incubated for a further 25-30 minutes. 
Freezing- thawing cycle (as above) was repeated and then solutions were centrifuged 
at 15000 × g for 40 minutes at 4 ºC. 
Supernatants were added to 1.5 ml of glutathione agarose slurry obtained by swelling 
0.07g of beads (Agarose 4B, Sigma Aldrich) overnight in water. Protein was allowed to 
bind to the beads overnight; incubation was carried out at 4 ºC with rotation. The 
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solution was then purified by sequential steps of washing and centrifugation at 750 × g 
for 2 minutes. Firstly, two wash steps were performed with previously used lysis buffer 
without protease inhibitors. Second, washing solution containing high salt (20 mM 
Tris-HCl pH 7.5, 300 mM NaCl) was applied twice. Lastly, two steps of washing were 
performed with low salt solution (20 mM Tris-HCl pH 8.0). The protein was harvested 
in solution with high glutathione concentration (0.1 M Tris-HCl pH 8.0, 10 mM 
glutathione) that out-competed glutathione immobilised on beads. 
Quality of purified protein was assessed by SDS-PAGE (described in 2.20) followed by 
Coomassie staining and Western Blot analysis (see chapter 2.21). Samples were 
quantified in Pierce BCA protein assay. 
2.25. Bicinchoninic acid (BCA) protein assay 
Quantitation of total protein in samples was performed in a colorimetric reaction based 
on bicinchoninic acid [343]. 
A commercially available kit (Thermo Scientific) was used for ǤɊ
of serial diluted samples were transferred to a microtiter plate in parallel to Bovine   ȋȌ  Ǥ  Ɋ    ȋ ? ǡ ? ? ?ɊȋȌȌǤe wrapped in cling film to 
avoid evaporation and incubated at 37ºC for 1 hour. Absorbance was read in 
spectrophotometer at 550 nm. 
Standard curve for BSA dilutions was generated in Prism and concentrations of protein 
samples were calculated. 
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2.26. ELISA 
Enzyme Linked ImmunoSorbent Assays [214] [344] were used to characterise antibody 
binding to target E1E2 glycoproteins. 
2.26.1. GNA capture ELISA 
96-well Immulon (Thermo) plates were coated with the Galanthus Nivalis Agglutinin ȋ
Ȍ   ?ɊȀ   ? ? ɊȀ -bicarbonate buffer (schematic design in 
Figure 2.4). Incubation was carried out at room temperature for 2 hours or overnight at  ? ?Ǥ
 ? ? ? ?ɊǤǡ
prevent interactions between the plate wells and the antibody, a solution of 5% milk 
powder in 0.05% PBST was added for 1 hour at room temperature or 4ºC overnight. 
Tested proteins were then captured from cell lystates overnight at 4ºC. Lysates 
containing proteins were purified prior to use by centrifugation at 20000 × g for 30 
minutes at 4ºC. Unbound proteins were washed off as previously described. 
Detection of proteins was performed with different antibodies (see Table 2.9) at 
varying concentrations to obtain titration curves. Secondary antibodies used were 
conjugated with horse radish peroxidase (HRP) and colour reactions were developed   ? ? ? Ɋ  ȋȌ Ǥ      ? ? ? ? ? ?Ɋ ?sSO4 at 
450nm. 
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Figure 2.4. Schematic representation of GNA capture ELISA. 
 
Table 2.9. List of primary antibodies used in GNA capture ELISA. 
Antibody Origin 
Epitope/ aa 
residues
1 
CD81 
binding 
competition 
HCVpp 
neutralisation 
Reference 
AP33 Mouse 412-424 + + [342], kindly provided by 
Arvind Patel 
ALP98 Mouse 640-654 - + [342], kindly provided by 
Arvind Patel 
1:7 Human 525, 530, 535 + + [345] Kindly provided by 
Matts Persson 
ML1 Human 424, 525, 530, 
535 
+ + [169] *described as AR3A, 
Kindly provided by 
Mansun Law 
ML2 Human Discontinuous + + [169] *described as AR3B, 
Kindly provided by 
Mansun Law 
DB1 Human 540, 549 - - Kindly provided by 
Mansun Law 
1
 amino acid position numbered according to H77 polyprotein coordinates 
 
2.26.2. CD81 capture ELISA 
ELISA was also applied to investigate glycoprotein binding to the putative HCV receptor 
CD81 (schematic design in Figure 2.5)Ǥ 	 Ɋ  
-CD81- ȋ ? ? ɊȀ 
carbonate-bicarbonate buffer) was incubated at 4ºC overnight in wells of Immulon 
microtitre plate. Excess of CD81 was removed and blocking performed as described 
above. Similarly prepared lysates were captured by CD81 in wells at 4ºC overnight. To 
reduce background, primary antibody ALP98 was diluted in 5% milk in PBST and 
hybridised to proteins for 2 hours at room temperature. After washing, probing was 
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carried out with anti-mouse antibodies conjugated with alkaline phosphatase (AP) 
(Sigma) at 1:1000 dilution in PBST.  
Detection of E1E2 capture by CD81 with antibody ALP98 results in very low signals. To 
overcome this obstacle AMPAK ELISA detection system (Invitrogen) was used. 
Excess of alkaline phosphatase was removed by washing the plate  ? ? ? ?ɊǤǯǤ ? ?Ɋ
reconstituted AMPAK substrate were carefully sampled to wells. After 15 minutes of 
incubation at room temperature, reconstituted amplifier was added in the same 
manner. Reactions were incubated until sufficient colour intensity was observed and  ? ?Ɋ ?Ǥ ?2SO4. Absorbance was read at 495 nm. 
 
Figure 2.5. Schematic representation of CD81 capture ELISA. 
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3. Transmission of HCV in the xenomouse model 
3.1. Results 
In natural infection, identifying the genetic and phenotypic determinants which 
facilitate HCV transmission is challenging as most cases of acute HCV infection are 
asymptomatic. Many previous studies of acute HCV infection are missing samples from 
donor populations, which precludes assessment of the dynamics of viral populations at 
transmission. Studies performed in experimentally infected chimpanzees have multiple 
drawbacks and limitations. In this study we utilised immunocompromised mice with 
human liver grafts to allow assessment of HCV envelope glycoprotein evolution at the 
transmission step of the viral life cycle, defining viral populations in both the donor 
inoculum and recipient chimeric mice. 
3.1.1. Amplification of full-length E1E2 sequences 
A cohort of eleven Alb-uPA/SCID mice transplanted with human hepatocytes from 
different donors were inoculated with HCV infected serum from a single source. Donor 
sera (KP) was obtained from an HCV+ patient in the chronic phase of infection, with 
time since initial infection estimated at more than 5 years. Mice were bled at different 
time-points post infection (see Table 2.1 in 2) and HCV RNA was extracted. HCV RNA 
was also extracted from the donor serum. 
To accurately assess the changes in E1E2 population dynamics occurring during our in 
vivo HCV transmission events, a single genome amplification (SGA) approach was 
employed, followed by direct sequencing. Full-length E1E2 genes from sequential 
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serum samples (2 time points), derived from 4 mice were amplified. Full-length E1E2 
sequences were directly sequenced and aligned.  
In total we obtained 36 end-point titrated full length E1E2 sequences from KP 
inoculum and 136 sequences derived from four mice (24 to 44 for each mouse, median 
35 and 11 to 22 sequences for each time point, median 18). A total of 10 bulk amplified 
consensus E1E2 sequences derived from all 10 experimentally infected mice were also 
obtained for control purposes (see Table 3.1).  
Table 3.1. Summary of mice and donor data for sequences amplified by bulk and end-
point titration methods. 
Patient/ 
Mouse ID 
Population 
sampling 
Serum 
HCV (IU/ml) 
Hepatocyte 
donor 
Time post- 
inoculation 
(days) 
Number of 
SGA 
amplicons 
KP KP 1 ×10
6
 - - 36 
A594 594_1 8.09 ×10
5
 II 32
 
13 + Bulk 
 594_2 1.01 ×10
6
 II 59 17 
N666 666_1 2.69 ×10
6
 I 14 22 
 666_2 2.49 ×10
6
 I 28 20 
N714 714_1 1.16 ×10
6
 I 14 21 
 714_2 1.54 ×10
6
 I 28 19 
A931 931_1 8.61 ×10
7
 III 21 11 
 931_2 2.94 ×10
7
 III 42 13 
 A931 8.04 ×10
7
 III 28 NA, Bulk 
A583 A583 8.40 ×10
5
 II 32 NA, Bulk 
A596 A596 1.73 ×10
5
 II 32 NA, Bulk 
A585 A585 2.99 ×10
5
 II 32 NA, Bulk 
A587 A587 9.79 ×10
6
 II 32 NA, Bulk 
A902 A902 4.46 ×10
7
 III 28 NA, Bulk 
A909 A909 1.96 ×10
7
 III 28 NA, Bulk 
A965 A965 7.73 ×10
6
 III 28 NA, Bulk 
I = 36 year old female, II = 45 year old female 92% viability polycystic tissue, III = 4 year old male 92% 
viability normal tissue 
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3.1.2. Assessment of intra and inter population genetic 
distances and diversity 
To determine whether there were significant differences in the genetic  diversity 
apparent in pre and post transmission viral populations, genetic distances were 
calculated using MEGA 5.0 [346]. Genetic distance was calculated individually for KP 
inoculum derived sequences and compared to genetic distance from post transmission 
sequences at two time points (only SGA derived sequences were included in 
calculations). These analyses show that pairwise genetic distance within sequence 
populations rises significantly after transmission (see Figure 3.1 and Table 3.2). When 
post transmission viral populations were analysed according to sampling points, a 
significant rise in genetic diversity was observed for all comparisons with the exception 
of 594 time point 2, when compared to KP source. When genetic distance was 
calculated for total post transmission populations (both time points combined) all 
apart from mouse 594 showed significant rise as compared to KP (see Figure 3.2 and 
Table 3.3). Together these data demonstrate an increase in genetic diversity post 
transmission in Alb-uPA/SCID chimeric mouse model. 
Additionally we also calculated the diversity index for pre and post transmission viral 
populations (Table 3.4 and Figure 3.3 A). Diversity index is a measure of the number of 
unique sequences in a population. In a similar fashion to increasing intrapopulation 
genetic distance, we also observe increasing diversity index post transmission i.e. there 
are more unique sequences identified after the transmission event than prior to it. Next 
we calculated the ratio of non-synonymous to synonymous substitutions (dN/dS) in all 
viral populations using MEGA 5.0 (Table 3.4 and Figure 3.3 B). dN/dS ratio is a measure 
of positive diversifying selection. A dN/dS ratio <1 indicates purifying selection. A 
dN/dS ratio equal to 1 indicates genetic drift. And dN/dS ratio >1 indicates positive 
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selection is acting upon our sequence population. Unlike genetic distance and diversity 
index the dN/dS ratio does not change significantly between pre and post transmission 
populations. All dN/dS ratios are significantly below 1 indicating purifying selection as 
the major evolutionary pressure shaping viral populations pre and post transmission. 
Together these analyses indicate that viral population complexity increases upon 
experimental transmission in chimeric mouse model, and purifying selection is the 
dominant evolutionary process shaping envelope glycoprotein evolution [239]. 
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Figure 3.1. Genetic distance (nucleotide substitution per site) values 
for full length E1E2 sequence populations (derived from SGA) per 
time-point in each xenomouse host. 
Table 3.2. Statistical analysis of differences between pre and post-
transmission populations by time-point in each xenomouse host. 
 Number of 
values 
Min Max Mean 
Std. 
Deviation 
KP 625 0 0.008 0.002402 0.001419 
594/1 78 0.00058 0.00813 0.003622 0.001592 
594/2 136 0 0.00347 0.000943 0.000869 
666/1 231 0 0.01048 0.003259 0.00196 
666/2 190 0.00058 0.00697 0.003526 0.001336 
714/1 210 0.00058 0.00755 0.003554 0.001505 
714/2 171 0 0.00697 0.003066 0.001325 
931/1 55 0.00058 0.00872 0.004847 0.001921 
931/2 78 0.00231 0.00522 0.003813 0.000721 
 
Dunn's Multiple Comparison Test Difference in 
rank sum 
Significant? 
P < 0.05? 
Summary 
KP vs 594/1 -404.0 Yes *** 
KP vs 666/1 -246.7 Yes *** 
KP vs 714/1 -396.9 Yes *** 
KP vs 931/1 -667.3 Yes *** 
KP vs 931/2 -551.9 Yes *** 
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Figure 3.2. Genetic distance (nucleotide substitution per site) values 
for full length E1E2 sequence populations (derived from SGA) per 
each xenomouse host (sampling time points combined). 
Table 3.3. Statistical analysis of differences between pre and post-
transmission populations by each xenomouse host (time points 
combined). 
 Number of 
values 
Min Max Mean 
Std. 
Deviation 
KP 625 0 0.008 0.002402 0.001419 
594 435 0 0.008 0.002147 0.001542 
666 861 0 0.01 0.003329 0.001731 
714 780 0 0.008 0.003277 0.001483 
931 276 0.001 0.009 0.004279 0.001577 
 
Dunn's Multiple Comparison Test Difference in 
rank sum 
Significant? 
P < 0.05? 
Summary 
KP vs 594 114.2 No ns 
KP vs 666 -499.5 Yes *** 
KP vs 714 -520.5 Yes *** 
KP vs 931 -990.5 Yes *** 
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] 
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Table 3.4. Diversity index and dN/dS ratio comparison between donor HCV populations 
circulating in donor and mice hosts. 
Patient/ Mouse 
ID 
Sequence 
population 
Number of SGA 
amplicons 
Diversity 
Index*  
Mean dN/dS 
ratio 
KP KP 36 0.472 0.2177 
A594 594_1 13 0.846 0.2420 
 594_2 17 0.235 0.06840 
N666 666_1 22 0.545 0.2020 
 666_2 20 0.700 0.1984 
N714 714_1 21 0.667 0.2073 
 714_2 19 0.737 0.2640 
A931 931_1 11 0.909 0.1793 
 931_2 13 0.846 0.2860 
* Calculated as number of unique sequences per total number of sequences in given population 
 
A 
 
B 
 
Figure 3.3. Diversity index (A) and dN/dS ratio (B) comparison between HCV populations 
circulating in donor and mice hosts. 
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3.1.3. Composite phylogenetic analysis of donor/recipient 
viral populations 
In order to reveal specific patterns of sequence evolution occurring during HCV 
transmission, a combined alignment containing all 172 SGA derived full length E1E2 
sequences from the donor and four recipient mice, was subjected to Maximum 
Likelihood [330] phylogenetic reconstruction. For control purposes bulk amplified 
E1E2 sequences derived from inoculum and mice samples were also included. The best 
fit substitutional model which gave rise to our observed sequence data set was 
estimated in Model Test v3.7 [335].  The best fit model (HKY+G) was utilised for the 
combined phylogenetic reconstruction and generated in PAUP under the ML criterion 
(Figure 3.4). 
The composite ML tree in Figure 3.4 depicts phylogenetic relationships between all 
sequences obtained in the chimeric mouse transmission study. Donor sequences of KP 
inoculum cluster together in an antecedent clade. Surprisingly, we do not observe 
monophyletic clustering of post transmission samples on the basis of the host mouse 
from which they were derived. All post transmission sequences cluster together in a 
mixed clade. However, interestingly two sequences from the donor inoculum clustered 
with the mixed recipient clade (KP_7, KP_22).  
Star-like phylogenies were constructed for each post transmission sequence population 
by the Neighbour Joining method (Figure 3.5). The majority of sequences derived from 
both donor and recipient chimeric mice were unique. However, groups of identical 
sequences were identified within the composite tree in both the donor and mixed 
recipient clades (and Figure 3.6). In the mixed post transmission clade identified 
groups of identical sequences were not necessarily derived from the same chimeric 
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mouse. Together these data suggest that the post transmission sequences do not cluster 
on the basis of recipient mouse and are genetically distinct from the donor sequences. 
While most sequences identified were unique, this data indicates there are genetic 
determinants, related to composition of incoming sequence population and, associated 
with transmission and establishment of initial infection in chimeric mouse model. 
These determinants are further analysed in following subchapters. 
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Figure 3.4. Phylogenetic 
reconstruction of envelope 
glycoprotein sequence 
complexity.  
Composite mid-point rooted ML 
(HKY+G) tree of SGA and bulk 
derived E1E2 sequences from KP 
inoculum and populations 
circulating in mice post 
transmission. Despite lack of 
contamination sequences do not 
cluster on the basis of study 
subject. Key: red circles- KP 
inoculum, green squares- mouse 
594 time point 1, green triangles- 
594 tp2, black squares- mouse 
666 time point 1, black triangles- 
666 tp2, blue squares- mouse 714 
time point 1, blue triangles-714 
tp2, pink squares- mouse 931 
time point 1, pink triangles- 931 
tp2, turquoise circles- bulk 
amplified sequences. The scale 
bar represents 0.005 nucleotide 
substitution per site. 
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Figure 3.5. Radiation Neighbour Joining trees for each intrahost viral population post- 
transmission.  
Panel A- Mouse 594, panel B- mouse 666, panel C- mouse 714, panel D- mouse 931. Key: 
Squares- sampling time point 1, triangles- sampling time point 2: green- mouse 594, black- 
mouse 666, blue- mouse 714, pink- mouse 931. 
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Figure 3.6. Ratio of unique sequences versus groups of identical nucleotide sequences in 
pre- and post- transmission viral populations. 
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3.1.4. HVR1 sequence analysis 
Previous experimental infections of chimpanzees with HCV indicate the majority HVR1 
sequence in the source inoculum is effectively transmitted and becomes the majority 
circulating variant post transmission. We next wanted to assess whether genetic 
determinants of effective transmission and establishment of initial infection were 
located within the HVR1 region. To compare transmission of HCV in uPA/SCID mice to 
previously reported studies of transmission in chimpanzees and humans [90, 207, 216] 
we translated HVR1 nucleotide sequences from both donor and recipient uPA/SCID 
mice into amino acid sequences. Analysis of 172 translated HVR1 amino acid sequences 
revealed that the major HVR1 variant in the donor population was also the major 
variant circulating in all inoculated mice (see Figure 3.7).  
A 
 
B 
 
 
Figure 3.7. Alignment of HVR1 amino acid sequence variants (A) and HVR1 variant 
frequencies amongst total populations of end-point titrated sequences in the donor and 
recipient mice (B). 
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Overall the major HVR1 sequence variant (seq1, Figure 3.7) was present in 83.14% of 
all analysed sequences. The major HVR1 variant was present in over 86% of donor 
sequences and constituted 100% of sequences in populations circulating in mouse 594 
and 931. None of the minor HVR1 variants present in KP inoculum were detected in 
any of the inoculated mice. In mouse 666 one new minor variant appeared (seq 2, 
Figure 3.7). This HVR1 variant also arose in mouse 714 and constituted over 42% of the 
population. Additionally another minor sequence variant (seq 7) was also detected. 
Interestingly all new HVR1 variants differed from the majority sequence only by one 
amino acid. Together these analyses indicate that the HVR1 is relatively stable upon 
transmission, mirroring the findings of transmission studies in chimpanzees. 
Importantly these data suggest that determinants of effective transmission and 
establishment of initial infection reside outside HVR1 and indicate the necessity of 
using full length E1E2 when studying HCV transmission. 
3.1.5. Individual phylogenetic analyses of donor/recipient 
intrahost populations 
Individual donor-recipient transmission events were further analysed using a 
combination of Highlighter plots coupled with phylogenetic analysis (Figure 3.8). While 
sequence diversity was limited in all xenomice, mirroring the restricted diversity 
observed prior to seroconversion in human hosts, the majority of sequences identified 
were unique. As in the combined analysis, donor sequence populations were largely 
distinguishable from xenomouse derived E1E2s. Highlighter plots and phylogenetic 
trees revealed mutational patterns associated with defined sequence variants within 
pre- and post-transmission populations. When compared to the KP consensus master 
sequence, three non-synonymous substitutions that were present at a low level in the 
source inoculum predominated in post transmission populations. All three of these 
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non-synonymous substitutions were located outside HVR1 (see Figure 3.8). The same 
mutational pattern was observed in each experimental transmission event. 
Analysis of encoded amino acid sequence alignments allowed us to identify four key 
E1E2 residues which are likely to be important in effective transmission and 
establishment of productive infection in a new host. Substitutions at amino acid 
residues 198, 448, 474 and more subtle variation at 570 were consistently observed 
when compared to the donor inoculum, irrespective of xenomouse host. Consensus and 
MRCA residues at these positions in each xenomice viral population can be seen in 
Figure 3.9 A. Substitutions at these positions appeared in one of 5 possible 
combinations SNHV, SDHV TDYD, and SDYV and TDYV/A, the frequencies of which are 
summarised in Figure 3.9 B.  
The majority E1E2 variant in the donor population possesses the SNHV discontinuous 
quartet combination. This combination of residues is encoded in ~90% of all donor 
E1E2 amplicons. The N448 residue is part of an NXS/T potential N-linked glycosytalion 
(PNG) motif which is highly conserved in the donor inoculum and in the majority of 
globally sampled HCV strains, presumably due to functional constraint. Surprisingly the 
concerned PNG site is absent in all post transmission sequences. The major pre-
transmission variant (SNHV), possessing functional glycan site at position 448, is not 
detectable in any mouse population. The TDYV/A quartet, which is undetectable in the 
donor population (see Figure 3.9) becomes the dominant post-transmission variant, 
irrespective of the recipient xenomouse host. Two additional combinations, TDYD and 
SDHV, appear at low frequency in all recipient xenomice viral populations. Both of 
these minority combinations possess a PNGS knockout at position 448. Both of the 
variants are also detected at low frequency in the donor E1E2 population. Additionally 
a novel SDYV variant, previously undetected in the donor virus population, was also 
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detected within first sampling time points of recipient mice 666 and 931. This rare 
variant was absent in later sampling time point of both xenomice. 
In conclusion, these data demonstrate that whilst HVR1 sequences remain stable in 
HCV transmission, key residues elsewhere in E1E2 are important in viral transmission 
and initiation of infection in a new host.  The application of the SGA method allowed 
accurate assessment of E1E2 sequence variant distribution in donor and recipient 
plasma. Analysis of full-length E1E2 allowed identification of key residues outside of 
HVR1 associated with establishment of initial infection and indicate that the major post 
transmission variant (TDYV/A) was undetectable in the donor population. However, 
the TDYD variant was detectable in the donor inoculum, and this sequence variant is 
only one substitution away from the major post transmission variant. In conclusion 
these findings suggest that a E1E2 key residue variant that is undetectable in the source 
inoculum is selectively amplified post transmission. It is likely that this key residue 
combination confers a fitness advantage in the new selective environment. 
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A 
 
I  T I A I C I G I silent I non-silent I transversion I C-T transition I A-G transition 
KP con 
nucleotide substitutions silent/ non-silent substitutions transitions/ transversions 
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B 
 
I  T I A I C I G I silent I non-silent I transversion I C-T transition I A-G transition 
KP_con 
nucleotide substitutions silent/ non-silent substitutions transitions/ transversions 
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C 
 
I  T I A I C I G I silent I non-silent I transversion I C-T transition I A-G transition 
KP_con 
nucleotide substitutions silent/ non-silent substitutions transitions/ transversions 
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D 
 
I  T I A I C I G I silent I non-silent I transversion I C-T transition I A-G transition 
Figure 3.8. Identification of transmitted variants of envelope glycoprotein genes in experimentally infected mice on the basis of phylogenetic 
reconstructions and highlighter plots.  
SGA derived sequences from post transmission samples from mouse 594 (A), 666 (B), 714 (C), 931 (D) were analysed by phylogenetic reconstructions 
(left panels) and Highlighter plots (right panels) including pre transmission donor population KP. Maximum Likelihood trees are rooted on KP 
consensus sequence which is a master sequence in corresponding highlighter plots. Highlighter diagrams depict location of substitutions in each E1E2 
sequence as compared to chosen master pre transmission sequence (KP consensus). 
KP_con 
nucleotide substitutions silent/ non-silent substitutions transitions/ transversions 
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A 
 
B 
 
Figure 3.9. Location of key transmission residues and frequency distribution of key 
residue variants in donor and recipient mice.  
(A)  Schematic E1E2 diagram depicting the locations of 4 key residues involved in 
transmission. Position of conserved PNG sites are indicated above the E1E2 protein with 
absolute polyprotein co-ordinates of four key residues positioned beneath numbered 
relative to homologous positions in the H77 reference strain polyprotein ORF (accession no. 
NC_004102). Coloured vertical columns located below key residues indicate donor and 
recipient consensus (top) and MRCA [164] amino acids derived from SGA amplicon 
populations, in addition to majority consensus amino acids bulk amplified from recipient 
xenomice [273]. (B) Frequencies of key residue combinations circulating within 
donor/recipient hosts. TP1 = time point 1; TP2 = time point 2. 
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3.1.6. Phenotypic analysis 
To test whether different key residue variants possessed different phenotypic 
properties, and assess the effect of the N448D knockout, three sequence variants 
(SNHV, SDHV and TDYD) were cloned into a pcDNA3.1 expression vectors. 
Unfortunately we were unable to clone the majority mouse variant (TDYV).  
3.1.6.1. Protein expression and antibody recognition 
Variant proteins were expressed individually in 293T cells. Although this method is not 
quantitative, Western Blotting analysis showed similar amounts of proteins being 
produced (see Figure 3.10) indicating no difference in translational efficiency and E1E2 
expression between the tested variants. Furthermore, variants were compared in plate 
based assays to assess any differences in binding to a panel of monoclonal antibodies as 
described in 2.26  
        1              2             3                4            5  
 
Figure 3.10. Expression of clones derived from representative sequences from variants 
circulating in experimentally infected mice.  
10% SDS-PAGE followed by Western Blotting hybridisation with AP33. Key: 1- H77.20, 2- 
SNHV, 3- SDHV, 4-TDYD, 5- mock. 
Results of GNA capture ELISAs with 5 recognised anti-E2 antibodies are presented in 
Figure 3.11. Figure 3.12 presents CD81 capture ELISA with detection by linear anti-E2 
antibody ALP98. Probing with antibodies recognising linear (AP33, ALP98) and 
conformational epitopes (Ab1:7, ML1, ML2, DB1) did not reveal any significant 
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differences in recognition. All analysed variants of E1E2 glycoproteins appear to be 
expressed at similar levels and folded correctly when expressed in 293T cells.  
A 
0.0001 0.001 0.01 0.1 1 10 100
0
1
2
3
H77
SNHV
SDHV
TDYD
mock
AP 33 concentration [ug/ml]
O
D
 6
2
0
 n
m
 
B 
0.0001 0.001 0.01 0.1 1 10 100
0.0
0.5
1.0
1.5
H77
SNHV
SDHV
TDYD
mock
ML1 concentration [ug/ml]
O
D
 6
2
0
n
m
 
  
120 Transmission of HCV in the xenomouse model 
C 
0.0001 0.001 0.01 0.1 1 10 100
0.0
0.5
1.0
1.5
H77
SNHV
SDHV
TDYD
mock
ML2 concentration [ug/ml]
O
D
 6
2
0
n
m
 
D 
0.0001 0.001 0.01 0.1 1 10 100
0.0
0.5
1.0
1.5
2.0
H77
SNHV
SDHV
TDYD
mock
DB1 concentration [ug/ml]
O
D
 6
2
0
n
m
 
  
121 Transmission of HCV in the xenomouse model 
E 
0.0001 0.001 0.01 0.1 1 10 100
0.0
0.5
1.0
1.5
2.0
H77
SNHV
SDHV
TDYD
mock
1:7 concentration [ug/ml]
O
D
 6
2
0
n
m
 
Figure 3.11. Antibody recognition of selected E1E2 in ELISA.  
Panels A, B, C, D, and E depict recognition of selected clones by antibodies AP33, ML1, ML2, 
DB1 and Ab 1:7 respectively. GNA capture ELISA, titration of antibody against set amount of 
proteins.  
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Figure 3.12. E1E2 binding to CD81-LEL in ELISA. 
CD81-LEL capture ELISA, titration of antigens against set concentration [1µg/ml] of antibody 
ALP98. 
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3.1.6.2. HCV pseudotyping 
HCV pseudotype (HCVpp) infection of Huh7 hepatoma cells by key residue E1E2 
variants was then performed (for method see sections 2.22 and 2.23). All tested 
HCVpps had comparatively low infectivity (when compared to the H77 E1E2 positive 
control) despite being recognised by antibodies in a similar manner to the control 
strain (Figure 3.14). However, a significant increase in capacity for target cell entry 
stage was noted for the TDYD and SDHV variants containing the N448D substitution, 
when compared to dominant donor SNHV variant. Thus we propose that the observed 
substitutions outsi  ?       ǯ    
level and that this may be modulated by the N448D substation which results in a PNG 
knockout. 
Subsequent HCVpp infection of primary hepatocytes and Huh 7.5 cells performed by 
our collabators at the University of Birmingham (Brown et al. Manuscript submitted) 
confirmed our preliminary data regarding differential entry fitness of key residue 
variants and indicate that the N446D substitution is integral in enhanced infectivity.  
     1              2                3             4                5            
 E1E2 
 GAG- POL 
Figure 3.13. Western Blotting analysis of HCV pseudoparticles.  
Upper panel- E1E2 detected by AP33 probing, lower panel- Gag-Pol MLV protein detected 
by Anti-GAG antibody. Key: 1- H77, 2- SNHV, 3- TDYD, 4- SDHV, 5- ȴ ? ? ? 
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Figure 3.14. Phenotypic analysis of selected E1E2 by HCVpp infectivity assay. 
3.2. Discussion  
In the first part of this study, the xenomouse model was utilised to investigate the 
evolutionary mechanisms underlying HCV transmission. The majority of studies 
focussing on acute HCV infection are unable to assess the dynamics of the preceding 
transmission event due to lack of known donor samples. This is largely as a result of the 
asymptomatic nature of acute infection. Additionally, many studies of HCV variants 
evolution utilise only partial E1E2s, centred on the HVR1 region. Regions important in 
HCV transmission and establishment of productive infection outside of HVR1 may be 
missed using only partial envelope sequences. Using partial E1E2 sequences also 
precludes meaningful subsequent phenotypic investigation. Contrastingly, our 
investigation is the first to describe HCV full-length E1E2 glycoprotein variants 
distribution from a defined source at transmission. E1E2 sequences were derived from 
single genome templates, minimising in vitro generated artefacts, which may skew the 
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sequence variants distribution and misrepresent evolutionary processes underlying 
observed sequence diversity. In addition, Alb uPA/SCID xenomice were experimentally 
infected with a known source inoculum whose sequence population was also 
interrogated. The full-length nature of the E1E2 sequences retrieved also enabled 
phenotypic characterisation of donor and recipient glycoproteins at transmission. 
To ensure accurate and representative sampling of both donor and recipient 
quasispecies populations, an SGA approach was utilised. The SGA method, followed by 
direct sequencing, has been previously applied to characterise viral quasispecies 
populations in HIV-1 [220, 320-322] and HCV infection [323]. PCR Amplification from 
single molecule cDNA templates is preferable to the standard bulk amplification and 
cloning approach when analysing viral quasispecies as it excludes polymerase induced 
nucleotide misincorporation, amplicon re-sampling, selective amplification of specific 
isolates, cloning bias and the generation of in vitro recombinants via polymerase 
template switching. In traditional approach of clonal analysis low frequency population 
variants can be missed or overrepresented, which can be precluded by use of SGA 
approach. Furthermore, SGA is not affected by the limitations of ultra-deep sequencing 
technologies. Whilst the apparent nucleotide frequencies at each position within any 
given sequence population can be assessed using UDS, genomic linkage between 
substitutions cannot be ascertained via this method.    
When the total donor/recipient data set was analyzed in a composite tree, a lack of 
monophyletic clustering based on recipient xenomouse was observed. However, the 
majority of donor E1E2 sequences were phylogenetically distinct, residing in an 
antecedent clade.  The branching pattern observed in the composite tree is due to 
synapomorphic substitutions common to all post transmission populations. These data 
suggest the different xenomouse hosts constitute highly similar selective environments, 
despite possessing human liver grafts from differen
  
125 Transmission of HCV in the xenomouse model 
transmission clade contains two isolates derived from the KP source inoculum. 
Analyses of individual donor/recipient populations revealed that the composition of 
sequence populations changed dramatically in separate parallel transmission 
experiments from the composition observed in donor inoculum. Irrespective of 
recipient xenomouse viral sequences analysed, a minor E1E2 variant circulating within 
the donor becomes the dominant variant within the newly infected xenomice. It is 
likely that this minor variant, present in the source incoculum at low frequency, would 
have been either absent or overrepresented if a clonal analysis of the viral sequence 
population had been employed. Previous investigations report low genetic diversity 
shortly after infection, which has been interpreted as founder effect: infection 
originating from limited diversity inoculum or single virus. The genetic signature of 
founder effect (establishment of infection from a single strain) is indistinguishable from 
a selective sweep (a selectively advantageous genetic variant is swept to fixation in the 
recipient) in contemporaneously sampled populations. However, knowledge of the 
genetic composition of the donor viral population allows us to assess which of these 
two competing evolutionary scenarios is most likely to have given rise to the sequence 
distributions observed in recipient xenomice. By comparison of donor and recipient 
viral sequence populations, our analyses indicate a selective sweep occurring upon 
transmission, whereby the frequency of one of the minor variants at undetectable level 
in donor inoculum becomes the major variant within all the experimentally infected 
xenomice. This phenotype is advantageous in the immunocompromised mouse, which 
possesses no adaptive immune system, and is swept to fixation due to increased fitness 
in a new selective environment. Analysis of transmission events in several mice 
suggests that this variant arose in the host, preceding the experimental infection, as 
opposed to developing independently post-transmission in each host. 
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Our findings are in agreement with previous reports, suggesting the major HVR1 donor 
variant is established as the major variant in recipients after transmission [212, 213, 
215, 217]. In this respect, the xenomouse Alb uPA/SCID model appear to mimic the 
HVR1 evolutionary stasis observed at transmission between human hosts and 
experimental transmission from human to chimpanzee. However, expanding the 
sequence coverage to encompass full-length E1E2 sequences revealed contrasting 
results to previous transmission studies, that advocated phylogenetic grouping of 
envelope sequences based on HVR1 sequence analysis [236].  
Our data revealed three key amino acid sites (198, 448 and 474) and subtle variation at 
a fourth position (570) played a role in establishment of a productive infection in a new 
host in the xenomouse system. The major donor variant SNHV appeared unsuccessful 
in establishing infection post transmission and was outcompeted by the TDYD variant, 
which became the dominant component in all recipient xenomice. All post-transmission 
E1E2s harbour an NoD PNGS knockout, which presumably confers a selective 
advantage in each xenomouse host. A PNGS knockout at position 448 (corresponding to 
glycan E2N4) has previously been shown to abrogate H77 E1E2 pseudoparticle 
infectivity [347]. However, in the JFH-1 HCVcc system PNGS 448, has not affected 
infectivity although has been demonstrated to render envelopes more susceptible to 
neutralisation by a panel of anti-E2 monoclonal antibodies, indicating PNGS 448 is 
critical in shielding neutralisation sensitive epitopes from immunological targeting 
[71]. This would suggest that TDYV variant is selectively amplified due to the fitness it 
harbours in the new host in the absence of neutralising antibodies. Unfortunately we 
were unable to access any of the original KP inoculum to perform neutralisation tests to 
assess this hypothesis. However, none of the variants demonstrated variability in 
sensitivity to antibodies whose epitopes overlap or are the in vicinity of the CD81 
binding site. This indicates that antibody selective pressure against the TDYV sequence 
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variant in the donor population would have been directed outside the CD81 binding 
site. 
In our hands pseudotype KP and mouse-derived E1E2 clones showed very low level 
infectivity in HCVpp when used to infect Huh7 cells. Nevertheless the infectivity 
conferred by the mouse derived E1E2 was greater than that conferred by the major 
variant present in the KP inoculum. Further analysis, performed by our collaborators, 
showed significance of this difference by use of primary hepatocytes and obtaining 
higher levels of infectivity (Brown et al. submitted). This fact is in agreement with 
observations made in the liver transplantation setting, where viral variants with 
increased capacity for cell entry have been shown to lead the re-infection of grafted 
liver [236]. 
A number of different donors were used to supply hepatocyte grafts for the xenomice 
utilised in this investigation. HCV infection of recipient xenomice is dependent on a 
high percentage of human graft in each uPA/SCID mouse [277]. It has previously been 
demonstrated that HCV does not replicate in mouse hepatocytes [348]. Thus 
productive viral replication and infectious particle production observed in recipient 
xenomice can only be sustained by engrafted human hepatocytes. The observed E1E2 
adaptations in recipient xenomouse virons will therefore have been driven to fixation 
by their ability to enter and replicate in human hepatocytes, indicating the xenomouse 
system is a useful surrogate model to enable interrogation of HCV quasispecies 
transmission to a HCV naïve host and establishment of initial infection prior to 
seroconversion.  
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4. Tracking a naturally occurring HCV transmission 
event 
4.1. Results 
Having assessed the dynamics of HCV experimental transmission in the chimeric mouse 
model, we then investigated a case of HCV transmission acquired through sharing a 
haemodialysis machine. Patients undergoing haemodialysis are at increased risk of 
HCV infection [317]. Horizontal transmission between haemodialysis patients has been 
well documented [318, 349]. Standard infection control procedures have been shown 
to drastically reduce nosocomial spread of HCV within dedicated haemodialysis units 
[350]. Transmission of HCV to multiple patients using the same haemodialysis machine 
is not well documented. Consequently dedicated hemodialysis machines for HCV 
infected patients are not routinely used. Using phylogenetic analysis we confirm a case 
of nosocomial HCV transmission between patients receiving haemodialysis in the same 
unit, after sharing the same machine. These analyses have implications for health care 
management guidelines. 
4.1.1. Case study background 
A 51-year-old HCV negative woman had been receiving regular haemodialysis at the 
Glasgow unit for 7 years. Routine anti-HBV and anti-HCV antibody testing 
demonstrated negative results throughout this period. However anti-HCV antibody and 
corresponding HCV PCR returned positive in September 2009. Retrospective analysis of 
samples acquired in June 2009 confirmed HCV PCR positivity and antibody negativity 
indicating acute infection, giving a likely window the time line for the infection event. 
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Other risk factors for HCV infection were eliminated. All regular unit patients were HCV 
antibody negative. However, the index patient received four separate dialysis sessions 
immediately following a known HCV positive patient, at a different inpatient unit after 
hospital admission for unrelated complication in late March/early April [317].  
4.1.2. Amplification of full-length E1E2 sequences 
To ascertain whether index case and hypothetical source viruses were related, multiple 
samples from both patients were received from the renal unit in Glasgow. Subsequently 
viral RNA was extracted, cDNA reverse transcribed and used for template in PCR 
amplification. Received samples had very low viral titres and consequently it proved 
difficult to amplify full-length E1E2 sequences. Serum samples that did not yield       ?ǯ-NCR fragments or E1E2 after QIAGEN RNA 
extraction were extracted subsequently using the EasyMAG technique (seeTable 3.5, 
both methods described in 2.2). Amplification of full length glycoprotein sequences was 
performed from viral cDNAs and were directly sequenced. From three samples derived 
from the suspected source, only one yielded a full length E1E2 sequence.  For five index 
case samples only three yielded sequences. Reasons for these apparent low titres could 
be due to repeated freeze-thawing of the sera prior to arrival to Nottingham, or 
contamination with RNAses.  For the purposes of comparison an additional 19 
genotype 3A infected serum samples from Glasgow renal unit were also acquired. Full 
length E1E2 sequences were derived from six of these samples.   
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Table 4.1. Summary of extraction and DNA amplification results within low titre 
transmission samples.  
ZEƐĂŵƉůĞƐƚŚĂƚĚŝĚŶŽƚǇŝĞůĚĞŶŽƵŐŚĐEĨŽƌ ? ?EZŽƌ ? ?ĂŵƉůŝĨŝĐĂƚŝŽŶwere 
extracted again with alternative method. For second batch of samples only Easy-MAG 
method was applied. 
 
Sample 
Label 
QIA- RNA extracted MAG- RNA extracted 
  ? ?EZ
amplification 
E1E2 
amplification 
 ? ?EZ
amplification 
E1E2 
amplification 
Index case 
samples 
IC1  ?  ? + (faint)  ? 
IC2 + (faint) + N/A N/A 
IC3 + (faint) + N/A N/A 
IC4 + (faint)  ? N/A N/A 
IC4 (RNA) + (faint) + N/A N/A 
Hypothetical 
source samples 
HS1  ?  ?  ? N/A 
HS2  ?  ? +  ? 
HS3 + (faint)  ? + + 
Unrelated 
control patient 
samples 
PG  ?  ? +  ? 
PF  ?  ? + + 
PC + (faint)  ?  ? N/A 
PD  ?  ? +  ? 
PA  ?  ?  ? N/A 
PE + (faint) + N/A N/A 
PB + (v faint) + N/A N/A 
PH  ?  ?  N/A 
PI  ?  ? +  ? 
 PT N/A N/A + - 
 PS N/A N/A - N/A 
 PR N/A N/A + - 
 PP N/A N/A - - 
 PO N/A N/A + + 
 PN N/A N/A + + 
 PM N/A N/A + - 
 PL N/A N/A + - 
 PK N/A N/A + + 
 PJ N/A N/A + - 
N/A- result not available/ amplification was not performed 
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4.1.3. Phylogenetic analysis of outbreak and control samples 
Nine epidemiologically unrelated Nottingham E1E2 genotype 3A sequences were also 
introduced to analysis. Composite phylogenetic analysis of source, index and control 
sequences was conducted. Bootstrapped phylogenetic trees for HCV E1E2s, both 
nucleic acid and amino acid sequence revealed clustering of suspected 
epidemiologically linked sequences, indicating that HCV transmission on the renal unit 
was indeed the source of the outbreak. This analysis suggests infection with closely 
related strain of virus and high probability of index case infection acquired from the 
hypothetical source (Figure 3.15). The same relationship is evident for related control 
sequences. UKN3A2.12, UKN3A2.28 and UKN3A2.4/SP-1/B4 E1E2s cluster together 
with 100% bootstrap support and are derived from the same patient at different 
sampling time points. Sequences UKN3A4.6 and UKN3A4.37, which are also both 
derived from an additional patient also cluster together with significant bootstrap 
support. Other unrelated control samples do not cluster, or if they do- bootstrap values 
are below 70% (apart from PN and PO) and internal branches are relatively long. 
These analyses confirm a case of nosocomial HCV transmission acquired from sharing a 
haemodialysis machine, using phylogenetic analysis. No fault was found with the 
dialysis machine in question. Thus, on the basis of this data, we propose that HCV 
infected patients should receive dedicated haemodialysis machines which should not 
be shared with non-HCV infected patients, which is not currently standard practice. 
Implementation of this strategy would remove the HCV infection risk factor associated 
with haemodialysis. 
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 IC 2
 IC 3
 IC 4
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 UKN3A4.6
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 PE
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100
100
100
100
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0.005  
B 
 HS 3
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 IC 4
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 UKN3A2.12
 UKN3A2.28
 UKN3A2.4/SP-1/B4
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 UKN3A18.13
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100
100
99
100
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0.005  
Figure 4.1. Phylogenetic Neighbour-Joining reconstruction of genotype 3A transmission.  
Clustering of the source and recipient derived sequences is supported by 100% of the 
bootstrapped replicate trees. Panel A- nucleic acid, Panel B- amino acid sequence 
phylogeny. Bootstrap values below 70% are hidden. Key: red circle- hypothetical source 
samples, blue squares- index case samples, black triangles- unrelated control patient 
samples from Glasgow, black rhombuses- unrelated patient sequences from Nottingham. 
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4.2. Discussion  
In the second part of the study we have demonstrated that the virus strain infecting the 
index case patient indeed originated from the suspected source, by use of phylogenetic 
analysis. Molecular techniques have been successfully introduced to evolutionary study 
of relationships between organisms. The information obtained from nucleic acid 
sequences has undermined previous location of the human branch on the evolutionary 
tree, based on fossil data [351]. In case of viral diseases fossils are not available leaving 
only evolutionary biology as the means of resolving their origins and relationships. 
Precedence for use of phylogenetic relationship as an evidence of viral transmission 
has been long observed for HIV-1 outbreaks. The case of a dentist, whose unsafe 
procedures resulted in multiple patients becoming HIV-1 positive, has been amongst 
the first ones [352, 353]. Following this case many dental surgeries have undergone 
screening and guidelines were revised. Molecular proof of relationship between 
suspected donor and recipient HIV-1 sequences have become a standard evidence for 
the occurrence of transmission widely used to support criminal cases [354-356]. 
Similar approach has been employed to investigate HCV outbreak in anti-D 
immunoglobulin recipient cohort [357].  
The investigated infection, as corroborated from the epidemiological data, could have 
occurred within a very limited time whilst index case individual was hospitalised and 
used the same haemodialysis unit as the suspected donor. The machine was thoroughly 
cleaned and prepared according to guidelines, which has not precluded HCV carryover. 
This supports the notion that ability of HCV to establish productive infection from very 
small initial inoculum volume should not be neglected. Unfortunately we were not able 
to obtain SGA sequences for the circulating viral populations to be able to shed light on 
the number of founder viruses and possible dynamics of viral variants.  
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Although routine screening of blood products for presence of Hepatitis C Virus was 
introduced in early 1990s, new nosocomial infections are noted each year. Patients 
receiving haemodialysis are especially at risk and many direct environmental cross-
infections have been reported [350]. Most evidence, correlating HCV contamination to 
haemodialysis event, include the observation that more haemodialysis patients possess 
anti-HCV antibodies than peritoneal dialysis patients [358]. Moreover patients dialysed 
adjacent to HCV infected individuals more often develop anti-HCV antibodies [359], and 
physical isolation of non-infected patients, from those carrying HCV, correlated with 
lower contamination rates [360]. Strict appliance of infection control policies seems to 
have an effect on lowering HCV incidence [359], whereas poor control measures 
correlate with HCV outbreaks [361].  
Guideline bodies have updated standard precautions that have been shown to reduce 
the risk of cross-infections in haemodialysis units. However use of separate machines 
for infected individuals was not suggested as a policy to limit HCV transmission, 
probably due to low number of reports evidencing transmission of HCV to sequential 
patient via a haemodialysis machine [362, 363]. 
Current guidelines have been strictly followed in the unit described in this study, 
however horizontal HCV transmission has occurred. In this unit the population of 
hepatitis C patients is not isolated from HCV- negative individuals. It seems viable to 
recommend extending infection control guidance by dedicating separate haemodialysis 
machines to patients carrying viral diseases. 
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5. Acute HCV infection 
5.1. Results 
In the previous two sections we have described experimental HCV transmission in the 
chimeric mouse model and a hospital acquired patient to patient transmission event. In 
the UK most HCV infection is acquired through intravenous drug use (IVDU).  
Consequently identifying source samples of HCV transmission in natural infection is 
challenging due to the chaotic life styles of drug users. Whilst diagnosis of acute HCV 
infection is still rare, due to the large size of the Trent Cohort HCV infected sera sample 
collection (greater than 5000), we were able to retrospectively identify a number of 
HCV positive samples derived from the acute phase of infection. Strains that establish 
initial infection are important for prophylactic and therapeutic vaccine development. In 
this section we describe genetic and phenotypic diversity associated with viral 
envelopes derived from acute HCV infection, and compare those to envelopes in 
chronic infection. 
5.1.1. Amplification of full-length E1E2 sequences 
Amplification of full length E1E2 via SGA was successfully achieved from acute serum 
samples. In total we obtained 126 end point titrated full length E1E2 sequences from 
infected patients, 41 acute window sequences from 4 samples, 17 sequences from 2 
patients shortly post seroconversion and 68  sequences from chronically infected ǤǯTable 3.6. All 
SGA amplicons derived from chronic phase infection were generated by my colleague 
Mr Shafiq ur Rehman. 
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Table 5.1. Details of patients' samples. 
Patient Sample Label/ Time point Sample date 
Number of 
SGAs 
1A20 1A20 ACUTE 1.1 NA 10 
1A30 1A30.3 ACUTE 2.1 07/10/2003 9 
 
1A30.12
1 
ACUTE 2.2 04/02/2005 7 
1A57
 
1A57.2
 
ACUTE 3.1 02/09/2004 9 
 1A57.14
1 
ACUTE 3.2 01/02/2008 10 
1A65 1A65.1 ACUTE 4.1 05/04/2005 9 
1A83 1A83.8 ACUTE 5.1 NA 4 
1A67
 
1A67.5
2
 
 
CHRONIC 1.1 15/07/1998 9 
 
1A67.9
2 
CHRONIC 1.2 13/02/2001 8 
1A68 1A68.1
2
 CHRONIC 2.1 22/12/1992 7 
 1A68.5
2
  CHRONIC 2.2 10/01/1994 9 
1A69 1A69.1
2
  CHRONIC 3.1 12/08/1997 6 
 1A69.2
2
  CHRONIC 3.2 12/03/2002 10 
1A70 1A70.1
2
 CHRONIC 4.1 04/10/1999 10 
 1A70.4
2
 CHRONIC 4.2 01/10/2002 9 
1
Indicates post seroconversion samples 
2
Indicates samples obtained and sequenced by Shafiq ur Rehman, further analysis performed by the 
author 
5.1.2. Assessment of genetic distances and diversity in viral 
populations 
To compare and contrast sequence data sets derived from acute and chronic phase 
infections, genetic distance and diversity analyses were performed. As expected, 
analyses revealed that sequence genetic distances in pre- seroconversion populations 
are lower than the ones observed in chronic infection (see Table 3.7 and Figure 3.16). 
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Table 5.2. Genetic distance (nucleotide substitutions per site) in SGA derived intrahost 
populations. 
Label/ time point E1E2 E1 HVR1 E2 
ACUTE 1 0.00046 0.00031 0.00254 0.00040 
ACUTE 2.1 0.00125 0.00069 0.00276 0.00149 
ACUTE 2.2 0.00215 0.00089 0 0.00313 
ACUTE 3.1 0.00578 0.00628 0.00283 0.00571 
ACUTE 3.2 0.00757 0.00610 0.04350 0.00582 
ACUTE 4 0.00167 0.00139 0.00281 0.00177 
ACUTE 5 0 0 0 0 
CHRONIC 1.1 0.00507 0.00502 0.00422 0.00517 
CHRONIC 1.2 0.02369 0.01812 0.1281 0.02196 
CHRONIC 2.1 0.01314 0.01293 0.01222 0.01377 
CHRONIC 2.2 0.00838 0.0108 0.00847 0.00686 
CHRONIC 3.1 0.04327 0.01296 0.01754 0.0111 
CHRONIC 3.2 0.00978 0.00562 0.03017 0.00959 
CHRONIC 4.1 0.0078 0.00783 0.02833 0.00622 
CHRONIC 4.2 0.00791 0.00769 0.02756 0.00612 
 
 
Figure 5.1. Genetic distance (nucleotide substitutions per site) comparison for 
populations of full length E1E2 sequences from different patients and time points.  
Graph represents highlighted column in Table 3.7. 
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Moreover genetic distances of the intrahost populations at different time points vary 
for all data sets (see Table 3.7 and Figure 3.16) suggesting that populations are 
genetically dynamic over time. Sequential samples from the acute dataset obtained in 
this project: Acute 2.1 and 2.2; and Acute 3.1 and 3.2 show an increase of genetic 
distance with time. For sequential samples of chronic dataset the difference is variable.  
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Figure 5.2. Difference in genetic distance between acute and chronic phases of infection.  
ŽŵƉĂƌŝƐŽŶŽĨĨƵůůůĞŶŐƚŚ ? ?ĂŶĚƐĞƉĂƌĂƚĞĚŽŵĂŝŶƐ ?ƐĞƋƵĞŶĐĞƐ ?ZĞĚĐŝƌĐůĞƐ- genetic 
distances for acute populations, blue squares- for chronic populations. Horizontal bars 
represent mean values. P values associated with acute and chronic comparisons were 
calculated in GraphPad Prism using Mann-Whitney test. 
Figure 3.17 depicts the comparison of genetic distances between acute and chronic 
data sets. The genetic distance calculations were made on the basis of full length E1E2 
sequences as well as fragments spanning sequence coding E1, HVR1 and E2. These data 
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demonstrate there is a significant difference in genetic distance between sequences 
from acute and chronic phases of infection irrespective of domain analysed.  
As in the chimeric mice transmission experiment, variability of HVR1 variants in acute 
infection was assessed. All apart from one (Acute 3.2) populations contain either none 
or single nucleic acid substitutions within all SGA obtained sequences. In Acute 2.1, 
Acute 3.1 and Acute 4 these substitutions are non-silent leading to population 
consisting of 2 HVR1 variants- a highly dominant and a minor variant at a 10, 11.1 and 
11.1% frequency in respective populations. The HVR1 population in host Acute 3.2 is 
demonstrably more variable, with nucleic acid substitutions giving rise to 3 amino acid 
variants (see sequence logo alignments in Figure 3.18). The major variant comprises 
50% of sequences, with two minor variants comprising 20 and 30% respectively. The 
higher observed variability within this population is likely to be directly related to the 
time of sampling from initial infection. Acute 3.2 sequences were derived from a serum 
sample collected 4 years after the Acute 3.1 time point, and about 3 years post the 
seroconversion event (see Table 2.3 in chapter 2). We do not observe such increased 
diversity in another post seroconversion population derived data set, Acute 2.2. This is 
likely to be due to reduced sampling time since the presence of anti-HCV antibodies 
were detected when compared to Acute 3.2 (see Table 2.3). The diversity of HVR1 
sequences within assessed acute populations is generally very low, although it seems to 
increase after seroconversion. The restricted diversity we observe in the HVR1 in acute 
infection mirrors the limited diversity observed shortly after experimental 
transmission to chimeric mice and is in agreement with previous reports of acute 
infection [240, 364, 365]. We observe increased HVR1 diversity in the intrahost 
population of Acute 3.2 which is likely to be the result of escape from host humoral/ 
cellular immune responses [77, 235]. Due to the time from initial infection being in 
excess of 4 years this intrahost population is technically derived from the chronic phase 
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of infection. However these sequences served as a useful internal experimental control, 
and demonstrate increasing HVR1 diversity post seroconversion. Together these 
analyses show restricted HVR1 diversity in acute infection. This restriction is likely due 
to founder effect upon transmission or a selective sweep post transmission. Our 
experimental data from the xenomice portion of the study indicates that selective 
sweeps shape initial viral populations, and this may mirror the post transmission 
dynamics in natural infection. Due to the asymptomatic nature of acute HCV infection 
we were unable to identify donor samples to test this hypothesis.  
 
  
141 Acute HCV infection 
  
  
  
 
Figure 5.3. HVR1 sequences alignment for acute SGAs.  
Alignment presented as sequence logo obtained at 
http://weblogo.berkeley.edu/logo.cgi . Panel A- Acute 1, B- Acute 2.1, C- 
Acute 2.2, D- Acute 3.1, E- Acute 3.2, F- Acute 4, G- Acute 5. 
A B 
C D 
F E 
G 
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5.1.3. Phylogenetic analyses of sequence populations 
To further analyze viral populations in acute phases of HCV infection and compare 
these to populations from chronic phase of infection, phylogenetic analyses of full 
length E1E2 glycoproteins sequences were performed (see Figure 3.19). Sequences 
cluster on the basis of sample origin and time point indicating no cross-contamination. 
Within the acute set samples, where two sequential time points were analyzed, 
clustering is evident between sequential samples. Pre-seroconversion window 
sequences are highly similar, which has been detailed in Table 3.7 and is also depicted 
in the phylogenetic reconstruction in Figure 3.19. Seroconversion seems to have an 
effect on E1E2 evolution- tree branch length and genetic distance rise as compared to 
window sequence populations. Further comparison with variants from chronically 
infected patients depicted in Figure 3.19 B shows that branch lengths and genetic 
distances within populations depend on time of sampling. The longer post infection and 
post seroconversion the more diversified the populations. 
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A B
 
Figure 5.4. Phylogenetic 
reconstruction of sequences in 
acutely infected HCV patients. 
Maximum likelihood composite 
tree of all acute single molecule 
amplified sequences. HKY+G 
model of evolution calculated 
in modeltest 3.7.  
Panel A:  
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Full length E1E2 sequence populations derived from acute infection were compared to 
their respective most recent common ancestral sequences (MRCA), to elucidate 
substitutional patterns apparent in each host using highlighter plots (schematic 
representation in Figure 3.20).   
For Acute 1 and Acute 4 E1E2 sequences, there is extremely limited nucleotide 
diversity apparent. Additionally for Acute 5 there was no nucleotide diversity observed 
with all sequences being identical. Consequently sequences from this population were 
omitted from the highlighter analysis. In the sequences derived from patient Acute 1 
there is a low level of non-synonymous substitutions with two unlinked amino acid 
changes apparent. However in patient Acute 4 there is a slightly higher level of amino 
acid substitutions. Indeed at position 475 in the HVR2, roughly 50% of sequences 
contain Leucine while all the remaining sequences contain Proline. As these sequences 
are derived from pre-seroconversion any amino acid substitutions observed are not a 
result of escape from host humoral responses. Consequently any amino acid 
substitutions we see in Acute 1 and 4 sequences are likely to be selectively neutral, 
having negligible effect on viral envelope fitness. 
For the samples where sequential time point data is available differences in 
substitution patterns between pre- and post- seroconversion sampling times are 
distinguishable (Figure 3.20 B and D). In Acute 2 sequences, whilst multiple unlinked 
amino acid changes are apparent, non- synonymous substitutions at three positions are 
associated with differences between pre and post- seroconversion populations: one in 
E1 and two in E2. At position 312 in E1 we observe an EoD substitution. All pre- 
seroconversion sequences possess glutamic acid (E) whereas all post- seroconversion 
possess aspartic acid (D). There is extremely limited structural/ functional information 
available for the E1 protein so we are unable to ascertain what effect this substitution 
would have on E1 function, although this change is relatively conservative as both 
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glutamic and aspartic acid have similar physicochemical properties (polar, negative 
charge). The next non-synonymous substitution we observe at site 537 (AoV), with all 
pre-seroconversion possessing an alanine (A) whilst all post sero-conversion 
sequences possess a valine (V). The recent structural mapping of the E2 protein [75] 
suggests that this residue lies in the proposed Domain I, and is in close proximity to 
both an N-linked glycan and residues critical for CD81 binding. Whilst this substitution 
is relatively conservative it is possible that this change might have an impact on 
receptor binding or susceptibility to antibody mediated neutralisation.  This will need 
an experimental confirmation. Finally, in patient Acute 2, we observe an IoV 
substitution at position 627 within E2. This residue is located in proposed Domain III 
[75] and whilst it is again relatively conservative is located in close proximity to 
another N-linked glycan site, removal of which is associated with impaired 
heterodimerisation and folding [65]. Whilst this substitution does not knock- out this 
glycan site, it is plausible that this change may result in minor conformational shifts 
which may affect protein folding, susceptibility to host neutralising antibodies, and 
capacity for cellular entry, although this hypothesis would require experimental 
confirmation. 
Finally we observe multiple substitutions apparent in pre and post- seroconversion 
viral sequences from Acute 3. The majority of substitutions appear to be synonymous 
indicating purifying selection is the major force acting on these sequences, however 
multiple non- synonymous substitutions are also observed. Whilst a proportion of non- 
synonymus substitutions are unlinked and appear to have a random distribution, four 
sites in the E2 protein are associated with differences between pre- and post- 
seroconversion sequences. Substitutions at sites 386 (AoV) and 403 (FoL) are 
associated with seroconversion and exhibit complete compartmentalisation between 
time points. Substitutions at sites 395 (RoH) and 401 (AoT) appear to show 
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diversifying selection post-seroconversion, whilst these residues are completely 
conserved in the window phase. Whilst all window phase derived sequences possess 
arginine (R) and alanine (A) at positions 395 and 401 respectively, variability at these 
residues is observed post-seroconversion. Indeed 50% of sequences retain the 
ancestral amino acid combination (RA) whilst the other half harbours a new, histidine- 
threonine (HT), combination. Non- synonymous substitutions at 395 and 401 are 
linked. Unlike Acute 2, all changes associated with seroconversion are located in the 
HVR1. This region has been previously reported to act as immunological decoy and 
thus it is likely that these changes have been driven by host humoral immune targeting 
[77]. This region is also shown to be essential for SR-BI receptor binding [79] and 
consequently these mutations may have an impact on capacity for cellular entry. 
In summary these analyses demonstrate limited diversity is apparent in acute infection 
and identifies important molecular determinants associated with seroconversion. 
However these determinants do not appear to be universal, varying from patient to 
patient and are located in different functionally important regions. 
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5.1.4. Phenotypic analysis of acute clones 
To test whether different sequences within viral populations and between sampling 
points possessed varying phenotypic properties, E1E2 variants were analysed using the 
HCV pseudoparticle system. Representative major sequences from acute populations 
were identified and cloned into pcDNA3.1 background. Unfortunately due to time 
constraints comparison with minor variants was not possible. Available clones were 
analysed to confirm presence of a correct sequence or annotate changes (PCR or/and 
cloning artefacts) and subsequently used in pseudoparticle infectivity assays.  
Cloning of SGA products proved to be difficult and error prone. Most of the clones 
carried at least one amino acid substitution when compared to translated end point 
titrated sequences (details in Table 5.3). Topoisomerase cloning was initially applied 
but for this particular set of sequences the reactions had very low efficiency. 
Subsequently most of the E1E2 clones were obtained by restriction digestion cloning 
via an in-house optimised method (described in 2.10.2). SGA derived sequences are 
essentially a consensus of all PCR amplicons in a pool of PCR products and represent 
the single genome template from which they were derived. However due to inherent 
error rate of the polymerase a proportion of amplicons will contain artefactual 
substitutions, which will occur sporadically throughout the length of the sequence.  
Consequently sporadic PCR induced errors will not be detectable in sequencing as the 
minimal threshold for detection of minor variants in a chromatograph is approximately 
10%. Coupled with the inherent error prone nature of the bacterial replication 
machinery, which will also introduce sporadic mutations, these are the likely reasons 
for the high error rate we observe when cloning SGA derived full length E1E2 
sequences. This unexpectedly high level of artefactual substitutions associated with 
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SGA cloning has given us the opportunity to assess the effect on pseudoparticle 
infectivity. 
Table 5.3. Details of clones produced and their sequences. 
Sample Clone label Sequence differences
1 
Infectivity assessed 
restriction cloning 
Acute 1 lig1A20.1_1_c2 V623A Yes  
 lig1A20.1_1_c3 H262R;Y475C Yes 
 lig1A20.1_1_c5 L373V;G524C Yes 
 lig1A20.1_1_c8 L727P Yes  
Acute 2.1 lig1A30.3_26_c9 multiple Yes 
 lig1A30.3_26_c11 C645G;D654G Yes 
 lig1A30.3_26_c14 F292L;C453R Yes 
 lig1A30.3_38_c19 R574G; L736S Yes 
 lig1A30.3_38_c21 N/A Yes 
 lig1A30.3_38_c23 R574G Yes 
 lig1A30.3_C_c37 N411T;T436A;S456C Yes 
Acute 2.2 lig_1A30.12_2_c6 N/A Yes 
Acute 3.1 lig_1A57.2_1_c10 N/A Yes 
 lig_1A57.2_1_c12 N/A Yes 
 lig1A57.2_6_c28 C565R Yes 
Acute 3.2 lig_1A57.14_1.2_1_c20 multiple No 
 lig_1A57.14_1.2_1_c21 N/A Yes 
 lig_1A57.14_1.2_2_c30 N/A Yes 
 lig_1A57.14_1.2_2_c33 N/A Yes 
Acute 4 lig1A65.1_23_c33 L378P Yes 
 lig1A65.1_23_c35 N578S;C735R Yes 
 lig1A65.1_23_c37 no mutations Yes 
 lig1A65.1_23_c40 C185R;P472S Yes 
 lig1A65.1_24_c46 N/A Yes 
Acute 5 lig_6228.8_3_c41 N/A Yes 
 lig_6228.8_3_c42 L727P Yes 
 lig_6228.8_3_c47 N/A Yes 
topo cloning 
Acute 1 topo1A20.1_1 H262R;A320G;H445R Yes 
Acute 2.1 topo1A30.3_26_c7 multiple Yes 
 topo1A30.3_26_c15 P485S Yes 
Acute 3.1 topo1A57.2_1.32.2_c11 L346V Yes 
 topo1A57.2_1.32.2_c14 G279E;G574E
 
Yes 
Acute 3.2 topo1A57.14_1.2.1 multiple No 
Acute 4 topo1A65.1_23_c27 multiple No 
 topo1A65.1_23_c29 S284P Yes 
 topo1A65.1_23_c30 L183P Yes 
N/A- full sequence not available, sequencing reaction not performed for one or more amplicons 
1 
Numbering of amino acid position relative to protein start in H77  
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Amongst 9 clones derived from topoisomerase method all had mutations, only 4 of 
them singular. The restriction cloning yielded 27 clones, only 17 were fully sequenced 
owing to time constraints. Only one clone (lig1A65.1_23_c37) proved to possess the 
correct sequence of the consensus SGA sequence. Despite the presence of mutations a 
proportion of the clones were utilised in pseudoparticle assays and proved infectious. 
Furthermore, a number of plasmids possessing one single mutation were reverted by 
site directed mutagenesis to the SGA consensus (described in section 2.17) and 
infectivities compared. 
Infectivity assays were performed twice in triplicate. The averages of infectivities are 
presented in Table 5.4 and Figure 3.21 as a percentage of infectivity of H77 positive 
control, which was taken as 100%. A threshold of 10% infectivity as compared to 
positive control was set as a cut off for infectious (10% and above) or non- infectious 
(below 10%) E1E2 clones. 
A highly infectious clone lig1A30.3_38_c23 that possessed one mutation when 
compared to the original end-point titrated consensus sequence was reverted 
alongside non-infectious clones to compare the effect of reversion. A total of six clones 
were back mutated and assessed in pseudoparticle infectivity assays (see Table 5.4 and 
Figure 3.22). A previously infectious clone (lig1A30.3_38_c23) remained functional 
upon reversion of the artefactual substitution.  Infectivities of a further 3 constructs 
(lig1A20.1_1_c2, topo1A30.3_26_c15, lig_6228.8_3_c42) were brought above the 
threshold by restoring their sequence to the observed original. Clone 
topo1A65.1_23_c29 improved infectivity after back mutation, but the overall signal 
remained below the set threshold. 
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Table 5.4. Infectivity assay results before and after back-mutation. 
Sample Clone label 
infectivity as % H77 
I II Mutation
1 
III IV 
Acute 1 lig1A20.1_1_c2 1.69% 0.17% C2206T 11.93% 12.35% 
 lig1A20.1_1_c3 0.75% 1.35%    
 lig1A20.1_1_c5 0.25% 0.88%    
 lig1A20.1_1_c8 8.13% 12.43%    
 lig1A20.1_29_c1 0.24% 0.56%    
 lig1A20.1_29_c8 0.44% 1.69%    
 topo1A20.1_1 13.31% 18.52%    
Acute 2.1 lig1A30.3_26_c9 1.94% 2.95%    
 lig1A30.3_26_c11 1.19% 0.14%    
 lig1A30.3_26_c14 0.97% 0.08%    
 lig1A30.3_38_c19 5.38% 3.26%    
 lig1A30.3_38_c21 65.45% 75.95%    
 lig1A30.3_38_c23 98.60% 82.76% G2058A 87.09% 93.62% 
 lig1A30.3_1.8_c36 0.65% 0.97%    
 lig1A30.3_2_c29 0.07% 0.81%    
 lig1A30.3_2_c30 0.36% 3.35%    
 lig1A30.3_C_c37 0.92% 0.26%    
 topo1A30.3_26_c7 0.18% 2.09%    
 topo1A30.3_26_c15 3.74% 2.22% T1791C 112.88% 94.02% 
Acute 2.2 lig_1A30.12_2_c6 14.02% 2.67%    
Acute 3.1 lig1A57.2_6_c28 0.74% 0.13% C2031T 19.42% 22.14% 
 lig_1A57.2_1_c10 10.91% 5.04%    
 lig_1A57.2_1_c12 14.86% 1.99%    
 topo1A57.2_1.32.2_c11 25.82% 37.54%    
 topo1A57.2_1.32.2_c14 0.21% 0.67%    
Acute 3.2 lig_1A57.14_1.2_1_c20 13.00% 2.56%    
 lig_1A57.14_1.2_1_c21 16.60% 4.68%    
 lig_1A57.14_1.2_2_c30 98.41% 85.37%    
 lig_1A57.14_1.2_2_c33 19.37% 8.38%    
Acute 4 lig1A65.1_23_c33 0.65% 0.18%    
 lig1A65.1_23_c35 1.00% 3.19%    
 lig1A65.1_23_c37 0.36% 0.39%    
 lig1A65.1_23_c40 0.83% 2.05%    
 lig1A65.1_24_c46 0.91% 0.77%    
 topo1A65.1_23_c29 0.12% 0.11% T340C 11.60% 9.85% 
 topo1A65.1_23_c30 1.30% 0.44%    
Acute 5 lig_6228.8_3_c38 9.89% 3.85%    
 lig_6228.8_3_c41 11.85% 4.66%    
 lig_6228.8_3_c42 11.44% 9.87% T1670C 13.21% 12.72% 
 lig_6228.8_3_c47 11.35% 0.97%    
I, II, II, IV- sequential tests, results presented as an average of triplicate values 
1
Numbering of nucleotide position relative H77 genome 
Highlighted in red are values above 10 % threshold 
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Figure 5.7. Comparison of infectivity of clones prior and post back-mutation.  
Key: RLU- relative light units presented as ratio of positive control (positive control=1). Grey bars- two tests before, purple- after reverting 
mutations. Values as average of three replicas in each test. Green line- infectivity threshold of 10% control (H77).  
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In conclusion the above data demonstrates the necessity to check the sequences of 
cloned SGA products prior to any phenotypic analysis. It also reveals the extreme 
sensitivity of the HCV pseudoparticle system to single point mutations.  For example a 
non- infectious clone topo1A30.3_26_c15 containing a single point mutation resulting 
in a non- synonymous substitution (P315S) was reverted to SGA consensus. This 
resulted in a massive increase of infectivity well above the threshold. Unfortunately 
owing to time constraints and the unexpectedly high level of sporadic mutations, we 
were unable to further characterise phenotypic properties of E1E2 derived from acute 
phase of infection.  
Finally these data demonstrate the applicability of SGA to the study of intrahost E1E2 
viral populations at HCV transmission and in acute and chronic HCV infection. This 
technique has become the gold standard for analysis of HIV-1 intrahost diversity 
including analyses of anatomic compartmentalisation [366-368] and identification of 
number of transmitted variants [220, 369]. This technique has previously not been 
widely applied to HCV evolutionary studies. However caution must be applied when 
subsequent cloning of SGA products for phenotypic studies is performed, as this 
process is error prone: clones must have their sequences confirmed to ensure 
homology. 
5.2. Discussion  
The inherent sequence diversity of HCV represents a major challenge for any treatment 
of this disease. In vivo HCV E1E2 exhibits rapid adaptation to host humoral and cellular 
responses [16, 134, 228]. Cellular entry is an essential step in the life cycle of any virus 
and this step may serve as a potential candidate for drug targeting. Consequently, any 
new prophylactic or therapeutic agent will have to efficiently target structurally or 
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functionally conserved regions of the viral glycoproteins. Understanding the cellular 
and viral components of entry, coupled with the evolution of E1E2 in response to host 
immune targeting, should increase our understanding of the molecular mechanisms 
involved in the entry process.  
The last part of presented project aimed to describe the evolution of HCV envelope 
genes over several years of infection, including comparison of changes in acute and 
chronic phases between different patients. We have applied an approach for 
amplification of full length E1E2 sequences by titration PCR as described here earlier. 
In brief, our method allows an accurate assessment of the distribution of the viral 
quasispecies within a specific patient over time. Also, phylogenetic analysis of full 
length E1E2 sequences aimed to achieve more robust and representative results 
compared to analyses based only on the HVR1 region. 
Reports on tempo of evolutionary change are contrasting with some claiming evolution 
of HCV is more rapid during acute phase [370], some during chronic phase [218]. 
Different parts of the HCV genome undergo varying pressure. There has been a 
substantial interest in studying evolution of E1E2 glycoproteins which facilitate the cell 
entry and fusion and also undergo selection pressures from the immune system. 
Accuracy of phylogenetic reconstructions is influenced by the choice of sequence that 
undergoes analysis and HVR1, being a very short and the most rapidly evolving 
fragment of the HCV genome, does not allow in depth phylogenetic reconstruction of 
intrapatient sequence variants. Although HVR1 importance in HCV life cycle as a 
receptor binding epitope and antibody epitope has been proven, extending 
reconstructions to full length E1E2 sequences allows inclusion of other structurally and 
evolutionary important sites. Many receptor binding sites, antibody recognition sites 
and T-cell targeted epitopes have been characterised for the E1E2 heterodimer, hence 
analysis of the full length sequence is essential. 
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In our study the number of substitutions across full length E1E2 clearly increases after 
seroconversion. HCV E1E2 variants diversity in chronic phase of infection is vastly 
higher than in acute phase. These findings, suggesting that virus specific antibodies that 
arise in acute phase during seroconversion and further on drive sequence evolution of 
the virus, are in accordance with the literature [80, 235, 238]. Furthermore fluctuations 
of genetic diversity values within population sets at distinct time points of disease 
might indicate states of dynamic equilibrium between new arising antibody pressure 
on viral sequences and their adaptation. Moreover phylogenetic analysis shows that the 
pattern and tempo of substitutions in circulating virus are individual for each host.  
The development and implementation of a robust pseudotype cell- entry assay allowed 
analysis of the E1E2 glycoproteins derived from different genotypes and strains. This 
method has also been applied to screening for anti-HCV antibodies and neutralising 
antibodies have been described. Here we aimed to apply the pseudoparticle indectivity 
assay to study envelopes isolated at distinct disease stages, and further elucidate the 
relationship between E1E2 evolution, host antibody responses and receptor binding 
affinity. Unfortunately due to time limitations of the project these aims have been 
achieved only partially. 
Progress of this particular branch of the presented project has been stalled by suprising 
difficulties related to molecular cloning and high amount of artefact within clonal 
sequences. However this allowed us to make an observation of a relative sensitivity of 
the HCV pseudoparticle assay to mutations. This further proves that every precaution 
needs to be applied when obtaining viral sequences for further analysis of their 
phenotype. This study was also limited by the number of patient samples obtained and 
lack of the donor/ source information. Crude analysis of dynamic changes in 
intrapopulation diversity allows us to hypothesize complex interaction between 
neutralising antibodies and escape of newly arising variants, further change of antibody 
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target followed by escape event and transient fixing of a differing variant population. In 
depth phylogenetic and phenotypic analysis on larger amount of samples, including 
both infectivity and neutralising assays, would aid understanding of HCV evolution and 
its molecular determinants in the acute stage of infection. 
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6. Final conclusion  
Over two decades since the discovery of the causative agent of the Non-A-non-B 
hepatitis, the breadth of the gathered knowledge is still not enough to eradicate the 
virus from the human population. HCV is a pathogen establishing relatively often a 
chronic infection. Its high mutation rate and surprisingly late immune response within 
infected hosts precludes positive outcome of acute infection in more than half of 
infected individuals. Medical complications related to HCV infection have been an 
increasing worldwide burden- both moral and financial. Molecular investigation of HCV 
diversity is of major importance for the design of accurate treatment and development 
of a preventive vaccine. 
In this thesis we attempted to broaden our understanding of HCV evolutionary 
dynamics in three distinct settings: experimental transmission into 
immunocompromised mice, naturally occurring horizontal transmission and acute 
phase of infection. 
Overall our findings aid understanding of early post transmission viral glycoprotein 
populations. Identification of unique features of transmitted E1E2 glycoproteins may 
potentially be relevant to vaccine and therapeutic design strategies. Beyond this, our 
study utilises a methodological approach previously applied to evolutionary analyses of 
HIV-1 intrahost population diversity. Furthermore we confirmed that Alb uPA/SCID 
mouse model of HCV infection is robust and reliable for HCV transmission studies. 
These data also suggest universal mechanisms may underly HCV transmission and 
subsequent establishment of productive infection prior to seroconversion, irrespective 
of host. 
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We also confirmed that nosocomial transmission in haemodialysis unit occurred 
between hypothesised source and index case, highlighting the need for continuous 
revision of safety guidelines and suggesting possible future change to establishing 
separate dialysis machines for patients carrying blood borne infections. 
Comparison of HCV sequences obtained from human sera at differing sampling time 
points in the progress of infection provided us with an insight into diversification of 
viral population at early stages of infection that further sustained the notion that HVR1 
alone is not an indicator of evolutionary dynamics of HCV. Forces shaping evolution of 
HCV during acute infection, especially upon seroconversion are dependent on both the 
host and viral factors. Knowledge of the initial inoculum and host genetic make-up 
might in future help predict the course of the disease and aid administering successful 
treatment. 
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